TUESDAY PROGRAMS
Program A: (Sessions 1-8)
6:45 A.M. – 6:02 P.M. (9.75 CME Credits)
Heart Valves, Aortic And Carotid Diseases And Their Treatment
Location: Grand Ballroom East, 3rd Floor

Program B: (Sessions 9-16)
6:40 A.M. – 5:58 P.M. (10 CME Credits)
New Developments In AAAs, EVAR, Aortic Branch Lesions (Including Iliac, Visceral And Renal Arteries), Outpatient Issues, Laparoscopic Techniques, Complex AAAs, New Technologies And Open Or Hybrid Vascular Surgery
Location: Grand Ballroom West, 3rd Floor

Program C: (PART 1 - Sessions 17-18)
7:00 A.M. – 12:00 P.M. (4.5 CME Credits)
Management Of Pulmonary Embolism: Do We Know Enough
Course Leader: Michael R. Jaff, DO
Location: Trianon Ballroom, 3rd Floor

Program C: (PART 2 - Sessions 19-22)
1:00 P.M. – 5:45 P.M. (4.25 CME Credits)
New Developments In The Management Of Acute And Chronic Large Vein Occlusion
Course Leader: Kenneth O Yuri, MD, MBA
Location: Trianon Ballroom, 3rd Floor

Program D: (Sessions 23-30)
6:40 A.M. – 5:58 P.M. (10 CME Credits)
Lower Extremity Arterial Occlusive Disease And Its Treatment
Location: Grand Ballroom East, 3rd Floor

Program E: (Sessions 31-38)
6:40 A.M. – 6:05 P.M. (10 CME Credits)
Medical And Anti-Atherogenic Treatments; Anti-Hypertensive Treatments; Endoekale Management; Important Issues For Vascular Surgeons & Specialists, And Other Interesting Topics
Location: Grand Ballroom West, 3rd Floor

Program F: (Sessions 39-46)
6:45 A.M. – 6:00 P.M. (9.75 CME Credits)
Thoracic And Abdominal Aorta, Aortic Dissections, TEVAR, Parallel Grafts, Evbevar, TAAAs, Juxt- And Pararenal AAAs, Multilayer Flow Modulating (MLFM) Stents, AAAs & EVAR And Recorded Live Cases
Location: Trianon Ballroom, 3rd Floor

THURSDAY PROGRAMS
Program G: (Sessions 47-54)
6:40 A.M. – 5:54 P.M. (9.75 CME Credits)
New Technologies, Technology And Concepts; Advances In F/BEVAR And Parallel Grafts For Complex Aortic Aneurysms And TAAAs; Technical Challenges; Endovascular Repair Of Ruptured AAAs; Vascular Robotics For Embolectomy And Clot Removal
Location: Grand Ballroom West, 3rd Floor

Program H: (Sessions 55-62)
6:40 A.M. – 5:30 P.M. (9.5 CME Credits)
New Devices For EVAR And Juxta-renal AAA Repair; TEVAR And TAAA Repair; Lower Extremity Treatment Devices; Updates On Endoanchores; New Devices For Endolectomy And Clot Removal
Location: Grand Ballroom West, 3rd Floor

Program I: (Sessions 63-70)
7:29 A.M. – 5:15 P.M. (8.75 CME Credits)
Venous Topics – Superficial - Improved Treatments For Varicose Veins
Course Leaders: Jose I. Almeida, MD, RPVI, RVT, Lowell S. Katz, MD, RP, Thomas W. Wakefield, MD
Location: Trianon Ballroom, 3rd Floor

FRIDAY PROGRAMS
Program J: (Sessions 71-78)
6:40 A.M. – 5:38 P.M. (10 CME Credits)
New Carotid Technology, Techniques And Concepts; Spinal Cord Ischemia (SCI); Carotid Related Topics And Controversies – CEA vs. CAS vs. Medical Therapy; Late Carotid Follow-up After Carotid Endarterectomy
Location: Grand Ballroom East, 3rd Floor

Program K: (Sessions 79-86)
6:40 A.M. – 5:35 P.M. (9.5 CME Credits)
Pelopithe Aneurysms And Disease; Management Of Infected Arteries; Prosthetic Grafts And Endografts; Advances In Imaging And Hybrid Suites; New Developments In Thoracic Outlet Syndromes, Carotid Occlusion, Vascular Trauma, Medical Topics And Treatments; CCSVI And Radiation Safety; Recorded Live Cases From Münster & The Mayo Clinic
Location: Grand Ballroom West, 3rd Floor

Program L: (Sessions 87-91)
6:58 A.M. – 5:12 P.M. (9.25 CME Credits)
New Developments In Deep Venous Disease And Its Treatment
Course Leaders: Jose I. Almeida, MD, RPVI, RVT, Lowell S. Katz, MD, RP, Thomas W. Wakefield, MD
Location: Grand Ballroom East, 3rd Floor

Program M: (Sessions 92-98)
6:45 A.M. – 1:30 P.M. (6.25 CME Credits)
The Challenging World Of The Diagnosis And Treatment Of Vascular Malformations: An Orphan Disease That Has Now Come Of Age
Course Leaders: Wayne F. Yakes, MD, Krassi Ivanov, MD, PhD, Robert L. Vogelzang, MD
Location: Granmercy Suites East and West, 2nd Floor

SATURDAY PROGRAMS
Program N: (Sessions 99-105)
6:46 A.M. – 4:16 P.M. (8.25 CME Credits)
New Developments In The Treatment Of Diseases Of The Lower Extremities, Carotid Arteries, The Aorta And Its Branches And Traumatic Vascular Injuries
Location: Grand Ballroom East, 3rd Floor

Program O: (Sessions 106-110)
8:00 A.M. – 4:00 P.M. (6.75 CME Credits)
Improving Outcomes In Hemodialysis Access
Location: Grand Ballroom West, 3rd Floor

Program P: (Sessions 111-115)
6:50 A.M. – 2:00 P.M. (6.25 CME Credits)
New Developments In Treatment Of The Aorta Carotid And Lower Extremity Disease: Important Updates And New Concepts
Location: Trianon Ballroom, 3rd Floor

PROGRAM OUTLINE AT A GLANCE
CONTENTS

Program Outline At A Glance....................................................Inside Front Cover
Acknowledgments .................................................................5
General Information ...............................................................7
Accreditation ...................................................................................9
Faculty Disclosure ........................................................................9
Social Events ................................................................................10
Hotel and Travel ...........................................................................10
Agenda .....................................................................................11–116
VEITH On-Demand .................................................................116
Faculty Listing .............................................................................116
Registration ................................................................................117–124
Save the Date..................................................................................125–126

SYMPOSIUM CHAIRMAN
Frank J. Veith, MD

SYMPOSIUM CO-CHAIRMEN
Enrico Ascher, MD
Kenneth Ouriel, MD, MBA
Sean P. Lyden, MD

SYMPOSIUM MANAGING DIRECTOR
Jacqueline M. Simpson, BBA

SYMPOSIUM ASSOCIATE DIRECTOR
Steven J. Feld, MSW

CENTER FOR CONTINUING MEDICAL EDUCATION
Steven M. Kawczak, PhD

ADVISORY COMMITTEE
Ali F. AbuRahma, MD
Keith D. Calligaro, MD
Nicholas J.W. Cheshire, MD
Timur P. Sarac, MD

SCIENTIFIC COMMITTEE
Ali F. AbuRahma, MD
Mark A. Adelman, MD
Jean-Pierre Becquemin, MD
Giancarlo Biamino, MD, PhD
Keith D. Calligaro, MD
Nicholas J.W. Cheshire, MD
Roberto Chiesa, MD
Daniel G. Clair, MD
Jacob Cynamon, MD
Hans-Henning Eckstein, MD, PhD
Peter Gloviczki, MD
Roger M. Greenhalgh, MD
Krassi Ivancev, MD, PhD
Sriram S. Iyer, MD
Pedro P. Komlos, MD
Mario L. Lachat, MD
Christos D. Lapias, MD
Evan C. Lipsitz, MD
Germano Melissa, MD
Frans L. Moll, MD, PhD
Samuel R. Money, MD, MBA
Christoph A. Niemather, MD, PhD
Juan C. Parodi, MD
Vicente Rambau, MD, PhD
Jean-Baptiste Ricco, MD, PhD
Thomas S. Riles, MD
Plinio Rossi, MD
Timur P. Sarac, MD
Dierk Scheinert, MD
Carlo Setacci, MD
Cynthia K. Shortell, MD
Giovanni Torsello, MD
Eric L. G. Verhoeven, MD, PhD
Wayne W. Zhang, MD
21st European Vascular Course

March 5-7 2017
Maastricht
the Netherlands
www.vascular-course.com

100 invited lectures
Interactive case discussions
Hands-on training sessions
Arterial, Venous & Access
Master Classes & textbooks

Learning by training
COMPONENT MEETING LEADERS
Jose I. Almeida, MD, RPVI, RVT
George L. Berdejo, BA, RVT
Allan L. Brook, MD
Jacob Cynamon, MD
Krassi Ivancev, MD, PhD
Michael R. Jaff, DO
Lowell S. Kabnick, MD, RPhS
Natalie A. Marks, MD, RPVI, RVT
Larry A. Scher, MD
Anton N. Sidaway, MD, MPH
Robert L. Vogelzang, MD
Wayne F. Yakes, MD
Thomas W. Wakefield, MD

ACKNOWLEDGMENTS
The Cleveland Clinic Foundation Center for Continuing Education and VEITHsymposium acknowledge educational grants in support of this activity from:

Abbott Vascular
Bard Peripheral Vascular
BIOTRONIK AG
Bolton Medical
Boston Scientific Corporation
Cardiatis
Cook Medical
Cordis® A Cardinal Health company
Endologix, Inc.
Gore & Associates, Inc.
Medtronic, Inc.
Penumbra, Inc.
Proteon Therapeutics
Shockwave Medical, Inc.
Silk Road Medical
Vascutek Ltd, a Terumo Company
Vascular & Endovascular Consensus Update

25–28 APRIL 2017
OLYMPIA GRAND • LONDON • UNITED KINGDOM

See you in 2017
NEEDS ASSESSMENT

Vascular disease in all of its manifestations is a leading cause of death and disability affecting a large percentage of Americans over the age of 50. There is a critical need for physicians who diagnose, treat and manage patients with vascular disease to receive continuing medical education in this area. The latest pharmacologic, radiologic, surgical and endovascular techniques and technologies will be presented, along with discussions of when these treatments are justified and indicated and when they are not. Updates on clinical trials and opportunities for dialogue with experts in the field provide insight along with the latest data on the results of the various treatment modalities.

There is an enormous gap between actual practice and the current state of knowledge. This gap is filled imperfectly with material in books and published articles. These sources are also often negatively influenced by the biases of authors, reviewers and editors. VEITHsymposium attempts to fill this gap more perfectly and more currently by enlisting speakers with up-to-date information and data and also those on both sides of controversial issues. In this way, the audience gets a current view of the state-of-the-art in vascular disease management as of the date of the meeting. All important topics are covered at the meeting and for further reference in the web based library, a long-term permanent resource.

In addition, by having numerous short (5-6 minutes) talks followed by panel discussions and capturing the entire meeting on the web based library, the meeting will provide an electronic reference source to help vascular specialists in their practice decisions throughout the year. It will also provide the most up-to-date unbiased information possible to help with these decisions.

FOCUS

The VEITHsymposium provides Vascular Surgeons and other Vascular Specialists with a five-day conference on the most current information about new developments in clinical practice and relevant research. Beginning Tuesday, the symposium offers over 900 fast-paced presentations on what is new and important in the treatment of vascular disease. Important updates and reevaluations, as well as the latest significant advances, changing concepts in diagnosis and management, pressing controversies and new techniques, agents and diagnostic modalities will be presented. Video case presentations will also be included.

OBJECTIVES

Upon completion of the VEITHsymposium, the participants will, after learning about a wide array of topics, be able to:

- Explain the practical implications of clinical trial data on new technologies and techniques for endovascular repair of abdominal aortic aneurysm and thoracic aortic disease
- Summarize the impact of data on therapeutic advances for stroke and carotid disease management
- Compare the safety, efficacy, and therapeutic indications of pharmacologic agents to the management of vascular disease
- Assess data on the latest state-of-the-art for the treatment of superficial femoral and tibial artery disease and describe potential implications for clinical care
- Summarize recent data on treatment advances for venous disease and explain their clinical implications
- Provide new information about the latest developments in hemodialysis access and vascular malformations and tumors
TARGET AUDIENCE
Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists, Vascular Medicine Specialists and all others interested in the management of vascular disease.

ASSOCIATE FACULTY GLOBAL PODIUM PRESENTATIONS
In order to have more younger and less familiar vascular surgeons and vascular specialists play an active role as Associate Faculty at our meeting, we have initiated programs whereby they can present their scientific work at the podium. Vascular surgeons and vascular specialists participating in these programs will have submitted abstracts for a podium presentation, and these abstracts will be posted on our web site. Please visit our web site at www.veithsymposium.org for additional information and instructions on how to submit an abstract to the Associate Faculty Podium Presentations component of VEITHsymposium.

GENERAL SESSIONS
General Sessions will be held in the Grand Ballroom East, Grand Ballroom West, and in the Trianon Ballroom on the 3rd floor on Tuesday, Wednesday, Thursday, Friday and Saturday.

COMPONENT SESSIONS WILL BE HELD AS FOLLOWS:

Innovation and Investment Roundtable
Thursday, November 17, 2016
Location: Gramercy Suites East and West, 2nd floor

Hemodialysis Access
Saturday, November 19, 2016
Location: Grand Ballroom West, 3rd floor

AIMsymposium Multidisciplinary Acute Stroke Management
Thursday, November 17, 2016
Location: Murray Hill Suites East and West, 2nd floor

VEITHsymposium registrants are welcome to attend at no additional cost.

The VEITHsymposium Innovation and Investment (I&I) Roundtable, now in its third year, is a session dedicated to the presentation of novel medical products that have the potential to truly change patient care and the management of complex cardiovascular diseases. The presentations are by invitation only. Manufacturers and their topics are chosen by the VEITHsymposium Organizing Committee based upon knowledge of unique products that are at various stages of development. The roundtable session provides opportunities for manufacturers to showcase technology that, in many cases, will require further investment to complete development and clinical research. Similarly, the session provides an interactive setting for investors and investment firms to see novel technologies and probe the challenges and potential for each, with ample time for question and answer period that follows each presentation. Lastly, key cardiovascular thought leaders, physicians and scientists alike, are invited by the Organizing Committee to be in attendance and provide candid views on each innovation.

The VEITHsymposium Organizing Committee believes that the I&I Roundtable offers a unique opportunity to see the latest in novel, game-changing cardiovascular technology, all in one place and over the course of a half-day. This is an event that should not be missed by anyone with scientific or financial interests in emerging cardiovascular technology. (This is a non-CME activity.)
VENOUS VENOUS VENOUS WORKSHOPS AT VEITHsymposium

Wednesday, November 16, 2016
1:00 P.M. - 6:00 P.M.

Location: Americas Hall II, 3rd floor

Workshops will include lectures and demonstrations on vein management by experts, and hands-on opportunities where participants can rotate through multiple training stations staffed by faculty.

Registration Fee: $25 (available to fully paid VEITHsymposium Clinicians). Space is Limited.

Module 1: Superficial Truncal Disease Treatment - Thermal EVLA, RFA, PAPS

Module 2: DVT Treatment IVUS, Thrombolysis, Stents, Difficult Recanalizations, Oral Anticoagulation

Module 3: Superficial Cluster Vein Treatment Ambulatory Phlebectomy, TIPP, Sclerotherapy

Module 4: Diagnosis/Medical Treatment Duplex Imaging, Compression Bandaging, Lymphedema Massage

Module 5: Superficial Truncal Disease Treatment - Non-Thermal Mechanochemical Ablation, Cyanoacrylate Adhesive, Foam Sclerotherapy

Visit www.veithsymposium.org for details.

This activity has been approved for AMA PRA Category 1 Credits™.

ACCREDITATION STATEMENT

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 48 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

ABS MAINTENANCE OF CERTIFICATION

VEITHsymposium provides Category 1 CME and self-assessment credits toward Part 2 of the ABS MOC Program.

CME CERTIFICATES AND COURSE EVALUATION FORMS

CME certificates will be available online at www.veithsymposium.org. An e-mail with a unique password and instructions on how to obtain the certificate and complete a brief, optional course evaluation will be sent to all registered attendees after the meeting. The e-mail will be sent to the e-mail address that was used to register the attendee. Please note that CME Certificates must be claimed by February 28, 2017.

FACULTY DISCLOSURE

The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.
A block of rooms has been reserved at the conference rate of $399 plus taxes per night. This rate is available until the block is filled or until October 9, 2016. Please request the VEITH rate when reserving your accommodations.

New York Hilton-Midtown (Symposium Site)
1335 Avenue of the Americas
New York, NY 10019
(212) 586-7000 or 1-800-HILTONS (toll free U.S. only)
American Express Global Business Travel at The Cleveland Clinic
Phone: (800) 955-6111, prompt #5 (U.S. toll free)
(216) 444-2564 (U.S. and International)
Fax: (623) 748-4341
E-mail: Diane.M.Geneva@aexp.com

First Hand Tickets
The love of live entertainment is what drives us. Specializing in hard to find, and sold out events - our mission is to get everyone a great seat. With a seasoned staff, we guarantee to exceed your expectations. Most importantly we ensure a safe and friendly transaction. At First Hand Tickets we are proud to be the leading Ticket Agency in New York focusing in all Sports, Theater and Concert events around the world. From single tickets to large groups, we will accommodate your needs with professionalism and attention to detail. Experience a new level of entertainment with First Hand Tickets.

For more information or to arrange your social events while at VEITHsymposium, please contact:
Warren Schreiber at wschreiber@firsthandtickets.com
Zach Schreiber at zschreiber@firsthandtickets.com
Phone: 516-376-8092 or (866) 375-7591

ADA STATEMENT
The Cleveland Clinic Foundation Center for Continuing Education complies with the legal requirements of the Americans with Disability Act. If any participant of the VEITHsymposium requires special assistance, please send written request at least one month prior to the activity to admin@veithsymposium.org, or by fax to (845) 368-2324.

ONLINE CONFERENCE LIBRARY
The entire program with almost all the talks, slides, audio and videos - fully synchronized - and the panels, will be available in an Online Conference Library, which can be obtained at a nominal cost. For more information on how to obtain the VEITHsymposium Online Library, please visit www.veithondemand.com or call (800) 987-9314, ext. 300.

ONLINE ACCESS TO ABSTRACTS
Presentation slides will be used as abstracts and will be available on the program page of the VEITHsymposium web site at www.veithsymposium.org after the meeting. Abstracts will be available on the web site for one full year.
TUESDAY SESSION 1

6:00 A.M. General Registration – Rhinelander Gallery, 2nd Floor
6:00 A.M. Faculty Registration – Morgan Suite, 2nd Floor
6:15 A.M. Continental Breakfast – Rhinelander Gallery, 2nd Floor

CONCURRENT TUESDAY PROGRAMS

PROGRAM A: SESSIONS 1-8
Heart Valves, Aortic And Carotid Diseases And Their Treatment
6:45 A.M. – 6:02 P.M.
Grand Ballroom East, 3rd Floor

PROGRAM B: SESSIONS 9-16
New Developments In AAAs, EVAR, Aortic Branch Lesions (Including Iliac, Visceral And Renal Arteries), Outpatient Issues, Laparoscopic Techniques, Complex AAAs, New Techniques And Open Or Hybrid Vascular Surgery
6:40 A.M. – 5:58 P.M.
Grand Ballroom West, 3rd Floor

PROGRAM C: SESSIONS 17-18 (PART 1)
Management Of Pulmonary Embolism: Do We Know Enough
7:00 A.M. – 12:00 P.M.
Trianon Ballroom, 3rd Floor
Course Leader: Michael R. Jaff, DO

PROGRAM C: SESSIONS 19-22 (PART 2)
New Developments In The Management Of Acute And Chronic Large Vein Occlusion
1:00 P.M. – 5:45 P.M.
Trianon Ballroom, 3rd Floor
Course Leader: Kenneth Ouriel, MD, MBA

PROGRAM A (SESSIONS 1-8)
PROGRESS IN VALVE, AORTIC AND CAROTID DISEASES AND THEIR TREATMENT
Grand Ballroom East, 3rd Floor

Opening Remarks
Frank J. Veith, MD

SESSION 1 (Grand Ballroom East, 3rd Floor)
PROGRESS IN TRANSCATHETER HEART VALVES AND NEW APPROACHES TO ASCENDING AORTIC DISEASE
Moderators: Nicholas J.W. Cheshire, MD
Hazim J. Safi, MD

Current Status Of Transcatheter Aortic Valve Implantation (TAVI): A Cardiac Surgeon’s Perspective
Allan Stewart, MD

Current Status Of TAVI And What Is Beyond The Sapien And Core Valves: An Interventional Cardiologist’s Perspective
Dietmar H. Koschyk, MD

Transcatheter Mitral Valve Repair: Current Status And Devices
Lars G. Svensson, MD, PhD
ASCENDING AORTIC ENDOGRAFTING

7:08 – 7:13 Early Experience With Gore Endovascular Device For Type A Dissections: Advantages And Limitations
Michael J. Reardon, MD

7:14 – 7:19 Current And Future Role Of Endovascular Grafts For The Ascending Aorta And Aortic Root
Grayson H. Wheatley, MD

7:20 – 7:25 Advances And Limitations With Endograft Treatment Of Ascending Aortic Lesions
Ali Khoynezhad, MD, PhD

7:26 – 7:31 Promises And Current Limitations Of Ascending Aortic Endograft Treatment
Ralf R. Kolvenbach, MD

7:32 – 7:37 Progress With Ascending Aortic Endograft Treatment: What Lesions, Indications, Techniques And Results
Rodney A. White, MD
Carlos E. Donayre, MD

7:38 – 7:43 Panel Discussion

SESSION 2 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN TREATMENT OF AORTIC ARCH LESIONS AND AORTIC DISSECTIONS
Moderators: Lars G. Svensson, MD, PhD
Timothy A.M. Chuter, DM

Joseph S. Coselli, MD
Ourania Preventza, MD

7:50 – 7:55 Status Of Open Repair For Complicated Type B Aortic Dissections (TBADs): It Is Still The Best Treatment If Certain Conditions Apply
Hazim J. Safi, MD
Anthony L. Estrera, MD

7:56 – 8:01 Hybrid Repair Of Aortic Arch Aneurysms And Dissections Is The Best Treatment Option In Fit Patients
Roberto Chiesa, MD
Germano Melissano, MD

8:02 – 8:07 Hybrid Approaches To Aortic Arch Lesions: What Is Their Role And Value
Eric E. Roselli, MD

8:08 – 8:13 Endovascular Arch Repair After Open Repair Of Type A Aortic Dissection (TAAD): Indications, Precautions And Results
Stephan Haulon, MD

8:14 – 8:19 Techniques For And Long-Term Results Of Treating Zone 0 Aortic Arch Lesions Endovascularly: Including The Use Of Bolton's Branched TEVAR Device
Toru Kuratani, MD, PhD

8:20 – 8:25 Thoracic Single Endobranch Endograft (Gore TAG) For Treating Arch Aneurysms In Zones 0, 1 And 2: Technique, Advantages, Limitations And Early Results
Michael D. Duke, MD
Michel Makaroun, MD

8:26 – 8:31 Update On Mona LSA Single Branched Graft (Medtronic) For Revascularization Of The Left Subclavian Artery With TEVAR: Advantages And Results
Frank R. Arko, MD
Eric E. Roselli, MD
Endovascular Treatment Of Aortic Arch Lesions With Chimney Grafts And The Nexus Fenestrated Endograft
Mario L. Lachat, MD
Nicola Mangiardi, MD

Tips And Tricks To Make Chimney TEVAR (Ch/TEVAR) In The Aortic Arch Successful
Chang Shu, MD

Panel Discussion

SESSION 3 (Grand Ballroom East, 3rd Floor)
TYPE B AORTIC DISSECTIONS (TBADs) AND THEIR TREATMENT: INCLUDING SECONDARY THORACOABDOMINAL ANEURYSMS (TAAAs)
Moderators: Joseph S. Coselli, MD Michael D. Dake, MD

New Developments In The Treatment Of TBADs: Where Are We Headed
Christoph A. Nienaber, MD, PhD

Best Medical Treatment For Uncomplicated TBAD: Factors Predicting Need For TEVAR And Significance Of Aortic Arch Tears
Santi Trimarchi, MD, PhD

 predictors Of Need For Intervention (TEVAR, Etc.) And Mortality With Uncomplicated Acute TBAD: Total Aortic Diameter >44 mm Matters Most
Ali Azizzadeh, MD
Anthony L. Estrera, MD
Hazim J. Safi, MD

Natural History Of TEVAR Treated TBADs: One-Third Of TEVAR Treated Patients Don’t Remodel And Develop Aneurysms – Usually In Thoracic Aorta: How To Treat And Prevent Rupture
Tilo Kölbel, MD, PhD
Sebastian E. Debus, MD, PhD

Advantage Of The 2-Component Petticoat System: Overdilatation Of The Bare Stent Can Disrupt The Dissection Flap And Facilitate Distal False Lumen Obliteration Improving Outcomes With Acute TBADs: Technique And Results
Jean-Marc Alsac, MD, PhD

Disadvantages Of The Petticoat Technique: Why It May Not Be Beneficial
Ludovic Canaud, MD, PhD

Tips And Tricks To Avoid Pitfalls In The TEVAR Treatment Of TBADs
Weiguo Fu, MD

Open Surgery Is The Best Treatment For Thoracoabdominal Aneurysms (TAAAs) Complicating TBADs
Michael J. Jacobs, MD
9:51 – 9:57 Panel Discussion
9:58 – 10:10 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 4 (Grand Ballroom East, 3rd Floor)
MORE ABOUT NEW DEVELOPMENTS IN THE TREATMENT OF TBADs AND RELATED ENTITIES

Moderators: Christoph A. Nienaber, MD, PhD
Frank J. Veith, MD

10:10 – 10:15 Natural History Of Penetrating Ulcers In The Thoracic Aorta: When Should They Be Treated Conservatively And When By TEVAR
Thomas C. Bower, MD

10:16 – 10:21 Natural History Of Intramural Hematomas In The Thoracic Aorta: When Should They Be Treated Conservatively And When By TEVAR
Santi Trimarchi, MD, PhD

10:22 – 10:27 How To Follow TBAD Patients On Medical Treatment And After TEVAR: What Secondary Interventions May Be Required And When
Götz M. Richter, MD, PhD

Rachel E. Clough, MD, PhD

10:34 – 10:39 DEBATE: When Performing TEVAR For Acute Uncomplicated TBAD, The Procedure Should Be Delayed 2-12 Weeks (~6 Weeks) After The Event To Decrease Chances Of Retrograde Dissection
Matt M. Thompson, MD

10:40 – 10:45 DEBATE: It Is Safe To Perform TEVAR For Uncomplicated TBAD Within <2 Weeks Of The Acute Event If Certain Precautions Are Taken
Jan S. Brunkwall, MD, PhD

10:46 – 10:51 4-Year Results With Bolton Relay Graft For TEVAR And New Modifications Of The Platform Including Proximal And Distal Scallops And Ways To Prevent Proximal Migration
Vicente Riambau, MD, PhD

10:52 – 10:57 Why Patients With TBAD Can Benefit From Dissection Flap Disruption (Septotomy): How It Can Be Done Safely And A Device To Do It
Ramon Berguer, MD, PhD
Juan C. Parodi, MD

10:58 – 11:04 Panel Discussion
Moderators: Hazim J. Safi, MD
Roberto Chiesa, MD

11:04 – 11:09 There Is No Such Thing As A Chronic TBAD: Why Our Thinking And Nomenclature Should Change
Firas F. Mussa, MD

11:10 – 11:15 Staged Hybrid Procedure (Proximal TEVAR And Open Distal TAAA Repair) Is A Better Way To Treat TBAD With Extensive TAAA: Technique, Advantages And Limitations
Gilbert R. Upchurch, MD

11:16 – 11:21 False Lumen Outflow Resistance As A Predictor Of The Need For Late Reintervention With Uncomplicated TBAD: How To Measure And What To Do With This Measurement
Geert Willem H. Schurink, MD, PhD
Michael J. Jacobs, MD
SESSION 4 – 5

11:22 – 11:27
Expanding Midterm Experience With Fenestrated And Branched EVAR (F/BEVAR) For TAAAs From Chronic TBADs: Advantages And Limitations
Eric L.G. Verhoeven, MD, PhD
Piotr M. Kasprzak, MD

11:28 – 11:33
TEVAR Endografts For TBADs Can Cause New Distal Entry Tears: How To Detect And Treat Them
Chun-Che Shih, MD, PhD

11:34 – 11:39
Application Of Occlusive Devices In The Endovascular Treatment Of Difficult Aortic Lesions (Dissections And False Aneurysms) Unsuitable For Endograft Repair
Guangqi Chang, MD

11:40 – 11:45
Peripheral Vascular Complications Of TEVAR And TAVI: How To Prevent And Treat Them
Ali Khoynezhad, MD, PhD

11:46 – 11:51
What Proportion Of Strokes With TEVAR Are Due To Air Emboli And Not Particulate Emboli: CO2 Flushing Of Devices Can Prevent Air Embolic Strokes
Tilo Kolbel, MD, PhD
Sebastian E. Debus, MD, PhD

11:52 – 12:00
Panel Discussion

12:00 – 1:00
Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 5 (Grand Ballroom East, 3rd Floor)
NEW KEY DEVELOPMENTS IN THE MANAGEMENT OF PATIENTS WITH CAROTID DISEASE
Moderators: Frank J. Veith, MD
Klaus D. Mathias, MD

1:00 – 1:05
Endovascular Repair Of Saccular Aneurysms Of The Extracranial Internal Carotid Artery Is No Longer Hazardous But Fusiform Aneurysms Remain A Challenge: Tips And Tricks: Long-Term Results
James May, MD, MS

1:06 – 1:11
Value Of OCT And IVUS Evaluation Before And After CAS: How Can They Improve Results
Bernhard Reimers, MD

1:12 – 1:17
Optimal Medical Management To Decrease Cardiovascular And Stroke Risk As In The SAMMPRIS Trial: It Is Not Simple And Requires Training: How To Do It And What Are The Treatment Goals
Colin P. Derdeyn, MD

1:18 – 1:23
Despite Level I Evidence To The Contrary, Patches Are Not Always Necessary With CEA And Patches Can Cause Serious Complications: How To Avoid Patch Closures
Robert B. McLaugherty, MD

1:24 – 1:29
With High-Grade Asymptomatic Carotid Stenosis (ACS) There Is A Low Rate Of Occlusion And Stroke In Patients On Current Best Medical Therapy (BMT)
J. David Spence, MD

1:30 – 1:35
DEBATE: The 10-Year CREST Trial Results Indicate That CAS Is Equivalent To CEA In Both Symptomatic And Asymptomatic Carotid Stenosis Patients
Thomas G. Brott, MD
Brajesh K. Lal, MD

1:36 – 1:41
DEBATE: Not So Fast: There Are Other Ways To Interpret The 10-Year Results From CREST
J. David Spence, MD
How Best To Manage Acute Carotid Occlusion After CEA: Why Endovascular Treatment Can Be The Best Option
Alejandro M. Spiotta, MD

Panel Discussion
Moderators: Claudio J. Schonholz, MD
L. Nelson Hopkins, MD

DEBATE: 5-Year Results From The ACT-1 Trial Show That CAS Is Equivalent To CEA For Asymptomatic Carotid Stenosis (ACS)
Kenneth Rosenfield, MD
Jon S. Matsumura, MD

DEBATE: Not So Fast: There Is Another Interpretation To ACT-1: It Does Not Change Current Evidence That BMT Alone Is Best For Asymptomatic Carotid Stenosis
Anne L. Abbott, MD, PhD

Systemic Biomarkers Can Predict The Stroke Risk Of Carotid Plaques And Cognitive Decline After CEA And CAS: Are There Differences Between The 2 Procedures
Wei Zhou, MD

DEBATE: How To Identify Those ACS Patients Who Can Benefit From An Invasive Intervention (CEA Or CAS): What Is That Percentage Of ACS Patients
Andrew N. Nicolaides, MS

DEBATE: The Rationale For A Differing Viewpoint: What Percentage Of ACS Patients Should Be Treated Invasively And Why CEA Is The Best Treatment
Bruce A. Perler, MD, MBA

In Light Of The 10-Year CREST Results And The 5-Year ACT-1 Results, How Should We Regard The Future Of CAS For Symptomatic And Asymptomatic Carotid Stenosis Patients: A UK And European Perspective
Ross Naylor, MD

In Light Of The 10-Year CREST And 5-Year ACT-1 Results How Should We Regard The Future Of CAS For Symptomatic And Asymptomatic Carotid Stenosis: A US Perspective
Jon S. Matsumura, MD

Panel Discussion

Emergency Management Of Acute Strokes: What Can Be Done Intracranially And At the Carotid Bifurcation: How To Do CAS Safely In The Acute Setting
Klaus D. Mathias, MD

Set Up Of An Organization Within A Hospital To Treat An Acute Stroke: To Determine If Intervention At Carotid Or Intracranial Levels Is Appropriate And To Do So Rapidly
Luigi Inglese, MD
Update On Positive Randomized Controlled Trials (RCTs) Of Intracranial Clot Removal For Stroke: How To Select Patients Currently: Should Indications Be Broadened And Ongoing RCTs
L. Nelson Hopkins, MD

Improvements In Intracranial Clot Removal By Direct Aspiration For Acute Strokes: Technique, Equipment And Results: What Does The Future Hold For Stroke Endovascular Therapy
Alejandro M. Spiotta, MD

Advantages Of Direct Carotid Access (Percutaneous Or By Open Exposure) For Acute Ischemic Stroke Intervention At Carotid Or Intracranial Levels
Mark H. Wholey, MD

URGENT CAROTID TREATMENT (SEE SESSION 75 FOR MORE RELATED TOPICS)

DEBATE: Urgent CEA Within 1 Week After A Stroke Or TIA Is Relatively Safe Whereas Urgent CAS Is Generally Not Safe
Gustav Fraedrich, MD

DEBATE: CEA Within 48 Hours Of Symptom Onset Is Not Safe: Best To Delay CEA For Two Weeks But The Evidence Is Mixed
Martin Björck, MD, PhD

Urgent Carotid Interventions For Acute Stroke: CEA vs. CAS: When And When Not To Intervene: CT Perfusion Studies Can Help In Decision Making
Hernan Bazan, MD

DEBATE:

Panel Discussion

SESSION 7 (Grand Ballroom East, 3rd Floor)
MORE NEW DEVELOPMENTS IN TEVAR, TAAA AND TBAD TREATMENTS
Moderators: Mark A. Farber, MD
Stephan Haulon, MD

Update On Embolic Brain Protection Devices And Techniques During TEVAR And TAVI: Do They Prevent Strokes Or DW-MRI Hits And When Will They Be Available In The US
Jeffrey P. Carpenter, MD

Value Of TEVAR In Treating Chronic TBADs And Associated Aneurysms: It May Prevent Death But Often Requires Reintervention: How Can The Latter Be Prevented
Matt M. Thompson, MD

Advanced CTAG Designs For Treating Complex Thoracic Aortic Lesions Close To The Arch Or With Tortuous Anatomy By TEVAR
William J. Quinones-Baldrich, MD

Panel Discussion

ADVANCES IN TREATMENT OF TAAAs

Value Of Branched Endografts (From Cook) For Treating TAAAs: Lessons Learned, Long-Term Results, Advantages And Limitations
Timothy A.M. Chuter, DM

Value And Limitations Of Sandwich Grafts For Treating TAAAs: Technical Tips
Armando C. Lobato, MD, PhD
Gore Multibranched Tambe Off-The-Shelf (OTS) Device For Treating TAAAs: Technique And Early Experience
Michel Makaroun, MD
Gustavo S. Oderich, MD
Mark A. Farber, MD

Valiant TAAA Device From Medtronic: Based On A Manifold Principle With Multiple Branches To Visceral, Renal And Iliac Arteries: Concept And Early Results With A Potentially OTS Device
Patrick W. Kelly, MD

When Should Endovascular Treatments Be Used With Marfan’s Patients And When Should They Not Be Used
Oourania Preventza, MD
Joseph S. Coselli, MD

Panel Discussion

SESSION 8 (Grand Ballroom East, 3rd Floor)
CONTROVERSY SURROUNDING TEVAR TREATMENT OF UNCOMPPLICATED TBADs; OTHER TBAD AND TAAA TOPICS & ONE CAROTID TOPIC
Moderators: Carlos H. Timaran, MD
Matt M. Thompson, MD

Why Is There Such Disagreement On TEVAR Treatment For Uncomplicated TBAD
Frank J. Criado, MD

DEBATE: Most Uncomplicated TBAD Patients Should Undergo TEVAR Since TEVAR Often Leads To False Lumen Thrombosis And Stability: We Do Not Need Further RCTs
Christoph A. Nienaber, MD, PhD

DEBATE: Not So, Many Uncomplicated TBAD Patients Should Be Treated Medically: TEVAR Treatment Should Be Selective And We Need More Trials
Michel Makaroun, MD

Why We Need Another Trial Comparing Medical Treatment Alone To Medical Treatment With Early TEVAR For Uncomplicated TBAD: What Is The Status Of Such A Trial
Firas A. Mussa, MD

What Are The In-Hospital Complications That Occur In Medically Treated Uncomplicated TBAD Patients (From IRAD): Can They Be Predicted And Do We Need More RCTs Examining Value And Timing Of TEVAR
Santi Trimarchi, MD, PhD

When Is Early TEVAR Indicated In Uncomplicated TBAD; What Are The Risks
Dittmar Böckler, MD

Why Shouldn’t All Acute TBAD Patients Be Treated With TEVAR: What Is The Best Timing For The Procedure And How To Distinguish Between “Acute” And “Chronic” TBAD
Johnny Steuer, MD, PhD

DEBATE: Long-Term Results Of Open Repair Of TAAAs: When Is Open Repair The Best Treatment And Who Should Be Doing It
Hazim J. Safi, MD
DEBATE: Long-Term Results Of Endovascular Repair Of TAAAs: When Is Open Repair Indicated
Matthew J. Eagleton, MD

Age, Contralateral ICA Occlusion And Time Since Symptom Onset Are Not Contraindications For CAS If Certain Precautions Are Taken
Horst Sievert, MD

Panel Discussion
End of Program A

PROGRAM B (SESSIONS 9-16)
NEW DEVELOPMENTS IN AAAs, EVAR, AORTIC BRANCH LESIONS, OUTPATIENT ISSUES, LAPAROSCOPIC TECHNIQUES, COMPLEX AAAs, NEW TECHNIQUES AND OPEN OR HYBRID VASCULAR SURGERY
Grand Ballroom West, 3rd Floor

SESSION 9 (Grand Ballroom West, 3rd Floor)
NEW DEVELOPMENTS IN AAAs AND EVAR
Moderators: Enrico Ascher, MD Ali F. AbuRahma, MD

Indications For Open AAA Repair In The Current Advanced Endovascular Era
Dittmar Böckler, MD

All AAA Patients Who Need Invasive Treatment Should Be Treated By EVAR If They Have Suitable Anatomy: This Includes Young Patients: This Is Why
Mark Conrad, MD, MMSc

Propensity Matched Comparison Of EVAR vs. Open Repair In A Large US Medicare Database Show EVAR Benefits Up To 7 Years Later: Nevertheless, Open Repair Is Indicated In Young AAA Patients: This Is Why
Marc L. Schermerhorn, MD

Interesting Insights From The RCTs Comparing EVAR To Open Repair After 12-15 Years Of Follow-Up: EVAR Benefits Are Not Durable And Reinterventions Continue To Be Needed
Jan D. Blankensteijn, MD

Long-Term Results Of EVAR With Standard AAA Endografts: How Do These Results Differ From Those In The EVAR RCTs And Why
Timur P. Sarac, MD

Are Advantages Of Lower AAA Related Mortality From EVAR vs. Open Repair Sustained Better With New Generation Devices: A Critical Comparison Of EVAR 1 vs. The ENGAGE Registry
Dittmar Böckler, MD

Panel Discussion
Moderators: Timur P. Sarac, MD Gregg S. Landis, MD

How To Enable EVAR To Be Done For AAAs With Neck Diameters >36 mm: A Combination Of An Endologix AFX Endograft And A Larger Diameter Valiant Tube Graft Makes It Feasible
Jean-Paul de Vries, MD, PhD
7:33 – 7:38 Value Of Hypnosis For EVAR And Other Endovascular Procedures 'To Make Them Even Less Invasive: How To Do It
Jean-Pierre Becquemin, MD

7:39 – 7:44 How Are Long-Term EVAR Outcomes Impacted By Extremely Angled Necks, Conical Necks, And Necks With Circumferential Thrombus: It Doesn't Seem To Matter If . . . Hence J.M. Verhagen, MD, PhD

7:45 – 7:50 Current Optimal Management Of Inflammatory AAAs: When Endo, When Open
Franco Grego, MD

7:51 – 7:56 Inflammatory AAAs: Open vs. Endo Treatment And Tips And Tricks For Safely Treating With Open Repair
Kenneth J. Cherry, MD

7:57 – 8:02 EVAR Techniques For Inflammatory AAAs And Other Rare AAAs Including Behçet's Disease: How Effective And Durable Are They
Furuzan Numan, MD

8:03 – 8:09 Panel Discussion

SESSION 10 (Grand Ballroom West, 3rd Floor)
NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC BRANCH LESIONS – ESPECIALLY OF THE AORTO-ILIAC SEGMENT
Moderators: Kenneth Ouriel, MD, MBA
Barry T. Katzen, MD

8:09 – 8:14 What Proportion Of Aorto-Iliac Lesions Require Open Treatment: Tips And Tricks For Treating Endo
Ali Amin, MD, RVT

8:15 – 8:20 Endovascular Treatment Of Juxtarenal Aortic Occlusions: Technique Of Treatment And Renal And Visceral Protection: Midterm Results
Sonia Ronchey, MD, PhD
Nicola Mangialardi, MD

8:21 – 8:26 3-Year Results With The CERAB Procedure For Stent-Graft Reconstruction Of The Occluded Aortic Bifurcation: Technical Precautions, Advantages And Limitations
Michel M.P. Reijnen, MD, PhD
Peter C.J. Goverde, MD

8:27 – 8:32 How Can Chimney Grafts Be Used Effectively With The CERAB Procedure: Techniques And Results
Peter C.J. Goverde, MD
Michel M.P. Reijnen, MD, PhD

8:33 – 8:38 Endologix AFX EVAR Endograft For The Treatment Of Complex Aorto-Iliac Occlusive Disease: When Is It Indicated, How To Perform And Early Results
Thomas S. Maldonado, MD

8:39 – 8:44 Is There Still A Role For Open Aortofemoral Bypass For Aorto-Iliac Occlusive Disease: What Is It And Why
Michael Belkin, MD

HYPOGASTRIC ARTERY ISSUES

8:45 – 8:50 At What Size Do Hypogastric Artery Aneurysms Rupture: At What Size Is Repair Indicated: Textbook Indications For Repair Should Change
Maarit Venermo, MD, PhD
What Should Be Done About Hypogastric Aneurysms Excluded Only Proximally By Overstenting: At What Size Should Something Else Be Done And What Is That Something
Frans L. Moll, MD, PhD

Comparison Of Available Iliac Branched Devices (IBDs) For Iliac Aneurysms And Hypogastric Revascularization: Advantages And Limitations Of Each
Timothy A. Resch, MD, PhD

Panel Discussion

Break - Visit Exhibits And Pavilions (2nd and 3rd Floors)

With New Developments In Laparoscopic Robotic Aortic Surgery, It May Still Have A Real Role In Vascular Treatment: Unlike My Impression Last Year
Willem Wisselink, MD

Advances In Laparoscopic Robotic Surgery Indicate It Has A Bright Future For Treating Aortic And Visceral Artery Disease: How The Gore Hybrid Graft Facilitates This
Fabien Thaveau, MD, PhD

Laparoscopic Aorto-Bifemoral Bypass: Indications And Advantages In An Endovascular World
Joseph S. Giglia, MD

Laparoscopic Aortic Surgery Has More Adverse Events Than Open Aortic Surgery: A Propensity Matched Comparison With Well-Trained Laparoscopic And Open Surgeons
Jean-Baptiste Ricco, MD, PhD

Endovascular Retroperitoneoscopic Technique Offers New Possibilities For Laparoscopic Aorto-Bifemoral Bypass In Complex TASC D Aorto-Iliac Lesions
Bernard J. Segers, MD

Comparison Of AAA Sac Shrinkage After Fenestrated EVAR (F/EVAR) And Standard EVAR: F/EVAR Wins
Neal S. Cayne, MD

Comparison Of Open Surgery, Hybrid Techniques And Fenestrated Or Branched EVAR (F/BEVAR) For TAAAs
Piergiorgio Cao, MD

False Lumen Obliteration In Chronic TBADs Using An Inverted (“Flipped”) Cook Converter And Occlusion Plug
Niten Singh, MD

Panel Discussion
SESSION 12 (Grand Ballroom West, 3rd Floor)
NEW DEVELOPMENTS WITH JUXTA AND PARARENAL AORTIC ANEURYSMS AND THORACOABDOMINAL ANEURYSMS (TAAAs)
Moderators: Kim J. Hodgson, MD
Giavanni Torsello, MD

10:20 – 10:25
Current Status Of The Only FDA Approved Fenestrated Graft (ZFEN From Cook) That Is Commercially Available In The US: How Is Its General Adoption Doing
Andres Schanzer, MD

10:26 – 10:31
With ZFEN F/EVAR, A Large SMA Scallop Can Cause Problems: What Are They And What Is The Solution
Carlos H. Timaran, MD

HOSTILE AAA NECKS

10:32 – 10:37
What Is A Hostile Infrarenal Neck And When Should F/EVAR Be Done Rather Than Standard EVAR
Matthew J. Eagleton, MD

10:38 – 10:43
When Can Standard EVAR Be Safely And Durably Performed In Patients With Hostile Necks
Hence J.M. Verhagen, MD, PhD

10:44 – 10:49
In Most AAA Patients With Hostile Necks F/EVAR Is The Best Treatment: What Are The Exceptions
Marcelo Ferreira, MD

10:50 – 10:55
In Most Patients With Hostile Necks Chimney EVAR (Ch/EVAR) Is The Best Treatment: What Are The Exceptions
Giovanni Torsello, MD
Konstantinos P. Donas, MD
Jason T. Lee, MD

10:56 – 11:01
When Does Hybrid Endovascular Repair With Renal And Visceral Debranching Have A Role In Treating TAAAs: Patient Selection And Technical Tips
Martin R. Back, MD

11:02 – 11:08
Panel Discussion
Moderators: James F. McKinsey, MD
Piergiorgio Cao, MD

F/EVAR FOR FAILED EVAR

11:08 – 11:13
Prevention Of Visceral And Renal Branch Artery Complications During F/BEVAR: Selection Of The Optimal Bridging Stent-Graft
Darren B. Schneider, MD

11:14 – 11:19
F/EVAR Cuffs vs. Ch/EVAR For Failed Standard EVAR: Indications, Advantages And Limitations Of Each
Bijan Modarai, PhD

11:20 – 11:25
F/EVAR For Failed Standard EVAR: When Is It Indicated And When Must Open Repair Be Done
Cherrie Z. Abraham, MD

11:26 – 11:31
Midterm Results Of Chimney Grafts For Pararenal AAAs: How To Make Them Work
Nicola Mangialardi, MD

11:32 – 11:37
Adjuncts To Improve Outcomes Of Treatment For Challenging (Juxta And Pararenal) AAAs: Parallel Grafts, Endoanchors, New Endografts, Better Imaging, Simulation: Are They All Essential Or Not
Isabelle van Herzeel, MD, PhD
23

11:38 – 11:43
Open Repair vs. Branched EVAR (B/EVAR) For Type IV TAAAs: When To Do Each And How Iliac Anatomy Influences Choice: B/EVAR Results
Andrea Stella, MD

11:44 – 11:49
The COLT Endograft System For Treatment Of TAAAs: A Novel Simplified Endograft System From Jotec: How It Works: What Makes It Different And Early Clinical Results
Piotr Szopinski, MD

11:50 – 12:00
Panel Discussion
12:00 – 1:00
Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 13 (Grand Ballroom West, 3rd Floor)
BUSINESS ISSUES, NEW CONCEPTS
Moderators: Richard J. Powell, MD
Enrico Ascher, MD

1:00 – 1:05
Value, Limitations And Abuses Of Outpatient Angio Centers: How To Limit Abuses
Stephen M. Bauer, MD

1:06 – 1:11
Massive Use Of Atherectomy In Outpatient Facilities Is Self-Serving And Does Not Help Patients
Dipankar Mukherjee, MD

1:12 – 1:17
What Is The Best Arterial Closure Device For Use In An Outpatient Setting: Incidence And Reasons For Failure And Technical Tips
Sam S. Ahn, MD, MBA

1:18 – 1:23
When Is Outpatient Treatment Justified For Peripheral Occlusive Lesions: Precautions And Techniques
Enrico Ascher, MD

1:24 – 1:29
How To Create A Medical Company Start-Up And Keep It: Creating A Corporation, Getting Funding, Value Of A Business Plan And More
Timothy K. Liem, MD, MBA

ISSUES AND NEW CONCEPTS

1:30 – 1:35
When Is Enough Enough With Endovascular Options: Why Open Surgery Will Never Die
Krishna Jain, MD

1:36 – 1:41
Endojunk And Its Management: What To Do With Materials Left In Situ Unintentionally During EVAR And TEVAR
Ramesh K. Tripathi, MD

1:42 – 1:47
The Piculet Recanalization Device For Crossing Difficult CTOs: How It Works And When Is It Indicated
Yann Gouëffic, MD, PhD

1:48 – 1:53
Intraoperative Arterial Quantitative Flow Measurements With The Medistem Vascular Flow Device: How Does It Work And Can It Help With Intraoperative Decisions And Postoperative Assessment
Tej M. Singh, MD, MBA

1:54 – 2:00
Panel Discussion
2:00 – 2:05 Value Of Phoenix 2.2 mm Atherectomy System (From Volcano) In Treating Lower Extremity Occlusive Lesions: It Cuts, Captures And Clears In 1 Step: How Does It Work And Early Results
Luis R. Leon, MD, RVT

Kenneth J. Cherry, MD

2:12 – 2:17 How To Make Thrombolysis More Precise And Effective With Microbubbles And EKOS Catheters: Results In Humans From The MUST Trial
Kak Khee Yeung, MD, PhD

2:18 – 2:23 Value Of Ultrasound In The Operating Room In Planning, Access, Control Of Angioplasty Above And Below The Knee (BTK) And Closure Of The Puncture Site
Enrique Puras, MD

2:24 – 2:29 Pioneering Techniques For The Endovascular Treatment Of Critical Upper Extremity Ischemia With Gangrene
Roberto Ferraresi, MD

2:30 – 2:35 Update On The Current Status Of Stem Cell And Bone Marrow Therapy For CLI And Gangrene With Unfixable Distal Arteries
Richard J. Powell, MD

2:36 – 2:41 Two Techniques To Facilitate F/BEVAR: 1) The Up-And-Over Technique For Endoconduit Solutions With Bad Iliac Access Arteries And 2) Progressive Main Graft Deployment With Sequential Branch Catheterization And Stent-Grafting To Permit Staging And To Deal With Narrow Aortas
Carlos H. Timaran, MD

Rachel E. Clough, MD, PhD

2:48 – 2:53 Radial Access For Most Non-Coronary Interventions: Equipment, Techniques, Advantages, Risks And Limitations
Marcelo Guimaraes, MD

2:54 – 2:59 Value And Advantages Of The Chocolate Balloon PTA Catheter (TriReme/Cordis): Theory Of Its Pillows And Groove Technology And Clinical Results (The ENDURE Trial)
Jihad A. Mustapha, MD
Andrew Holden, MBChB

3:00 – 3:20 Panel Discussion And Break
Visit Exhibits And Pavilions (2nd and 3rd Floors)
SESSION 15 (Grand Ballroom West, 3rd Floor)
RENAL AND VISCERAL ARTERY ISSUES AND NEW DEVELOPMENTS

Moderators: Kim J. Hodgson, MD
Keith D. Calligaro, MD

3:20 – 3:25
Pancreaticoduodenal And Gastroduodenal Aneurysms: Indications And Precautions For Treatment And Which Is Best – Open vs. Endo
James C. Stanley, MD

3:26 – 3:31
Pancreaticoduodenal Aneurysms: Technical Tips And Tricks For Open Repair
Ronald M. Fairman, MD

3:32 – 3:37
Visceral Artery Aneurysms: When And At What Size Are They Dangerous And How Should They Be Fixed
Armando Mansilha, MD, PhD

3:38 – 3:43
With Visceral And Renal Artery Aneurysms An Endovascular First Strategy Is Best For All Intact And Ruptured Cases: Are There Exceptions
Rabih A. Chaer, MD

3:44 – 3:49
Incidence Of Embolization In Association With F/BEVAR: Is Late Renal Salvage After Renal Artery Occlusion Possible And What Is The Mechanism
James F. McKinsey, MD

3:50 – 3:55
DCBs (In.Pact Admiral) Are A Better Treatment For Renal In Stent Restenosis (ISR) And Fibromuscular Hyperplasia
Fabrizio Fanelli, MD

3:56 – 4:01
Remedial Operations For Failed Endovascular Treatments On Pediatric Renal Arteries
Jonathan L. Elinson, MD
James C. Stanley, MD

4:02 – 4:07
What Is The Best Current Treatment For Mesenteric Ischemia; When Endo, When Open, When Hybrid: Based On Outcomes
Timur P. Sarac, MD

4:08 – 4:13
Retrograde SMA Revascularization Via Celiac Artery And Collaterals When Antegrade Techniques Fail: Technical Tips
Timothy A. Resch, MD, PhD
Nuno Dias, MD

4:14 – 4:19
Variably Curved Conformable Sheaths (Oscor Twist) Make A Major Difference In Endovascular Procedures: Like SMA Stenting From A Femoral Approach And Fenestrated And Branched EVAR
Joshua D. Adams, MD
Claudio J. Schonholz, MD

4:20 – 4:25
The Renal Guard Device To Prevent Contrast Induced Renal Injury In High Risk Patients: How Does It Work And Is It Effective
Horst Sievert, MD

4:26 – 4:32
Panel Discussion
SESSION 16 (Grand Ballroom West, 3rd Floor)

TOPICS RELATED TO OPEN SURGERY AND AORTIC COARCTATIONS

Moderators: Fred A. Weaver, MD
             Ronald M. Fairman, MD

4:32 – 4:37 Status Of Balloon Expandable Stents And Stent-Grafts (Atrium V12 LD) For Treatment Of Aortic Coarctation: Results Of The COAST I And II Trials
             Elchanan Bruckheimer, MBBS

4:38 – 4:43 Long-Term Outcome Of Celiac Trunk Release For Celiac Axis Compression Syndrome: When Does The Artery Have To Be Treated And Open Surgery Is Best
             Jan D. Blankensteijn, MD

4:44 – 4:49 Open Surgery Is The Best Treatment For Coral Reef Lesions Of The Aorta And Visceral And Iliac Arteries: How To Diagnose Them And Why Endo Treatments Are No Good
             Laurent Chiche, MD

4:50 – 4:55 Tips And Tricks For Open Repair Of TAAAs As Primary Procedures And After Failed Endo Procedures: Including Use Of Sutureless Hybrid Graft (Gore) For Renal Revascularization
             Roberto Chiesa, MD
             Yamume Tshomba, MD

4:56 – 5:01 Indications For Open TAAA Repair In The Endovascular Era
             Hazim J. Safi, MD
             Anthony L. Estrera, MD

5:02 – 5:07 Role Of Ascending Aorta To Supra-Aortic Trunk Bypasses In The Endovascular Era: Technical Precautions And Tips
             John E. Rectenwald, MD, MS

5:08 – 5:14 Panel Discussion
             Moderators: R. Clement Darling III, MD
             James H. Black III, MD

5:14 – 5:19 Treatment Of Post TEVAR Aorto-Eosophageal Fistula: Only Radical Surgery Can Prevent Patient Mortality: Steps In The Operative Treatment
             Michael J. Jacobs, MD

5:20 – 5:25 Distal Aortic Failure After TEVAR: When Is Open Repair Best And Tips And Tricks To Do It
             James H. Black III, MD

5:26 – 5:31 What Is The Role Of Aorto-Bifemoral Bypass For Aorto-Iliac Occlusive Disease In The Current Endovascular Era
             Mr. Michael G. Wyatt, MD

             Carlo Setacci, MD

5:38 – 5:43 What Is The Role Of Open Surgical Distal Lower Extremity Bypass In The Current Endovascular Era
             R. Clement Darling III, MD

5:44 – 5:49 After Multiple Failed Endovascular Treatments, Open Bypasses Can Save Limbs
             Julien G. Sfeir, MD

5:50 – 5:58 Panel Discussion

End of Program B
PROGRAM C (PART 1 – SESSIONS 17-18)  
MANAGEMENT OF PULMONARY EMBOLISM: DO WE KNOW ENOUGH  
Trianon Ballroom, 3rd Floor  
Course Leader: Michael R. Jaff, DO

SESSION 17 (Trianon Ballroom, 3rd Floor)  
THE BASICS OF PE DIAGNOSIS AND TREATMENT  
Moderator: Michael R. Jaff, DO

7:00 – 7:10  
Introduction To The Symposium  
Frank J. Veith, MD

7:10 – 7:15  
Welcome And Introduction  
Michael R. Jaff, DO

7:15 – 7:25  
The Basics Of Pulmonary Embolism: What Is The Role Of The History, Exam, Biomarkers  
Raghu Kolluri, MD

7:25 – 7:35  
What Does The CT For PE Actually Tell Us  
Brian B. Ghoshhajra, MD, MBA

7:35 – 7:50  
What Is State-Of-The-Art Medical Therapy For PE  
Geno J. Merli, MD, MACP

7:50 – 8:00  
Just Tell Me What I Need To Know: When Do I Look For Cancer And Perform Hypercoagulable Tests In PE  
Rachel Rosovsky, MD, MPH

8:00 – 8:10  
Setting The Stage: The Emergency Physician Algorithm For Acute PE Management  
D. Mark Courtney, MD

8:10 – 8:25  
Intravenous Thrombolytic Therapy For PE: Does It Actually Work, And Safely  
Mitchell D. Weinberg, MD

8:25 – 8:35  
Catheter-Directed Thrombolysis For PE: What Are The Outcomes  
Divya Sridhar, MD

8:35 – 8:45  
Percutaneous Pharmacomechanical Intervention For PE: Is There A Rationale  
Gary M. Ansel, MD

8:45 – 9:15  
Case Presentations/Discussion/Questions and Answers  
Moderator: Michael R. Jaff, DO  
Panelists: Raghu Kolluri, MD, Brian B. Ghoshhajra, MD, MBA, Geno J. Merli, MACP, Rachel Rosovsky, MD, MPH, D. Mark Courtney, MD, Mitchell D. Weinberg, MD, Divya Sridhar, MD, Gary M. Ansel, MD

9:15 – 9:45  
Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 18 (Trianon Ballroom, 3rd Floor)  
ADVANCED INTERVENTIONAL TREATMENT FOR PE  
Moderator: Michael R. Jaff, DO

9:45 – 9:55  
Technical Tips For Pharmacomechanical Intervention For PE: How Do I Do It  
Tod C. Engelhardt, MD

9:55 – 10:05  
Pulmonary Embolism Intervention With Angiojet  
Jeffrey Y. Wang, MD

10:05 – 10:15  
Vortex Strategy For Massive PE  
Christopher J. Kwolek, MD
10:15 – 10:30 ECMO And Surgical Thromboembolectomy For Massive PE: When, How And Why
Georges M. Haidar, MD
Mark G. Davies, MD

10:30 – 10:45 What Is The Modern Algorithm For Management Of Massive And Submassive PE
Ido Weinberg, MD, MSc

10:45 – 11:00 Vena Cava Filters In PE Treatment: Do We Need To Do This, And If So, When
Amy R. Deipolyi, MD, PhD

11:00 – 11:15 Balloon Angioplasty For Chronic Thromboembolic Pulmonary Hypertension: Is This Crazy
Ehtisham Mahmud, MD

11:15 – 11:30 The Team Approach To PE Management: The Emergence Of National PERT Centers
Kenneth Rosenfield, MD

11:30 – 11:45 Challenging Cases And “PERT” Decisions
Moderator: Michael R. Jaff, DO
Panelists: Tod C. Engelhardt, MD
Jeffrey Y. Wang, MD
Christopher J. Kwolek, MD
Mark G. Davies, MD
Ido Weinberg, MD, MSc
Amy R. Deipolyi, MD, PhD
Ehtisham Mahmud, MD
Kenneth Rosenfield, MD

11:45 – 12:00 Questions and Answers

12:00 – 1:00 Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

PROGRAM C (PART 2 – SESSIONS 19-22)
NEW DEVELOPMENTS IN THE MANAGEMENT OF ACUTE AND CHRONIC LARGE VEIN OCCLUSION
Trianon Ballroom, 3rd Floor
Course Leader: Kenneth Ouriel, MD, MBA

SESSION 19 (Trianon Ballroom, 3rd Floor)
THE RECENT EXPLOSION IN VENOUS INTERVENTIONAL TECHNOLOGIES: NEW OPPORTUNITIES FOR THE PATIENT
Moderators: Kenneth Ouriel, MD, MBA
Peter Gloviczki, MD

1:00 – 1:05 The Transformation Of Venous Therapy: From Observation, Stockings And Medicines To Endovenous Interventions And Beyond
Peter Gloviczki, MD

1:06 – 1:11 Natural History Of Iliofemoral Venous Thrombosis: Does It Justify Aggressive Intervention? Which Patients And When?
Nicos Labropoulos, BSc (Med), PhD, DIC, RVT

1:12 – 1:17 Diagnostic Biomarkers In Venous Thromboembolism
Thomas W. Wakefield, MD

1:18 – 1:23 The Failing And Failed AV Access: Routine Interrogation Of The Central Veins With IVUS
Rick De Graaf, MD, PhD

1:24 – 1:29 When And How To Treat Iliofemoral Venous Obstruction Continuing Into The IVC
David L. Gillespie, MD

1:30 – 1:35 Office-Based Venous Stenting For Octogenarians
Anil P. Hingorani, MD
1:36 – 1:41 Chronic Venous Ulcers: Diagnostic And Therapeutic Strategies To Improve Outcome  
Manj S. Gohel, MD

1:42 – 1:47 Gaging Outcome After Venous Interventions: Anatomy Isn’t Everything, Current And New Quality Of Life Measures  
Cees H.A. Wittens, MD, PhD

1:48 – 1:53 Recent Approval Of Payment For Outpatient IVUS: Has It Driven Changes In Practice Patterns  
Sean P. Roddy, MD

1:54 – 1:59 Panel Discussion

SESSION 20 (Trianon Ballroom, 3rd Floor)
ACUTE DVT: ENDOVASCULAR INTERVENTIONS AND PHARMACOLOGIC REGIMENS

Moderators: Anthony J. Comerota, MD  
Gerald J. O’Sullivan, MD

2:00 – 2:05 What Is The Proper Duration Of Anticoagulation For DVT  
Anthony J. Comerota, MD

2:06 – 2:11 Thrombolysis For Acute DVT In A Tertiary Care Setting: Where Have We Been, Current Concepts, And Predictions For The Future  
Brian G. DeRubertis, MD

2:12 – 2:17 Novel Oral Anticoagulation (NOACs) Dramatically Alter How We Treat Patients With Venous Disease  
Michael R. Jaff, DO

2:18 – 2:23 The Utility Of Ultrasound-Enhanced Thrombolysis For Acute And Chronic DVT And An Update From The ACCESS Study  
Mark J. Garcia, MD

David J. Dexter, MD

2:30 – 2:35 Use Of The Indigo Device For Acute DVT: Replacing Thrombus Dissolution With Thrombus Extraction  
Patrick E. Muck, MD

2:36 – 2:41 Open Venous Thrombectomy: It Is Still Necessary In Some Patients  
Elna M. Masuda, MD

2:42 – 2:50 Panel Discussion

2:50 – 3:15 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 21 (Trianon Ballroom, 3rd Floor)
NEW DEVICES AND IMAGING TECHNOLOGIES TO ACHIEVE SUPERIOR OUTCOMES IN TREATING LARGE VEIN OBSTRUCTION

Moderators: Enrico Ascher, MD  
Cees H.A. Wittens, MD, PhD

3:16 – 3:21 Multicenter Experience With The Cook TriForce Device To Cross Large Vein Obstructions  
Jean Bismuth, MD

3:22 – 3:27 DEBATE: We Need Venous Stents For Venous Disease: Arterial Stents Just Won’t Cut It  
Stephen A. Black, MD

3:28 – 3:33 DEBATE: Marketed Stents Designed For Arteries Are More Than Adequate For Treating Venous Disease  
Mark J. Garcia, MD
SESSIONS 21–22

TUESDAY

3:34 – 3:39  Comparison Of The Veniti VICI Stent And The Wallstent: Anatomy And Physiology In An Animal Model
William A. Marston, MD

3:40 – 3:45  Shortcomings With Current Stents For May-Thurner Lesions: An Oblique Stent Is Needed
Rick De Graaf, MD, PhD

3:46 – 3:51  One-Year Results From The Feasibility Phase Of The Veniti VIRTUS Trial
Lowell S. Kabnick, MD, RPhS

3:52 – 3:57  Long-Term Experience With The Cook Zilver Vena Stent
Gerald J. O’Sullivan, MD

3:58 – 4:03  Balloon Angioplasty Alone Is Inadequate For Iliac Vein Stenoses
Anil P. Hingorani, MD

4:04 – 4:09  What To Do When Inflow Is Needed For Iliofemoral Venous Stenting: The Role Of Endophlebectomy
Ramesh K. Tripathi, MD

4:10 – 4:15  Panel Discussion
Moderators: Kenneth Ouriel, MD, MBA
Paul J. Gagne, MD

4:16 – 4:21  Veins Are Not Round: Diagnostic And Stenting Implications Of Elliptical Structures
Erin H. Murphy, MD

4:22 – 4:27  Shortcomings Of Venography And The Use Of IVUS In Venous Stenting: The VIDIO Study
Paul J. Gagne, MD

4:28 – 4:33  3-Dimensional Imaging For Iliofemoral Obstruction: MRV And CTV
Jean Bismuth, MD

4:34 – 4:39  2-D Perfusion Imaging For Iliofemoral Venous Obstruction
Rick De Graaf, MD, PhD

4:40 – 4:45  Sizing Venous Stents With IVUS: You Don’t Need To Be A Euclidean Geometrician
Kenneth Ouriel, MD, MBA

4:46 – 4:51  Duplex Ultrasound For Iliofemoral Venous Obstruction And Follow-Up After Stenting
Michael R. Jaff, DO

4:52 – 4:59  Panel Discussion

SESSION 22 (Trianon Ballroom, 3rd Floor)
MY WORST VENOUS DISASTER OF 2016: RAPID-FIRE PRESENTATION OF RESCUES AND LESSONS LEARNED
Moderators: Lowell S. Kabnick, MD, RPhS
Seshadri Raju, MD

5:00 – 5:04  My Worst Venous Disaster Of 2016
Gerard J. O’Sullivan, MD

5:05 – 5:09  My Worst Venous Disaster Of 2016
Robert A. Lookstein, MD

5:10 – 5:14  My Worst Venous Disaster Of 2016
Stephen A. Black, MD

5:15 – 5:19  My Worst Venous Disaster Of 2016
Rick De Graaf, MD, PhD
6:00 A.M. General Registration — Rhinelander Gallery, 2nd Floor
6:00 A.M. Faculty Registration — Morgan Suite, 2nd Floor
6:15 A.M. Continental Breakfast — Rhinelander Gallery, 2nd Floor

CONCURRENT WEDNESDAY PROGRAMS

PROGRAM D: SESSIONS 23-30
Lower Extremity Arterial Occlusive Disease And Its Treatment
6:40 A.M. – 5:58 P.M.
Grand Ballroom East, 3rd Floor

PROGRAM E: SESSIONS 31-38
Medical And Anti-Atherogenic Treatments; Anti-Hypertensive Treatments; Endoleak Management; Issues And Other Interesting Topics
6:40 A.M. – 6:05 P.M.
Grand Ballroom West, 3rd Floor

PROGRAM F: SESSIONS 39-46
Thoracic And Abdominal Aorta, Aortic Dissections, TEVAR, Parallel Grafts, F/BEVAR, TAAAs, Juxta- And Pararenal AAAs, Multilayer Flow Modulating (MLFM) Stents, More EVAR Topics; Recorded Interesting Live Cases
6:54 A.M. – 6:00 P.M.
Trianon Ballroom, 3rd Floor

PROGRAM D (SESSIONS 23-30)
LOWER EXTREMITY ARTERIAL OCCLUSIVE DISEASE AND ITS TREATMENT
Grand Ballroom East, 3rd Floor
SESSION 23 (Grand Ballroom East, 3rd Floor)
LOWER EXTREMITY OCCLUSIVE DISEASE MANAGEMENT – HOT TOPICS AND NEW DEVELOPMENTS
Moderators: Enrico Ascher, MD
Craig M. Walker, MD

6:40 – 6:45
Some CLI Patients Are Better Managed Without Revascularization: Which Ones
Frank J. Criado, MD

6:46 – 6:51
What Is The Optimal Waiting Period After Endo Or Open Revascularization To Perform Local Procedures For Foot Infection, Gangrene Or Necrosis
Wayne J. Caputo, DPM

6:52 – 6:57
Tips And Tricks For Achieving Healing And Limb Salvage With Ischemic Heel Ulcers And Gangrene: The Achilles Tendon And Part Of The Os Calcis May Have To Go
Palma M. Shaw, MD
Frank J. Veith, MD
Delay In Revascularization May Lead To Disaster In Diabetic Patients With Diabetic Foot Ulcers And Infection: What Is The Optimal Treatment Sequence For Drainage And Revascularization
Katarina M. Noronen, MD

Single vs. Multivessel Tibial Interventions For CLI: A Large Single Institution Study Shows Multivessel Treatment Offers No Benefit
Marc L. Schermerhorn, MD

DEBATE: When Is CLI Best Treated By Endovascular Techniques And When By Open Bypass: The Latter Has An Important Role In Many Patients (What Percent)
Francesco Spinelli, MD

DEBATE: All CLI Patients Can And Should Be Treated By An Endo-First Approach: Few (What Percent) Will Require Open Surgical Revascularization At Any Point In Their Course
Andrej Schmidt, MD

True Lumen vs. Subintimal Routes For Lower Extremity Interventions Above-The-Knee (ATK) And Below-The-Knee (BTK): What Is Durability Of BTK Interventions
Marco G. Manzi, MD

Value Of The Bullfrog Balloon Catheter (Mercator) For Local Adventitial Drug Delivery Into Occlusive Lesions: Dexamethasone And Paclitaxel Can Be Injected: Results Of The DANCE And LIMBO Trials
George L. Adams, MD

Importance Of Foot And Ankle Occlusive Lesions In CLI With Gangrene: When And How To Treat It: Principles, Techniques And Limitations
Roberto Ferraresi, MD

Panel Discussion

THE SUPERA BIOMIMETIC INTERWOVEN STENT

The Best Special Wires, Sheaths, Catheters And Balloons For Treating Perimalleolar And Pedal Occlusive Lesions: What’s New In Tools For Crossing Total Occlusions
Craig M. Walker, MD

5-Year Results With The Supera Stent Are Better Than Those With Bare Metal Stents (BMSs) And Drug Coated Balloons (DCBs) In A Propensity Matched Analysis
Dierk Scheinert, MD
Andrej Schmidt, MD
Sabine Steiner, MD

Economic Considerations With The Supera Stent For Treating SFA Lesions: How Does It Compare With Plain Old Balloon Angioplasty (POBA), BMSs, Drug Eluting Stents (DESs) And Drug Coated Balloons (DCBs)
Brian G. DeRubertis, MD
8:04 – 8:09
Supera Stenting Of Lesions Seem To Restore Distal Blood Flow Better Than Other Endovascular Treatments And As Well As A Bypass
Steven Kum, MD

THE ZILVER PTX DES

8:10 – 8:15
New Findings From The RCT Of The Zilver PTX Stent vs. PTA And Bare Metal Stents: Interesting Findings From Subanalyses And 5-Year Result Show Widening Benefits From The DES
Michael D. Duke, MD

8:16 – 8:21
RCT Comparing Zilver PTX DES And Surgical Bypass For Long Fempop Lesions Suggest Better Results In The DES Arm: Is It Due To Differences In The Method Of Patency Assessment: The ZILVERPASS Trial
Koen Deloose, MD
Marc Bosiers, MD
Patrick Peeters, MD

8:22 – 8:27
Update On The 2-Year Results Of The Eluvia DES From Boston Scientific For SEA Lesions: Why Are The Results So Superior To POBA: From The MAJESTIC Trial: What Is Happening With The IMPERIAL Trial Comparing Eluvia And Zilver PTX DESs
Stefan Müller-Hülsbeck, MD

BIORESORBABLE STENTS

8:28 – 8:33
Favorable 1-2 Year Results With The Abbott Balloon Expandable Bioresorbable Drug Eluting Stent For BTK Occlusive Lesions: Do The Lesions Regress: The ABSORB BTK Trial
Ramon L. Varcoe, MS, PhD

8:34 – 8:39
Status Of Other Bioabsorbable Scaffolds (Stents) For Treating Peripheral Arterial Lesions Including 3-Year Results Of The ESPRIT Trial
Johannes Lammer, MD

DESs BELOW-THE-KNEE

8:40 – 8:45
DESs (Sirolimus) Are Better Than POBA For Treating CLI Caused By Infrapopliteal Lesions: Wound Healing And Quality Of Life Are Improved: The ACHILLES Trial
Konstantinos Katsanos, MSc, MD, PhD

8:46 – 8:51
3 RCTs Show That DESs Have Value In Treating Long And Short BTK Occlusive Lesions: When Should They Be Used: A US Perspective
Robert A. Lookstein, MD

8:52 – 8:58
Panel Discussion

SESSION 25 (Grand Ballroom East, 3rd Floor)
MORE ON LOWER EXTREMITY OCCLUSIVE DISEASE AND ITS TREATMENT: DEALING WITH CALCIFICATION; ATERECTOMY
Moderators:
Gary M. Ansel, MD
James F. McKinsey, MD

8:58 – 9:03
When Are POBA And BMSs Adequate Treatment For Fempop Lesions And When Should Other Modalities Like Atherectomy Or DCBs Be Used
Krishna J. Rocha-Singh, MD

9:04 – 9:09
DEBATE: A Skeptic’s View On The Value Of Atherectomy
Frank J. Criado, MD
9:10 – 9:15 DEBATE: New Developments In Atherectomy 
Indicate A Promising Future: The DEFINITIVE AR 
Trial Shows That Atherectomy Plus DCBs Have Value: 
When Are They Indicated
Ulrich Beschorner, MD
Thomas Zeller, MD

9:16 – 9:21 Update On Atherectomy For Calcified Lesions: 
What Devices Are Best: When Should They Be Used With 
DCBs: Value Of Lesion Prep: Precautions And 
Midterm Results
Lawrence A. Garcia, MD

9:22 – 9:27 When And How To Use Distal Embolic Protection 
Devices During Lower Extremity Interventions
D. Christopher Metzger, MD

9:28 – 9:33 Long Complex SFA Lesions Are Poorly Treated With 
Stents And DCBs: Atherectomy And DCBs Are The 
Treatment Of Choice: Which Device Is Best And 
Precautions
Brian G. DeRubertis, MD

9:34 – 9:39 Patterns Of Wall Calcification In Lower Extremity 
Arteries And How They Impact On Endovascular 
Treatments: Is There A Grading System And How To 
Cross Calcified CTOs
Jihad A. Mustapha, MD

9:40 – 9:45 What Is The Best Treatment For Long Or Calcified 
SFA Lesions Causing CLI: The Role Of DCBs, DESs, 
Atherectomy And Supera BMSs
Koen Deloose, MD
Mark Bosiers, MD

9:46 – 9:51 Value Of Atherectomy And DCBs In The Treatment 
Of Popliteal Occlusive Lesions: Is Distal Embolic 
Protection Possible
Marco G. Manzi, MD

9:52 – 9:57 Foot Artery Interventions: When And How Should 
They Be Attempted; What Are The Results Of 
Treatment In Terms Of Treated Lesion Patency And 
Wound Healing At 1, 2 And 3 Years Or Longer
Roberto Ferraresi, MD

9:58 – 10:04 Panel Discussion

10:04 – 10:13 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 26 (Grand Ballroom East, 3rd Floor)
MORE ON LOWER EXTREMITY OCCLUSIVE 
DISEASE: NEW DEVELOPMENTS IN DRUG COATED 
BALLOONS (DCBs); DEALING WITH COMPLEX 
LESIONS AND TRIALS
Moderators: Michael S. Conte, MD
Peter A. Schneider, MD

10:13 – 10:18 Basic Principles And Constraints Of Various Drug 
Delivery Systems: They Are Not Simple And Details 
Matter: Why Leaving No Hardware Behind Is 
Important
William A. Gray, MD

10:19 – 10:24 DEBATE: How Best To Manage Complex 
Femoropopliteal Lesions: A Vascular Surgeon’s 
Perspective
Scott L. Stevens, MD
10:25 – 10:30 DEBATE: How Best To Manage Complex Femoropopliteal Lesions: An Interventionalist’s Perspective
Ulrich Beschörner, MD
Thomas Zeller, MD

UPDATE ON DRUG COATED BALLOONS (DCBs)

10:31 – 10:36 Current Status, Limitations And Future Prospects For DCBs In Treatment Of Lower Extremity Ischemia: Are Their Benefits Sustained Mid- And Long-Term
Gunnar Tepe, MD

10:37 – 10:42 3-Year Results Of The IN.PACT SFA Trial Comparing The In.Pact Admiral DCBs (Medtronic) With Standard Uncoated Balloons: Are The Benefits Of DCBs Over POBA Sustained
John R. Laird, MD
Peter A. Schneider, MD

10:43 – 10:48 Current Status, Value And Limitations Of DCBs In Fempop Occlusive Disease: Updates On The IN.PACT GLOBAL Registry And The LEVANT II Of The Lutonix DCB (Bard): Are The Benefits Over POBA Sustained
Dierk Scheinert, MD
Marianne Brodmann, MD

10:49 – 10:54 Importance Of Vessel Preparation With DCBs: Value Of Enforce Scoring Balloon (Cook) And Atherectomy With DCBs: Effect Of Calcium On DCBs Efficacy: Does The Lutonix DCB Work On BTK Arteries
Fabrizio Fanelli, MD

10:55 – 11:00 Value Of The Legflow DCB vs. POBA For Long SFA Lesions: Proven By The RAPID RCT
Jean-Paul de Vries, MD, PhD

11:01 – 11:06 Panel Discussion
Moderators: Dierk Scheinert, MD
Gunnar Tepe, MD

Sean P. Lyden, MD
Stefan Müller Hülsbeck, MD
Marianne Brodmann, MD

11:12 – 11:17 Early Results Of The DRASTICO RCT Comparing DESs And DEBs For The Treatment Of Fempop Lesions
Francesco Liistro, MD

Krishna J. Rocha-Singh, MD

11:24 – 11:29 Why DCBs Have Not Worked Well For BTK Lesions, But They Will - Recent RCTs Prove It (Like The Aco ART BTK Trial With The LITOS DCB): Different DCB Platforms Have Different Efficacy Especially BTK: What Is The Future Of DCBs In Crural Arteries
Francesco Liistro, MD

11:30 – 11:35 DEBATE: Status Of The BEST-CLI Multicenter/ Multispecialty Trial Comparing Endovascular And Open Surgical Treatment Of CLI: It Will Be A Valuable Trial That Settles Controversy
Matthew T. Menard, MD
Alik Farber, MD
Kenneth Rosenfield, MD
Thursday
SESSIONS 26–27

11:36 – 11:41  DEBATE: Not So Fast: The BEST-CLI Trial May Not Be So Valuable And Here Is Why
Mehdi H. Shishehbor, DO, MPH, PhD

11:42 – 11:47  Status Of DCBs In The US: What Is Available; What Will Be Available And When
Edward Y. Woo, MD

11:48 – 11:53  How To Calculate Fractional Flow Reserve (FFR) And Collateral Reserve In The Periphery Without Pressure Wires And How Should This Information Be Used In Treatment Decisions
Konstantinos Katsanos, MSc, MD, PhD

11:54 – 12:00  Panel Discussion

12:00 – 1:00  Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 27 (Grand Ballroom East, 3rd Floor)
MORE ABOUT CLI; THE “NO-OPTION FOR TREATMENT” LIMB AND EXTREME LIMB SALVAGE TECHNIQUES AND RESULTS
Moderators:
Sean P. Lyden, MD
Richard F. Neville, MD

1:00 – 1:05  Treatment Economics For CLI Care; Based On The SUPERSUB Trial
Jihad A. Mustapha, MD

1:06 – 1:11  Why There Is So Much Variation In The Definition Of A “No Option For Treatment Limb” In CLI: What Is A True Definition: Duplex Is The Best Way To Image Foot Arteries
Hisham Rashid, FRCS

1:12 – 1:17  Little Known Tips And Tricks For Visualizing And Treating Occluded Distal Leg And Foot Arteries With CLI And Gangrene: Contrast Angiography Is Best And How To Do It
Roberto Ferraresi, MD

1:18 – 1:23  Pedal Bypasses With Deep Vein Arterialization For Unfixable (No Option) Distal Arteries: Technique And Long-Term Results
Pramook Mutirangura, FRCS

1:24 – 1:29  Percutaneous Deep Vein Arterialization For End Stage CLI With Unfixable (No Option) Distal Arteries: Technique And Multicenter Results With The LimFlow Device
Steven Kum, MD
Andrei Schmidt, MD
Daniel G. Clair, MD

1:30 – 1:35  PTFE Grafts To Crural Arteries Are Procedures To Save Gangrenous Feet When No Other Option Is Available To Avoid A Major Amputation: Long-Term Patency Results Prove It Although Reoperations May Be Required
Gregg S. Landis, MD
Neal S. Cayne, MD
Nicholas J. Gargiulo III, MD, RVT
Frank J. Veith, MD
Evan C. Lipsitz, MD

1:36 – 1:41  In Patients With CLI And Necrotic Or Gangrenous Foot Lesions, Follow-Up After Interventional Treatment Is Crucial And Behavior Of The Wound Should Guide Re-Imaging And Reintervention
Francesco Liistro, MD
Tips And Tricks For Performing Distal Bypasses Successfully In Dialysis Patients
Nobuyoshi Azuma, MD
1:42 – 1:47

New Approaches To Limb Salvage In Advanced CLI Due To Very Distal Disease: Transcollateral, Pedal Loop And Small Artery Access In The Foot: How Durable Is The Patency Of PTAs Done By These Approaches
Marco G. Manzi, MD
1:48 – 1:53

Value Of Bypasses To Pedal Arteries For Advanced CLI After 10 Years Of Follow-Up: Technical Tips And When Should These Bypasses Be Performed
Maarit Venermo, MD, PhD
1:54 – 1:59

Panel Discussion
2:00 – 2:06

SESSION 28 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN LOWER EXTREMITY DCBs, STENT-GRAFTS, PROSTHETIC GRAFTS AND THE TREATMENT OF IN-STENT RESTENOSIS (ISR)
Moderators: Johannes Lammer, MD Joseph L. Mills, MD

How Important Are DCBs Currently: What Are Their Limitations: What Prospects And Advances Are In Their Future
Giancarlo Biamino, MD, PhD
2:06 – 2:11

Heparin Bonded PTFE (Propaten) Grafts Have 5-Year Patency Rates Equal To Autologous Vein Grafts For Fempop Bypasses
Russell H. Samson, MD, RVT
2:12 – 2:17

A RCT Comparing Endoluminal Bypass With Heparin Bonded PTFE Stent-Grafts (Viabahn) To Open Fempop Bypasses: 1-Year Results Of The SUPER B Trial
Michel M.P. Reijnen, MD, PhD
2:18 – 2:23

How To Achieve Good Results With Gore Viabahn Stent-Grafts For Complex Fempop Occlusive Disease: IVUS, Proper Sizing And Other Tips Are The Secrets To Success
Hiroyoshi Yokoi, MD
2:24 – 2:29

New Balloon Expandable Stent-Grafts (Viabahn Bx): Early Experience And How They Can Improve Performance
Jean Bismuth, MD
2:30 – 2:35

IN STENT RESTENOSIS (ISR) AND ITS TREATMENT

Biology Of ISR And Rationale For Debubling Treatment: How Is ISR Best Treated At The Iliac And SFA Levels
Jos C. van den Berg, MD, PhD
2:36 – 2:41

What Are The Best Current Options For Treating ISR In The US: Role Of Atherectomy (With Laser And Other Devices), DCBs And Stent-Grafts
Craig M. Walker, MD
2:42 – 2:47

Role And Value Of Stent-Grafts In Treating ISR: Updated Results Of The RELINE Trial And Is Debubling Necessary
Patrick Peeters, MD Marc Bosiers, MD Koen Deloose, MD
2:48 – 2:53
2:54 – 2:59  Pitfalls In The Treatment Of ISR: What Is The Role Of The In.Pact Admiral DCB For SFA ISR: Is It Enough Alone
Gary M. Ansel, MD

3:00 – 3:05  Atherectomy Plus DCB Is The Best And Most Cost-Effective Treatment For SFA ISR: Based On The DEFINITIVE AR Trial: Tips And Tricks For Treating And Which Devices Are Best
Gunnar Tepe, MD
Thomas Zeller, MD

3:06 – 3:12  Panel Discussion

3:12 – 3:22  Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 29 (Grand Ballroom East, 3rd Floor)

NEW DEVELOPMENTS IN THE TREATMENT OF ACUTE LIMB ISCHEMIA (ALI) AND INTERMITTENT CLAUDICATION (IC)

Moderators: Thomas O. McNamara, MD
Mark A. Adelman, MD

NEW METHODS TO TREAT ALI

3:22 – 3:27  How To Perform A Femoral Embolectomy Without A Groin Incision: Technique And Advantages
Rajiv Parakh, MBBS, MS

3:28 – 3:33  Update On Percutaneous Thrombosuction Techniques For ALI: Equipment, Methods And Results
Athanasios Katsargyris, MD
Eric L.G. Verhoeven, MD, PhD

3:34 – 3:39  Role Of Percutaneous Aspiration In ALI: What Are The Best Devices Available In The US And How Should They Be Used
Michael H. Wholey, MD, MBA

3:40 – 3:45  Advantages Of The Indigo Thrombectomy Device From Penumbra To Treat ALI: How Does It Get Clot Out More Effectively: Does It Have Disadvantages Or Limitations
Patrick E. Muck, MD

NEW CONCEPTS IN THE MANAGEMENT OF INTERMITTENT CLAUDICATION (IC)

3:46 – 3:51  Use Of Electronic Devices To Improve Treatment Of Lower Extremity Intermittent Claudication: The Prospective FITBIT Study
Robyn A. Micsata, MD

3:52 – 3:57  A Wearable Exercise Tracker (NIKE + Fuel Band) Can Help To Improve Walking Distance In Intermittent Claudication: The wSTEP Trial
Celia Riga, BSc, MBBS, MD

3:58 – 4:03  What Is The Best Non-Invasive Treatment To Improve Walking Distance In Patients With IC
Alun H. Davies, MA, DM, DSc

4:04 – 4:09  DEBATE: Angioplasty (PTA) Plus Exercise Is Better Treatment Than PTA Alone For IC: The ERASE Trial Shows It And Why It Is A Better Trial Than The CLEVER And MIMIC Trials
Marc R.H.M. van Sambeek, MD, PhD

4:10 – 4:15  DEBATE: Nonsense: Exercise, Best Medical Management And Reassurance Are The Best Treatment For Most Patients With IC
Jonathan D. Beard, ChM, MEd

4:16 – 4:22  Panel Discussion
SESSION 30 (Grand Ballroom East, 3rd Floor)
VALUE OF DEEP VEIN GRAFTS; NEW CONCEPTS IN ASSESSING FOOT PERFUSION AND IMPROVING IT; MORE ABOUT THE ANGIOSOME CONTROVERSY; SOME ONGOING CLI TRIALS
Moderators: Kenneth Ouriel, MD, MBA
Timur P. Sarac, MD

4:22 – 4:27
A 40-Year Experience Using Femoropopliteal Veins For Below Knee FP Bypasses: Describing The Positive Means And Dispelling The Negative Myths - You Can Do It
Martin L. Schulman, MD

4:28 – 4:33
A Novel Use Of Audio Technology To Evaluate Lower Extremity Perfusion And Eliminate Errors From Pulse Exams And Doppler Signals: The DZAM Technique
Cynthia K. Shortell, MD
Leila Mureebe, MD

4:34 – 4:39
Value Of A Computerized Rewarming Thermoneumatic Boot To Increase Blood Flow To Ischemic Lower Extremities: How It Works And Results
Magdiel Trinidad Vasquez, MD

4:40 – 4:45
Home Treatment For CLI: The Art Assist Sequential Compression Device: Principles And How It Works: Its Results Are Often Better Than A Bypass Or Interventional Treatment
Sherif A.H. Sultan, MD

4:46 – 4:50
Panel Discussion

ANGIOSOME RELATED ISSUES AND TOPICS

4:50 – 4:55
The Orphan Heel Syndrome: How To Identify It And What To Do About Necrotic Lesions In This Area
Miguel F. Montero-Baker, MD

4:56 – 5:01
Importance Of The Wound Related Artery (Angiosome) Concept And Patterns Of Disease In CLI: Should They Influence Treatment And How
Roberto Ferraresi, MD

5:02 – 5:07
Why Is There So Much Disagreement Over The Angiosome Concept And How To Resolve It: When Should A Pedal Bypass Be The First Option
Hisham Rashid, FRCS

5:08 – 5:13
DEBATE: New Evidence For The Value Of The Angiosome Concept In CLI With Tissue Loss: Indocyanide Green Injection With Fluorescence Imaging Shows It: The Angiosome Concept’s Value Differs With Endo And Bypass Treatment
Maarit Venermo, MD, PhD

5:14 – 5:19
DEBATE: Despite All This, The Angiosome Concept Is Worthless And Here Is The Evidence
Frank E.G. Vermassen, MD, PhD

5:20 – 5:25
There Is Little Clinical Relevance To The Angiosome Concept: How Perfusion Can Be Measured In Parts Of The Foot So Healing Can Be Predicted
Bauer E. Sumpio, MD, PhD

5:26 – 5:31
When Is The Angiosome Concept Important And When Is It Not: How To Resolve The Controversy
Ignacio Escotto, MD

5:32 – 5:37
The Importance Of The Angiosome Concept And The Plantar Arch In CLI Patients With Extensive Foot Gangrene Or Ulceration: How To Evaluate Foot Perfusion And Potential For Healing
Werner Lang, MD
SOME ONGOING CLI TRIALS

5:38 – 5:43
What Is The SPINACH Trial Comparing Endo And Open Treatment Of CLI: What Useful Information Will It Provide
Nobuyoshi Azuma, MD

5:44 – 5:49
What Is The LIBERTY Trial And What Unique Information Will It Provide About Advanced CLI And Its Endo And Open Treatments
Jihad A. Mustapha, MD

5:50 – 5:58
Panel Discussion

End of Program D

PROGRAM E (SESSIONS 31-38)
MEDICAL AND ANTI-ATHEROGENIC TREATMENTS; ANTI-HYPERTENSIVE TREATMENTS; ENDOLEAK MANAGEMENT; ISSUES AND OTHER INTERESTING TOPICS
Grand Ballroom West, 3rd Floor

SESSION 31 (Grand Ballroom West, 3rd Floor)
MONITORING HEPARIN; SCREENING FOR AND ASSESSING ATHEROSCLEROTIC RISK; ANTI-ATHEROSCLEROSIS TREATMENT CHANGES IN LIGHT OF NEW TRIAL FINDINGS; UPDATE ON TIMING OF SURGERY IN PATIENTS WITH CORONARY STENTS

Moderators: Gary M. Ansel, MD
Russell H. Samson, MD, RVT

6:40 – 6:45
Incidence And Importance Of Heparin Resistance In Vascular Procedures And How Measurement Of ACT Can Offset This Problem: Value Of Medtronic Hemostasis Management System
Arno M. Wiersema, MD, PhD
Kak Khee Yeung, MD, PhD
Jan D. Blankensteijn, MD

6:46 – 6:51
Pleiotropic Effect Of Statins: What Are They And How Should They Be Monitored
Anthony J. Comerota, MD

6:52 – 6:57
The Value Of Ultrasound Screening Of Femoral And Carotid Arteries To Predict Atherosclerotic Risk And What To Do About It
Andrew N. Nicolaides, MS

6:58 – 7:03
The VIVA RCT Is A Game Changer: It Shows That Population Based Screening For AAA, PAD And Hypertension Allows Intensive Medical Treatment With Statins And Anti-Hypertensives And That These Drugs Save Lives (7%)
Jes S. Lindholt, MD

7:04 – 7:09
Current Role Of PCSK 9 Inhibitors In LDL-Cholesterol (LDL-C) Management: How Do They Work And When Should They Be Given (Alirocumab-Praluent From Sanofi & Regeneron And Evolocumab-Repatha From Amgen)
Ron Waksman, MD

7:10 – 7:15
How To Manage Muscle Pain And Apparent Statin Intolerance In Patients On Statins: It Can Be Often Done Safely And Effectively Without Stopping Statins: What Does The GAUSS-3 Trial Tell Us About Controlling The Side Effects Of Statins
Don Poldermans, MD
7:16 – 7:21
Why LDL-C (Or Non-HDL-C) Levels Are Important Guides To Treatment And Should Be Followed In Primary And Secondary Event Prevention For Vascular Patients At Risk: Coronary Lesions Regress When LDL-C Is <80 mm/dL
Jeffrey S. Berger, MD, MS
Caron B. Rockman, MD

7:22 – 7:27
Value Of Ezetimibe (Zetia) In Decreasing Death, Stroke And MI Rates When Added To Simvastatin: What Value Of LDL-C Should Our Patients Strive To Achieve: The IMPROVE-IT Trial: What Does The HOPE 3 Trial Tell Us About Crestor And Primary Prevention
Ido Weinberg, MD, MSc

7:28 – 7:33
New Key Findings From The JUPITER Trial: Statins (Crestor) Have Variability In Their LDL-C Lowering Ability; The Degree Of Cardiovascular Risk Reduction Correlates With The Percent LDL-C Reduction: Therapeutic Implications
Jeffrey S. Berger, MD, MS
Jonathan Newman, MD

7:34 – 7:39
What Is New About Optimal Timing For Elective Vascular Surgery After Coronary Stenting For Angina; For MIs; With BMSs; With DESs: Things Have Changed: Risks Are Higher If The Stenting Was Done For An MI
Caron B. Rockman, MD
Jeffrey S. Berger, MD, MS

7:40 – 7:46
Panel Discussion

SESSION 32 (Grand Ballroom West, 3rd Floor)
DRUG RESISTANT HYPERTENSION AND ITS CATHETER-BASED TREATMENTS; MEDICAL TREATMENTS; FRACTIONAL FLOW RESERVE; ASSESSMENT OF AAA RISK; UNUSUAL VASCULAR DISEASES
Moderators: Ron Waksman, MD
Anthony J. Comerota, MD

7:46 – 7:51
Why Pharmacological Treatments Are Insufficient To Control Hypertension In Some Patients And What Is The Outlook For Non-Pharmacologic Treatments Such As Renal Denervation And Baroreflex Stimulation (Neostim) And Modulation (Mobius)
Melvin D. Lobo, MBChB, PhD

7:52 – 7:57
Horst Sievert, MD

7:58 – 8:03
Renal Artery Denervation For Hypertension: Why Hasn't It Worked And Where Is It Going
Krishna J. Rocha-Singh, MD

8:04 – 8:09
Update On The ROX Endovascular System For Creating An Iliac A-V Fistula To Treat Resistant Hypertension: How It Works, Results And Complications
David H. Deaton, MD

8:10 – 8:15
Diagnostic Strategy For Children With Suspected Renin Mediated Hypertension Is Multimodal: Is Endovascular Treatment Ever Effective
Kyung Cho, MD
SESSION 33 (Grand Ballroom West, 3rd Floor)
SIGNIFICANCE AND TREATMENT OF ENDOLEAKS AND AORTO-BRONCHIAL FISTULAS
Moderators: Juan C. Parodi, MD Timur P. Sarac, MD

Embolization For Type 1A Endoleaks After Nellix And Standard Endografts: How To Do It And When Does It Work And When Does It Not
Robert A. Morgan, MD

How Does Onyx Work For Treating Type I Endoleaks: Limitations And Advantages
Thomas Larzon, MD, PhD

Value Of Duplex Ultrasound In Treating Endoleaks In The Presence Of Coils And Onyx And With Nellix Grafts
Dipankar Mukherjee, MD

Characterization System For Type 2 Endoleaks: What Is Its Clinical Significance
Nicos Labropoulos, BSc (Med) PhD, DIC, RVT

The Natural History Of Type 2 Endoleaks That Develop After 1 Year Is Different: >70% Persist And Require Closer Surveillance And More Interventions
Keith D. Calligaro, MD Matthew J. Dougherty, MD

Catheter-Based CT Guided Translumbar Endoleak Treatment: Technique And Advantages
Stephan Haulon, MD

Accessory Renal Arteries – A Significant Source Of Bad Type 2 Endoleaks: How To Prevent, Diagnose And Treat Them
Claudio J. Schonholz, MD Joshua D. Adams, MD

What Are The Causes Of Type 3 Endoleaks: Can Trauma Be One Of Them
Carlo Setacci, MD
SESSION 34 (Grand Ballroom West, 3rd Floor)
IMPORTANT ISSUES FOR VASCULAR SURGEONS AND SPECIALISTS; REMEMBRANCES; ASSET PROTECTION; KEY MEDICAL, HISTORICAL AND ETHICAL TOPICS
Moderators: Bruce A. Perler, MD, MBA
James C. Stanley, MD

10:16 – 10:21 Giants No Longer With Us: A Tribute To Allan Callow, Calvin Ernst And John (Jack) Connolly
Jerry Goldstone, MD

Mark A. Adelman, MD

Timothy M. Sullivan, MD

David H. Deaton, MD

10:40 – 10:45 Why Vascular Surgeons Are An Essential Operating Room Resource For Other Surgeons: They Must Be Valued As Such, Protected And Compensated
Gregory L. Moneta, MD

10:46 – 10:51 Is It A Wild West Bonanza Or A Feeding Frenzy: How To Stem The Surge In Unnecessary Lower Extremity Interventions That Cost So Much And Do Little To Benefit Patients
Scott L. Stevens, MD

10:52 – 10:57 Key Points In Asset Protection, Tax Planning And Succession Planning For Vascular Surgeons/Specialists
Hillel Presser, Esq., MBA

10:58 – 11:04 Panel Discussion
Moderators: Michael L. Marin, MD
Frank J. Veith, MD

KEY NON-SURGICAL ISSUES

11:04 – 11:09 Optimal Treatment For Left Main Coronary Lesion Is Changing: Stenting With DESs Is Replacing Open Coronary Bypass: Based On The EXCEL Trial
Gregg W. Stone, MD

11:10 – 11:15 COURAGE Trial Findings After 15 Years Follow-Up: It Still Shows No Advantage Over Medical Treatment In Some Coronary Disease Patients: Are Too Many Patients Getting Coronary Stents
Roxana Mehran, MD
11:16 – 11:21 Role Of Stents In The Treatment Of Lower Extremity Occlusive Lesions: Value Of DESs And DCBs: Will Bare Metal Stent Usage Decrease Or Disappear
John H. Rundback, MD

11:22 – 11:27 Current Status Of Cell And Gene Therapy For CLI Treatment: Do Either Have A Future
Sigrid Nikol, MD

11:28 – 11:33 Long-Term Results Of Autologous Bone Marrow Cell Treatment For No Option CLI: Results Of A Double Blinded RCT
Thomas F. O’Donnell, Jr., MD
Mark D. Iafrati, MD

AN HISTORICAL NOTE
11:34 – 11:39 What Are “Octopus” Endografts: Why Are They The Future Of Branched Endografting For TAAAs And What Is Their Origin
Karthikeshwar Kasirajan, MD

ETHICAL ISSUES
11:40 – 11:45 Ethical Conflicts In Providing Quality Care With All The Financial And RVU Pressures In The Current Health Care System: How To Resolve Them
James W. Jones, MD, PhD, MHA

11:46 – 11:51 How To Involve Vascular Patients In Decision Making About Their Surgical And Interventional Treatments
Dirk T. Ubbink, MD, PhD

11:52 – 12:00 Panel Discussion

12:00 – 1:00 Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 35 (Grand Ballroom West, 3rd Floor)
THE CURRENT HEALTH CARE SYSTEM; REIMBURSEMENT; IMPACT OF OBAMACARE (ACA), ACOs, ETC. ON VASCULAR SURGEONS/ SPECIALISTS AND OUR INDUSTRY PARTNERS
Moderators: Michel Makaroun, MD
John H. Furtek, BS, RT

1:00 – 1:05 Effects Of The Massachusetts Universal Health Care Program On Vascular Surgery And Its Outcomes: Is It A Model For What Will Happen Under Obama Care Or The Affordable Care Act (ACA)
Mohammad H. Eslami, MD, MPH

1:06 – 1:11 Obamacare 2016: Is It As Bad As Predicted Or Worse: Can It Be Fixed
Clifford J. Buckley, MD

1:12 – 1:17 Is The ACA (Obamacare) Increasing Or Decreasing Access To Affordable Care
Bruce A. Perler, MD, MBA

1:18 – 1:23 Impact Of The ACA On Vascular Surgery’s Value To The Health Care System: It’s Not Good
Richard J. Powell, MD

1:24 – 1:29 Impact Of The Medical Device Tax On Medical Innovation And Education: Will It Be Repealed Or Just Delayed: Other Effects Of The ACA On The Medical Device Industry And Its Support Of Continuing Medical Education
Allison H. Giles, RN, JD
1:30 – 1:35 Alternate Payment Models And ACOs (Accountable Care Organizations): How Are They Working, Will They Work And What Will Their Impact Be On Vascular Surgeons
Robert M. Zwolak, MD, PhD

Timothy F. Kresowik, MD

Sean P. Roddy, MD

Barry T. Katzen, MD

1:54 – 1:59 Starting A Vascular Surgery Service In A Public Safety Net Hospital Can Be Profitable: Tips And Strategies For Success During Insurance And Health Care Reform
Charles J. Fox, MD

2:00 – 2:06 Panel Discussion

SESSION 36 (Grand Ballroom West, 3rd Floor)
ACOs, GOVERNING BODIES (BOARDS/RRC), INDEPENDENCE, EDUCATION, REIMBURSEMENTS, TRAINING, SIMULATION
Moderators: Carlo A. Dall’Olmo, MD
William D. Jordan, Jr., MD

James C. Stanley, MD

2:12 – 2:17 Advantages To A Division Of Vascular Surgery When It Is Part Of A Department Of General Surgery
H. Leon Pachter, MD

2:18 – 2:23 Why Vascular Surgery Needs To Be A Totally Independent Specialty And How Can We Get There
Timothy M. Sullivan, MD

John F. Eidt, MD

2:30 – 2:35 Who Should Be Doing The Complex Open Vascular Surgery (Pararenal AAAs, TAAAs, Mesenteric And Tibial Bypasses): Trainee Experience Is Limited: Do We Need Regional Centers And What Are The Downsides
Ronald L. Dalman MD

2:36 – 2:41 Major Open Surgery Experience Differences Between 5+2 And 0+5 Vascular Trainees: Does It Matter
Murray L. Shames, MD

2:42 – 2:48 Panel Discussion
Moderators: Karl A. Illig, MD
Ronald L. Dalman, MD
SESSIONS 36–37

SESSION 37 (Grand Ballroom West, 3rd Floor)

NEW DEVELOPMENTS IN VASCULAR CARE, DRGs, TELEMEDICINE, REIMBURSEMENTS, REPORTING BAD PRACTICE AND THE FDA

Moderators: Bruce A. Perler, MD, MBA
Ronald M. Fairman, MD

3:40 – 3:45
How Does A Real-Time Dashboard Database Improve The Quality And Decrease The Cost Of Vascular Care
Timothy M. Sullivan, MD

3:46 – 3:51
How Can Hospitalists Improve A Vascular Service By Decreasing Mortality, Length Of Stay And Readmissions
Peter L. Faries, MD

3:52 – 3:57
Volume/Outcome Relationship With CEA And CAS: German Registry Data From 175,000 Patients
Hans-Henning Eckstein, MD, PhD

3:58 – 4:03
Hospital Volume Matters Most In Improving Outcome Of EVAR: Both Surgeon And Hospital Volume Matter For Open AAA Repair
Marc L. Schermerhorn, MD

4:04 – 4:09
How To Incorporate Virtual Visits Into A Vascular Practice: The Technology Is Here: What Is The Technology And How To Use It
John (Jeb) W. Hallett, MD

4:10 – 4:15
Role Of Telemedicine In A Vascular Practice: How To Be Reimbursed For It
Clifford M. Sales, MD, MBA

4:16 – 4:21
Benefit Of New AAA/EVAR DRGs On Hospital Economics: They Are A Game Changer And How They Can Benefit Vascular Surgeons
W. Charles Sternbergh III, MD
We Have A Duty To Report Unethical Procedures Or Malpractice To Hospital Administrators, State Misconduct Boards And Patients Seeking A Second Opinion: Why It Does Not Happen And What To Do If Such Reporting Does No Good Because Of Administrator Inaction

O. William Brown, MD, JD

Ezetimbe (Zetia) Lowers LDL-C And Decreases Cardiovascular Death, MI And Stroke Over Statins Alone: When Should It Be Given And Why Didn't The FDA Approve It

Russell H. Samson, MD, RVT

Why Does The FDA Approve Lower Extremity Devices With Only 6-12 Months Follow-Up: Shouldn't Longer Durability Be Required

Dorothy B. Abel, BSBME

TRIALS/REGISTRIES; FLAWS IN REPORTING AND RCTs; PUBLICATION QUALITY; SVS STANDARDS AND GUIDELINES; FAIR DEVICE EVALUATION; VALUE OF VQIs

SESSION 38 (Grand Ballroom West, 3rd Floor)


Vicente Riaymbau, MD, PhD

Why Kaplan-Meier Analyses Are A Poor Way To Compare Devices And Treatments For PAD: How Should It Be Done

Frank E.G. Vermassen, MD, PhD

Surgeon Outcome Reporting Can Be Inaccurate And Unreliable: What Is The Evidence

Mr. Jonathan R. Boyle, MD

RCTs Are Often Poorly Generalizable: What Strategies Can Overcome This Flaw

Charles C. Miller, PhD

With Published Articles In The Medical Literature Quality Should Trump Quantity: Does It And How Should Quality Be Evaluated

Clifford J. Buckley, MD

Panel Discussion

Moderators: Michael S. Conte, MD
Keith D. Calligaro, MD

WEDNESDAY SESSIONS 37–38
What Does Volume Analysis Of True And False Lumens Tell Us After Standard And Petticoat (Composite) TEVAR For Acute TBADs
Stephan Haulon, MD

5-Year Outcomes (Durability) Of TEVAR: For Thoracic Aortic Aneurysms: Data From The VALOR II Registry
Mark Conrad, MD, MMSc
Richard P. Cambria, MD

30 Years Of Chinese Progress In Treating TBADs: What Has Happened In The Last 5 Years And What Challenges Remain
Qingsheng Lu, MD
Zaiping Jing, MD

Panel Discussion

Endovascular Repair Of Ascending Aortic Lesions: Where Does It Stand
Ali Azizzadeh, MD

Advantages, Limitations And Long-Term Results Of Chimney And Periscope Grafts For Aortic Arch Lesions
Nicola Mangialardi, MD
Mario L. Lachat, MD

For Aortic Arch Aneurysms; Parallel Grafts vs. Open Surgical Debranching: When, Where And How
Franco Grego, MD

Chimney Grafts Are Better Than Other Techniques For Aortic Arch Lesions – And Are Simpler And Cheaper: How To Make Them Safe And Effective: Limitations
Jan S. Brunkwall, MD, PhD

Advantages, Limitations And Failure Modes Of Chimney Grafts For Aortic Arch Lesions: How To Prevent Failures
Ralf R. Kolvenbach, MD

A Novel (Nexus) Endograft When Parallel Grafts Won't Work In The Arch – Concept, Technique And Early Results
Mario L. Lachat, MD
Nicola Mangialardi, MD

Further Experience With Total Endovascular Repair Of Aortic Arch Lesions Using A Precurved Fenestrated Endograft (Naguta): Indications, Advantages, Results And Limitations
Yoshihiko Yokoi, MD

Branched Endograft vs. Chimneys For Treating Complex Arch Lesions: Advantages, Results And Limitations Of Each
Qingsheng Lu, MD
Zaiping Jing, MD
8:48 – 8:53 Open And Endo Options For Treating Kommerell’s Diverticula And Other Congenital Arch Lesions
Nicholas J.W. Cheshire, MD

8:54 – 9:00 Panel Discussion

9:00 – 9:18 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 41 (Trianon Ballroom, 3rd Floor)
MORE ABOUT JUXTA- AND PARARENAL AAAs; TAAAs; F/BEVAR; PARALLEL GRAFTS
Moderators: Timothy A.M. Chuter, DM
Eric L.G. Verhoeven, MD, PhD

9:18 – 9:23 Natural History Of TAAAs: How Should It Influence Treatment
Anthony L. Estrera, MD
Hazim J. Safi, MD

Wei Guo, MD

9:30 – 9:35 How Renal Artery Angulation And Respiratory Motion Affect The Long-Term Results Of Chimney EVAR (Ch/EVAR) And Fenestrated EVAR (F/EVAR)
Ronald L. Dalman, MD

9:36 – 9:41 Comparative Results Of F/EVAR And Ch/EVAR For Juxtarenal AAAs: Which Is Best And When
Murray L. Shames, MD

9:42 – 9:47 In Vitro Studies Allow Optimization Of Chimney Graft Details (Measurements, Types Of Graft, Overlap Length And Need For Endoanchors) With Standard, Nellix And Ovation Endografts: Gutter Endoleaks Can Be Prevented
Jan D. Blankensteijn, MD
Kak Khee Yeung, MD, PhD
Willem Wisselink, MD

9:48 – 9:53 Failure Modes After Branched EVAR (B/EVAR) For TAAAs And How They Can Be Prevented
Matthew J. Eagleton, MD
Tara M. Mastracci, MD

9:54 – 9:59 Tips And Tricks For And Results Of Open TAAA Repair After Failed TEVAR Or EVAR
Roberto Chiesa, MD
Germano Melissano, MD

10:00 – 10:06 Panel Discussion
Moderators: Matthew J. Eagleton, MD
Marcelo Ferreira, MD

10:06 – 10:11 What Are The Ideal Bridging Stent-Grafts For Use With F/EVAR And B/EVAR
Daniel G. Clair, MD

10:12 – 10:17 Target Branch Vessel Injuries In F/EVAR And B/EVAR: How To Prevent And Treat Them
W. Anthony Lee, MD

10:18 – 10:23 How To Predict Rotation And Torsion Of Fenestrated Endografts So These Problems Can Be Eliminated
Thomas L. Forbes, MD

Timothy A. Resch, MD, PhD
SESSION 42 (Trianon Ballroom, 3rd Floor)

UPDATE ON THE MULTILAYER FLOW MODULATING (MLFM) STENTS AND OTHER UNCOVERED STENTS FOR THE TREATMENT OF ANEURYSMS AND DISSECTIONS

Moderators: Rodney A. White, MD Frans L. Moll, MD, PhD

10:54 – 10:59 Value Of Flow Diverting Bare Stents In Treating Aneurysms: When Do They Work And When Don’t They: What Is The Theory And The Evidence
Fabrizio Fanelli, MD

11:00 – 11:05 Flow Diverting Bare Stents With Or Without Coils For Treating Visceral Or Renal Artery Aneurysms: How Well Do They Work And Could Similar Stents Work For Aortic Aneurysms
Michele Rossi, MD

11:06 – 11:11 Early Results With MLFM Uncovered Stents To Treat Acute Aortic Dissections: The DRAGON Trial: What About Their Use In Treating Aortic Aneurysms
Ralf R. Kolvenbach, MD

11:12 – 11:17 Updated Experience Treating Aortic Dissections And Complex AAAs With MLFM Uncovered Stents
Victor S. Costache, MD, PhD

11:18 – 11:23 Results Of MLFM Stents For Treating Aortic Dissections: When Are They The Best Treatment: What About For Complex Aortic Aneurysms (TAAAs)
Sherif A.H. Sultan, MD

Claude D. Vaislic, MD

11:30 – 11:35 The Japanese Registry Experience With The MLFM Stent For The Treatment Of Aortic Aneurysms And Dissections
Yoshikatsu Saiki, MD, PhD

11:36 – 11:41 Update On The Experience With Multilayered Uncovered Stents In Treating TAAAs: Value And Limitations
Qingsheng Lu, MD Zaiping Jing, MD

11:42 – 11:47 Theoretical Considerations In Using MLFM Uncovered Stents (From Cardiatis) To Treat Aortic Dissections
Lambros Athanassiou, PhD Elazer R. Edelman, MD, PhD

11:48 – 11:53 Another Observer’s Opinion On The Value Of Uncovered Flow Modulating Stents In The Treatment Of Aneurysms And Dissections
Michael D. Dake, MD
WEDNESDAY
SESSIONS 42–44

11:54 – 12:00  Panel Discussion
12:00 – 1:00  Lunch Break – 2nd Floor Promenade And Rhinlander Gallery Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 43 (Trianon Ballroom, 3rd Floor)
MORE INTERESTING TOPICS RELATED TO THE ABDOMINAL AORTA, AAAs AND EVAR
Moderators: Roger M. Greenhalgh, MD Timur P. Sarac, MD

1:00 – 1:05  Value Of Simulation With EVAR: Does It Improve Seal Zone Coverage: Other Advantages Vikram S. Kashyap, MD
1:06 – 1:11  How To Do EVAR Safely With Almost No Contrast In Patients With Chronic Renal Disease: Is It Of Value Andrea Stella, MD
1:12 – 1:17  Aortic Neck Enlargement Differs After EVAR With Balloon-Expandable And Self-Expandable Endografts: Why Does It Matter Dainis K. Krievins, MD
1:18 – 1:23  DEBATE: Large Diameter Aortic Necks (>32 mm) Are Associated With More Type 1A Endoleaks, Migration And Other Problems And Should Be A Relative Contraindication To EVAR Ali F. AbuRahma, MD
1:24 – 1:29  DEBATE: Large Diameter Aortic Necks (35-36 mm) Are Not Associated With More Type 1A Endoleaks, Migration, Etc.: What Techniques Can Help Michael J. Singh, MD
1:30 – 1:35  Nellix Endografts And EVAS Can Be Effective In Treating AAAs With Large Common Iliac Aneurysms: Technique And Results: From A Multicenter Experience Jean-Paul de Vries, MD, PhD
1:36 – 1:41  DEBATE: The Case For Lowering The Threshold For AAA Treatment In Many Patients Ronald M. Fairman, MD
1:42 – 1:47  DEBATE: Not So: Why We Should Sometimes Be Raising The Threshold For Treatment In Many Patients Ross Naylor, MD
1:48 – 1:53  How To Promote AAA Sac Thrombosis And Prevent Type 2 Endoleaks After EVAR By Placing Coils In The Lumbar And IMA Branches: Technical Tips Dominique Fabre, MD
1:54 – 2:00  Panel Discussion

SESSION 44 (Trianon Ballroom, 3rd Floor)
MORE NEW DEVELOPMENTS RELATING TO AAAs AND EVAR
Moderators: Juan C. Parodi, MD Daniel G. Clair, MD

2:00 – 2:05  An Evolution Related Classification System To Help Select The Optimal AAA Endograft For Each EVAR Patient Claude Mialhe, MD
2:06 – 2:11  High 18 F-FDG Uptake On PET CT In The Aortic Wall Of AAAs Predicts Poor Results Of Treatment And Poor Patient Survival: Why Natzi Sakalihasan, MD, PhD
Why Diabetes Is Negatively Associated With AAA Incidence And Growth: A Possible Clue To Medical Treatment Of AAAs
Jes S. Lindholt, MD

Do New Low Profile EVAR Devices Come At The Cost Of Poorer Durability
Michel Makaroun, MD

Despite The Declining Incidence Of AAAs, Current AAA Screening Programs Have Value And Save Lives: How Should They Be Structured In 2016 And Beyond
Martin Björck, MD, PhD

DEBATE: On Label Use (Within The IFU) Of Endografts For EVAR Is Key To Achieving Good Results
Andres Schanzer, MD

DEBATE: Not So: Outcomes For EVAR Using Endografts Outside Their IFU Can Be As Good As Those Within The IFU If Certain Conditions Are Met
Peter L. Faries, MD

Risk Assessment And Risk Scores Have Little Value In The EVAR Treatment Of AAAs – In Contrast To Open Treatment
Hence J.M. Verhagen, MD, PhD

Risk Scoring For Ruptured AAAs Is Of No Value And A Waste Of Time
Janet T. Powell, MD, PhD

Nellix Endografts (EVAR) Are Useful For Relining And Treating Failed Previous AAA Repairs (Open And Endo): Technique And Results: The Dutch Experience
Barend M.E. Mees, MD, PhD

Panel Discussion (Refreshments Available In Back Of Room)

SESSION 45 (Trianon Ballroom, 3rd Floor)
INTERESTING RECORDED LIVE ENDOVASCULAR CASES AND THOSE EMPLOYING NEW AND INNOVATIVE TECHNIQUES
Moderators: Plinio Rossi, MD Carlo Setacci, MD Andrew Holden, MBChB Fabrizio Fanelli, MD Frank J. Veith, MD

Edited Live Case With The Use Of The Zenith Alpha Thoracic Endograft In Conjunction With A 4X Fenestrated Graft In A TAAA
Eric L.G. Verhoeven, MD, PhD

A New Approach To Calcified Femoral Artery Lesions – Lithoplasty
Andrew Holden, MBChB

Distal Arteriovenous Fistulas In CLI: The Last Resort
Marco G. Manzi, MD

Thoracic Aortic Repair After Failed TEVAR
Domenico Baccellieri, MD Germano Melissano, MD Roberto Chiesa, MD

Severe Calcium - One Of The Major Limitations Of Endovascular Therapy: The Role of Lithoplasty - Lessons Learned
Gunnar Tepe, MD
WEDNESDAY/THURSDAY
SESSIONS 45–46

4:05 – 4:16
Aneurysm Formation After Use Of Drug Coated Balloons Following Perforation Of A Degenerative Saphenous Vein Graft
Erwin Blessing, MD

4:16 – 4:27
Long-Term Follow-Up Of Critical Hand Ischemia In Hemodialysis Patients
Roberto Ferraresi, MD

4:27 – 4:37
Panel Discussion

SESSION 46 (Trianon Ballroom, 3rd Floor)
RECORDED LIVE CASES FROM LEIPZIG AND LINC; EXCITING TECHNICAL CHALLENGES AND SOLUTIONS
Moderators: Dierk Scheinert, MD
Giancarlo Biamino, MD, PhD
Andrej Schmidt, MD

4:37 – 6:00
LINC PROGRAM
Please visit www.veithsymposium.org for updates.
End of Program F
NEW TECHNIQUES, TECHNOLOGY AND CONCEPTS; ADVANCES IN F/BEVAR AND PARALLEL GRAFTS FOR COMPLEX AORTIC ANEURYSMS AND TAAAS; TRIBUTE TO OUR MILITARY: ENDO vs. OPEN TREATMENT FOR RUPTURED AAAs; VASCULAR ROBOTICS & GUIDANCE SYSTEMS; NEW CONCEPTS AND CONTROVERSIES

Grand Ballroom East, 3rd Floor

SESSION 47 (Grand Ballroom East, 3rd Floor)
NEW TECHNIQUES, TECHNOLOGY AND CONCEPTS
Moderators: Frank J. Veith, MD
Barry T. Katzen, MD

6:40 – 6:45
Importance Of Vessel Preparation Before DCB Use: Value Of The Cogent Serranator Device For Producing Controlled Lesion Serration Before DCB Inflation
Peter A. Schneider, MD

6:46 – 6:51
Creation Of A Spliced Vein Conduit Using A Microvascular Coupler (Technique Video): Where Can The Resulting Product Prove Essential
Benjamin M. Jackson, MD

6:52 – 6:57
What Are The Components Of A Stent's Radial Force And Why Do They Matter
Koen Deloose, MD

6:58 – 7:03
Lithoplasty From Shockwave Medical For Treating Heavily Calcified Lower Extremity Occlusive Lesions: Concept, Indications, Techniques And Results: From The DISRUPT PAD 1 And 2 Trials
Gunnar Tepe, MD
Thomas Zeller, MD
Andrew Holden, MBChB

7:04 – 7:09
How To Improve Patients And Your Own Intelligence And Cognitive Function By Increasing Brain Blood Flow Pharmacologically
Juan C. Parodi, MD

7:10 – 7:15
The Arsenal AAA Sac Filling System (Medtronic) For EVAR: How Does It Work; What Is Its Value: Early Results
Andrew Holden, MBChB

7:16 – 7:21
3D Printed AAA Templates With The AortaFit System From Aortica: How Do They Simplify And Improve F/EVAR Procedures: How Do They Work And Improve Fenestration/Branch Alignment
Benjamin W. Starnes, MD

7:22 – 7:27
Richard F. Neville, MD

7:28 – 7:33
Centerline Biomedical GPS-Like Vascular Navigation System To Decrease Radiation And Contrast Dosage By Using Sensor Equipped Catheters And Guidewires Located And Guided Through A 3-D Virtual Vascular Tree – iOPS (Intraoperative Positioning System)
Matthew J. Eagleton, MD

7:34 – 7:40
Panel Discussion
Use Of Parallel Grafts Is Expanding: So What Is The Basis For The Widespread Skepticism Concerning Parallel Grafts (Chimney, Periscope And Sandwich Grafts) 

Frank J. Criado, MD

DEBATE: Parallel Grafts Are Of Limited Value In Juxta- And Pararenal AAAs And TAAAs: Results With Them Are Not So Good Or Durable In Some Circumstances 

Adam Beck, MD
W. Anthony Lee, MD

DEBATE: Not So: If Done With Appropriate Precautions, The Results With Parallel Grafts Are Good, Durable And The Best Option In Many Circumstances 

Mario L. Lachat, MD

Tips And Unilateral Tricks For Simple Safe Axillary Access For Placement Of Multiple Parallel Grafts In The Treatment Of Complex AAAs: A Conduit Can Help 

Ross Milner, MD

Utility Of Access Scallops In Difficult Fenestrated EVAR Anatomy: How Do They Work: Is Selective Or Universal Stenting Of The Scalloped Branch Best 

Raghuveer Vallabhaneni, MD

How To Minimize Prolonged Lower Extremity And Pelvic Ischemia From Prolonged Occlusive Sheath Placement During F/BEVAR: Technique And Advantages 

Gustavo S. Oderich, MD

Physiologic Basis For Staging In Extensive Endovascular TAAA Repairs: How To Do It: What Are The Indications, Advantages And Limitations 

Matthew J. Eagleton, MD

How Infrarenal Endografts Can Safely And Effectively Be Extended To The Suprarenal Level With Chimney Grafts Using Currently Available Stent-Grafts: Tips And Tricks 

Claude Mialhe, MD

DEBATE: Value And Limitations Of Nellix Endografts With Chimneys For Juxta- And Pararenal AAAs: They Compare Favorably With F/BEVAR And Other Parallel Graft Treatments 

Matt M. Thompson, MD Iain Loftus, MD

DEBATE: Not So: F/BEVARs Are The Best Treatments For Most Juxta- And Pararenal AAAs 

Marcelo Ferreira, MD

DEBATE: Not So: Parallel Grafts With Standard EVAR Endografts Are The Best Treatment For Most Juxta- And Pararenal AAAs 

Jason T. Lee, MD Konstantinos P Donas, MD Giovanni Torsello, MD
Panel Discussion

Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 49 (Grand Ballroom East, 3rd Floor)
MORE ABOUT F/BEVAR AND PARALLEL GRAFTS FOR COMPLEX AAAs AND TAAAs; MORE RELATED CONTROVERSIES
Moderators: Frank J. Veith, MD
Carlos H. Timaran, MD

9:10 – 9:15
Advances In Branched EVAR (B/EVAR) For TAAAs: Viabahn/Zilver Stent Combination Is Better Than Fluency/Wall Stent Combination And Other Lessons Learned
Timothy A.M. Chuter, DM

9:16 – 9:21
How To Reduce Spinal Cord, Lower Extremity And Pelvic Ischemia During F/BEVAR For TAAAs
Athanassios Katsargyris, MD
Eric L.G. Verhoeven, MD, PhD

9:22 – 9:27
Classification Systems For Characterizing Aortic Necks And Type 1A Endoleaks After Chimney EVAR (Ch/EVAR): They Provide Clues To Make Ch/EVAR Have Better Outcomes
David J. Minion, MD
Konstantinos P. Donas, MD
Giovanni Torsello, MD

MEGA DEBATE

9:28 – 9:33
DEBATE: Ch/EVAR With More Than 2 Chimneys Do Not Have Good Outcomes And Should Not Be Used
Dittmar Böckler, MD

9:34 – 9:39
DEBATE: Ch/EVAR With More Than 2 Chimney Grafts Have A High Incidence Of Gutter Endoleaks, Other Complications And Poor Outcomes
W. Anthony Lee, MD
Adam Beck, MD

9:40 – 9:45
DEBATE: Not So: With Appropriate Techniques Using 2 Chimney Grafts And 2 Sandwich Grafts Pararenal AAAs Can Be Safely And Effectively Excluded: Exactly How Is This Done
Frans L. Moll, MD, PhD

9:46 – 9:51
DEBATE: Pararenal And TAAAs Can Be Effectively Excluded With Parallel Grafts Which Revascularize 4 Branch Arteries: The Stepwise Technique For Doing So
Manish Mehta, MD, MPH

9:52 – 9:58
Panel Discussion

Moderators: Matthew J. Eagleton, MD
James F. McKinsey, MD

How To Choose Between F/EVAR And Ch/EVAR In Patients With Complex AAAs: Both Procedures Have A Role
Jason T. Lee, MD

Tips And Tricks For F/BEVAR Including The Value Of Inner Branches And Retrograde Branch Punctures As A Bailout
Eric L.G. Verhoeven, MD, PhD
Athanassios Katsargyris, MD
**THURSDAY SESSIONS 49–50**

10:10 – 10:15
Conduit Use In F/BEVAR: Indications, Advantages And Techniques
Mark A. Farber, MD

10:16 – 10:21
What The PERICLES Registry Tells Us About The Value Of Parallel Grafts For Complex AAAs: Data From 513 Patients From 13 Centers: What Stent-Grafts Work For Ch/EVAR
Jason T. Lee, MD
Konsantinos P. Donas, MD
Giovanni Torsello, MD

10:22 – 10:27
2 ½ - 7-Year Results From 244 Selected PERICLES Registry Patients With Longer Follow-Up (Mean 4 Years) Show Sustained Good Results With Low Type IA Endoleak Rates And High Branch Patency Rates Equal To Those Of F/BEVAR
Jason T. Lee, MD
Konsantinos P. Donas, MD

10:28 – 10:33
DEBATE: F/BEVAR Results From Multiple UK Centers Are Better Than Open Repair Results For Complex AAAs
S. Rao Vallabhaneni, MD

10:34 – 10:39
DEBATE: Not So: French Multicenter Results Show That F/BEVAR Is No Better Than Open Repair For Complex AAAs
Jean-Pierre Becquemin, MD

10:40 – 10:45
In An Experienced Center Open Repair Of These Complex AAAs Are Better Than F/BEVARs
Germano Melissano, MD
Roberto Chiesa, MD

10:46 – 10:52
Panel Discussion

**SESSION 50 (Grand Ballroom East, 3rd Floor)**

A TRIBUTE TO THE MILITARY AND SERVICE PHYSICIANS HERE AND EVERYWHERE

**Moderators:** Eric Elster, MD
Norman M. Rich, MD

10:52 – 10:59
US Army Rangers And How They Saved The World On June 6, 1944 At Pont Du Hoc: They Made All The Difference
Wayne F. Yakes, MD

11:00 – 11:07
Accomplishments Of Dr. Norman Rich And The Vietnam Vascular Registry On Its 50th Anniversary
Todd E. Rasmussen, MD

11:08 – 11:15
Surgery In Space: Present Status, Future Challenges And Possible Solutions
Lee M. Morin, MD, PhD

11:16 – 11:23
Is New York City Organized For A Terrorist Attack: How Should Cities And Their Hospitals Prepare
Mark A. Adelman, MD

11:24 – 11:31
Organization Of The Surgical Response To The November 13, 2015 Paris Terror Attack: Lessons Learned
Eric Allaire, MD, PhD

11:32 – 11:39
Laurent Chiche, MD
59

THURSDAY
SESSIONS 50–51

11:40 – 11:47 Training For Vascular Damage Control: The NATO Perspective
  Michael Engelhardt, MD

11:48 – 11:55 Endovascular Capibility For Wartime Injuries: Lessons Learned And Implications For Future Innovation And Practice
  Todd E. Rasmussen, MD

11:55 – 12:00 Panel Discussion

12:00 – 1:00 Lunch Break - 2nd Floor Promenade And Rhinelander Gallery
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 51 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN THE TREATMENT OF RUPTURED AAAs (RAAAs): RELATED CONTROVERSIES
Moderators: Matt M. Thompson, MD
  Mario L. Lachat, MD

1:00 – 1:05 Impact Of Abdominal Compartment Syndrome (ACS) And Abdominal Decompression On The Outcomes Of EVAR For Ruptured AAAs (RAAAs): How To Diagnose And Treat ACS
  Cynthia K. Shortell, MD

1:06 – 1:11 New Developments In The Diagnosis And Treatment Of ACS After EVAR For RAAAs: What Is The Medical Treatment, When Is It Indicated And When Is Open Abdomen Treatment Mandatory
  Martin Björck, MD, PhD

MEGA DEBATE

1:12 – 1:17 DEBATE: Sometimes Repair Of A Ruptured AAA Is Not Worthwhile: Patients Who Have Had A Cardiac Arrest Is One Such Instance And Age >80 And BP <70 Are Other Indications Of 100% Mortality
  Benjamin W. Starnes, MD

1:18 – 1:23 DEBATE: Not So: Repair Of A Ruptured AAA After Cardiac Arrest Can Be Worthwhile
  Robert S. Crawford, MD
  Donald G. Harris, MD

1:24 – 1:29 DEBATE: Predictive Models For Mortality After RAAA Repair Do Not Predict Absolute Futility And Are Not Useful In Clinical Decision Making
  Matthew W. Mell, MD, MS

1:30 – 1:35 DEBATE: All Patients With RAAAs Should Have Repair Attempted: There Should Be No Exclusions Because All Patients Have A Chance At Survival – Especially With EVAR
  Jan S. Brunkwall, MD, PhD

1:36 – 1:42 Panel Discussion
Moderators: Martin Björck, MD, PhD
  Frank J. Veith, MD

1:42 – 1:47 Advantages And Value Of The Zurich-ESVS Ruptured AAA Workshop: What It Teaches About EVAR, ACS, Aortic Balloon Use And Other Adjuncts To Improve Outcomes: What Difference Has It Made
  Zoran Rancic, MD, PhD
  Mario L. Lachat, MD
  Dieter O. Mayer, MD
  Anders Wanhainen, MD, PhD
  Isabelle van Herzeele, MD, PhD
MEGA DEBATE

1:48 – 1:53
DEBATE: The IMPROVE RCT Shows No Mortality Benefit From An EVAR Strategy Over Open Repair For RAAAs – Although There Are Other Benefits To EVAR
Janet T. Powell, MD, PhD

1:54 – 1:59
DEBATE: Other RCTs (AJAX And ECAR) Comparing EVAR To Open Repair For RAAAs Also Show No Decreased Mortality For EVAR
Willem Wisselink, MD
Ron Balm, MD, PhD
Pascal Desgranges, MD, PhD

2:00 – 2:05
DEBATE: Not So: Why The RCTs Got It All Wrong: EVAR Is Best For RAAAs, Lowers Mortality And Has Other Benefits
Martin Malina, MD, PhD

2:06 – 2:11
Open Repair vs. EVAR For RAAAs: The Landscape Is Changing – Even In The UK: EVAR Is The New Gold Standard
Sherif A.H. Sultan, MD

2:12 – 2:17
EVAR LOWERS Mortality From RAAAs And Decreases “Turn Down For Treatment” Rates: With Adjuncts (Chimney Grafts, Etc.) Almost All RAAAs Can Be Treated Endovascularly
Thomas Larzon, MD, PhD
Dieter O. Mayer, MD
Mario L. Lachat, MD

2:18 – 2:24
Panel Discussion

SESSION 52 (Grand Ballroom East, 3rd Floor)
MORE RUPTURED AAA TOPICS AND CONTROVERSIES
Moderators: Cynthia K. Shortell, MD
Ali F. AbuRahma, MD

2:24 – 2:29
When An AAA Ruptures After EVAR: Optimal Management Techniques And How Does Prognosis Differ From A Usual RAAA
Aishraf Mansour, MD

MEGA DEBATE

2:30 – 2:35
DEBATE: Hostile Neck Anatomy Is A Major Determinant Of RAAA Treatment Outcome (Mortality): From The IMPROVE Trial
Janet T. Powell, MD, PhD

2:36 – 2:41
Marc R.H.M. van Sambtek, MD, PhD

2:42 – 2:47
With EVAR For RAAAs Clinical Success Can Be Achieved Despite Technical Failure With Incomplete RAAA Exclusion: How Can That Be
Francesco Setacci, MD

2:48 – 2:53
How Proper Use Of Supraceliac Aortic Balloon Control And Local Anesthesia Can Improve The Results Of EVAR For RAAAs
Jan M.M. Heyligers, MD, PhD
Endovascular vs. Open Repair For RAAAs In A Chinese Population: What Lessons Have Been Learned That Are Universally Applicable
Weiguo Fu, MD

Panel Discussion
Moderators: Michel Makaroun, MD
Michael B. Silva, Jr., MD

Late Results Of Treatment For RAAAs: EVAR vs. Open Repair: Improved Mortality Of EVAR Is Sustained
Dieter O. Mayer, MD
Stephanie Aeschbacher, MD
Mario L. Lachat, MD (Presenter)
Zoran Rancic, MD, PhD

DEBATE: Hypotensive Hemostasis (Fluid Restriction) Before Definitive Treatment Harms Patients With RAAAs: What Blood Pressure Should Be Maintained
Janet T. Powell, MD, PhD

DEBATE: Hypotension In RAAA Patients Restricts Bleeding And Is Beneficial: What Is The Lowest Level Of Blood Pressure (BP) That Should Be Tolerated: Should BP Ever Be Lowered With Drugs
Mario L. Lachat, MD

Use Of Nellix Device And Endovascular AAA Sealing (EVAS) For RAAAs: Advantages, Limitations And Results
Michel M.P. Reijnen, MD, PhD

Short- And Long-Term Outcomes Of Emergency Repair Of RAAAs In 80- And 90-Year-Old Patients: Is It Worthwhile And Does EVAR Improve Outcomes
Björn Sonesson, MD, PhD

Panel Discussion

Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

Technical Tips To Facilitate F/BEVAR: Including Use Of Medtronic Tour Guide System To Facilitate Complex Catheterizations And Decrease Radiation Times And Contrast Use
Fabien Thaveau, MD, PhD

The Magellan Robotic System From Hansen: One Key Value Is That It Can Reduce Radiation Exposure During Endovascular Procedures: Where Did It Come From And Where Is It Going
Barry T. Katzen, MD

Safety, Feasibility And Value Of The Magellan Endovascular Robot Based On Clinical Experience With 150 Cases
Celia Riga, BSc, MBBS, MD
Nicholas J.W. Cheshire, MD

New Developments In Endovascular Robotics With The Magellan Robotic System: What Does The ROVER Registry Show About The Advantages Of The System
Jean Bismuth, MD
How The Vascular Robotic Magellan System Can Improve A Vascular Practice And Make Failed Standard Manual Procedures Possible
Patrick E. Muck, MD

Combining Endovascular Robotics (Magellan) With Electromagnetic 3D Catheter Tracking To Facilitate Complex Endovascular Procedures And Make The Difficult Simple And The Impossible Possible
Alan B. Lumsden, MD
Jean Bismuth, MD

Current And Future Roles And Value Of Vascular Robotics In Endovascular Procedures And Especially Difficult Embolizations
John H. Rundback, MD

Vascular Robotics And Guidance Systems: Current Status And Future Prospects
Hans M.E. Coveliers, MD, PhD, MBA

Advantages Of Distal Tip Control During EVAR And TEVAR: What Are The Devices And Techniques For Achieving It
Jon S. Matsumura, MD

Panel Discussion

SESSION 54 (Grand Ballroom East, 3rd Floor)
SOME RADIATION SAFETY TOPICS AND OTHER NEW CONCEPTS AND DEVICES
(SEE SESSION 85 FOR OTHER RELATED TOPICS)
Moderators: Barry T. Katzen, MD Klaus D. Mathias, MD

RADIATION SAFETY TOPICS

Does A Hybrid Operating Room With Fixed X-Ray Equipment Increase Or Decrease Radiation Exposure To Staff Compared To A Portable C-Arm Cine Fluoroscope
Jan M.M. Heyligers, MD, PhD

How To Protect Yourself In An Interventional Career: 10 Top Tips For Vascular Surgeons, Interventional Radiologists And Cardiologists
Lindsay Machan, MD

OTHER NEW CONCEPTS & DEVICES

The General Electric Assist Systems To Help Plan And Guide Endovascular Procedures: How They Work
Stephan Haulon, MD

Differences In Pedal Arch Patenty In Patients With Diabetes And Those With ESRD: Which Is Harder To Treat
Iris Baumgartner, MD

Image Guided Directional Atherectomy With The Pantheris-Lumivascular System (From Avinger) Using OCT (Optimal Coherence Tomography) Guidance: How It Works, Advantages, Limitations And Results
Marianne Brodmann, MD
Patrick E. Muck, MD

New Developments In Treating Pediatric Limb Ischemia (Acute And Chronic) From Arterial Injuries
Dawn M. Coleman, MD

New Concepts And Techniques For Treating Pediatric Vascular Trauma (Civilian And Iatrogenic)
Samy S. Nitecki, MD
5:34 – 5:39 Smartphone App For Wound Assessment: Area, Depth And Tissue Composition: How It Works And Value
Richard F. Neville, MD

5:40 – 5:45 What Does The Belgian In.Pact Trial Show About The Value Of DCBs For BTK And Calcified Lesions And Those In Renal Failure Patients
Erik E. Debing, MD, PhD

5:46 – 5:54 Panel Discussion
End of Program G

PROGRAM H (SESSIONS 55–62)
NEW DEVICES FOR EVAR AND JUXTARENAL AAA REPAIR; TEVAR AND TAAA REPAIR; LOWER EXTREMITY TREATMENT; UPDATES ON ENDOANCHORS; NEW DEVICES FOR EMBOLECTOMY AND CLOT REMOVAL
Grand Ballroom West, 3rd Floor

SESSION 55 (Grand Ballroom West, 3rd Floor)
NEW AND IMPROVED DEVICES FOR EVAR AND JUXTARENAL AAA REPAIR (4 ½-MINUTE TALKS)
Moderators: Kenneth Ouriel, MD, MBA
William D. Jordan, Jr., MD

6:40 – 6:45 The CHAP Project (Characterization Of Human Aortic Anatomy Project): How Well Are Current EVAR Devices Able To Deal With Patient Diversity
Thomas S. Maldonado, MD

6:45 – 6:50 AAA Sac Compressibility After EVAR: A New Way To Detect Or Rule Out Endoleaks: How To Determine It With Contrast Enhanced Ultrasound (Duplex)
Henrik Sillesen, MD, DMSc

6:50 – 6:55 EVAR Durability Up To 14 Years With The Cook Zenith Flex AAA Endograft
Fabio Verzini, MD, PhD

6:55 – 7:00 The Cook Zenith Alpha AAA Endograft System: Advantages, Limitations And 1-Year Results
Eric L.G. Verhoeven, MD, PhD

7:00 – 7:05 Advantages Of The New Medtronic Endurant EVO Device For EVAR: What Makes It Different And Early Global Results
Gilbert R. Upchurch, MD

7:05 – 7:10 Clinical Results With The Cordis Incraft Endograft Device For EVAR: Advantages And Limitations
Germano Melissano, MD
Robert Chiesa, MD

7:10 – 7:15 Panel Discussion
Moderators: Hence J.M. Verhagen, MD, PhD
Nicholas J.W. Cheshire, MD

7:15 – 7:20 Long-Term (5-8 Years) Results With The Lombard Aorfix Graft And 3-Year Results With The Improved Intelliflex Delivery System: How It Works
Mahmoud B. Malas, MD, MHS
Mark F. Fillinger, MD
Andrew Holden, MBChB

7:20 – 7:25 Update On The ARCHYTAS Registry Results With The Lombard Aorfix Endograft Used In Unfavorable Anatomy
Vicente Rimbau, MD, PhD
7:25 – 7:30 Update On The World Experience With The Ovation Endograft For EVAR: From TriVascular And Now Endologix
Patrick Peeters, MD

7:30 – 7:35 Single Center Experience With The Ovation Endograft (TriVascular/Endologix) For EVAR: Advantages, Limitations And Use With Chimney Grafts
Venkatesh G. Ramaiah, MD

7:35 – 7:40 Can Polymer Sealing Technology With The Ovation Endograft Treat Short Necked AAAs As Well As Fenestrated And Chimney Grafts: What Are The Limitations
David J. Minion, MD

7:40 – 7:45 Aortic Neck Evolution After EVAR With The Ovation Endograft: Does It Dilate As With Other Self-Expanding Endografts
Francesco Setacci, MD

7:45 – 7:50 Panel Discussion
Moderators: Keith D. Calligaro, MD
Ali F. AbuRahma, MD

7:50 – 7:55 Advantages And Limitations Of Lombard’s Altura Endograft Device To Simplify EVAR Procedures: A Multicenter Study
David Murray, FRCS

7:55 – 8:00 Early Clinical Results With The Actively Conformable Gore Excluder (CEXC) EVAR Device For AAAs With Severely Angulated Necks: Concept And Advantages
Marc R.H.M. van Sambeek, MD, PhD

8:00 – 8:05 US Experience With The Gore Iliac Branch Device (IBD) Excluder To Preserve Hypogastric Flow: Advantages, Limitations And Tips For Use
Darren B. Schneider, MD

8:05 – 8:10 Results With The Cook Zenith IBD To Preserve Hypogastric Flow: The PRESERVE II Trial And A Ten-Year European Experience: Advantages And Limitations
W. Anthony Lee, MD
Fabio Verzini, MD, PhD

8:10 – 8:15 Parallel Grafts Work Very Well For Hypogastric Revascularization If Done Right: Tips For Doing And How They Are More Versatile Than IBDs
Armando C. Lobato, MD, PhD

8:15 – 8:20 Panel Discussion

SESSION 56 (Grand Ballroom West, 3rd Floor)
MORE NEW AND IMPROVED DEVICES FOR EVAR AND EVAS – SIMPLE AND COMPLEX; LIMITATIONS AND COMPLICATIONS (4 ½-MINUTE TALKS)
Moderators: Luis A. Sanchez, MD
Sean P. Lyden, MD

8:20 – 8:25 Durability Is An Issue With The Newer Ultra Low Profile Endografts: How Can It Be Resolved
Giovanni Pratesi, MD

8:25 – 8:30 Single Sided Access For EVAR With The Horizon Nexus Endograft: How Does It Work
Mario L. Lachat, MD

THURSDAY SESSIONS 55–56
8:30 – 8:35
The Bolton Treovance Endograft For EVAR: Unique Features, Advantages, Limitations And Early US Results
Daniel G. Clair, MD
Matthew J. Eagleton, MD

8:35 – 8:40
European Experience With The Bolton Treovance Endograft For EVAR: Midterm Results And Unique Advantages Including A Better Method For Revascularizing Hypogastric Arteries
Afshin Assadian, MD
Burkhart Zipfel, MD, PhD
Carlo Setacci, MD

8:40 – 8:45
Improvements In The Endologix AFX Device For EVAR: Mid- And Long-Term Complications And How They Can Be Avoided And Treated
Ignacio Escotto, MD

8:45 – 8:50
Failure Modes Of The AFX Endograft: How They Can Be Detected And Treated
Venkatesh G. Ramaiah, MD

8:50 – 8:55
Panel Discussion
Moderators: Martin Malina, MD, PhD
Rodney A. White, MD

8:55 – 9:00
Long-Term Perspective On The Nellix Endograft From Endologix For Endovascular AAA Sealing (EVAS): From The GLOBAL FORWARD Registry: Will Nellix Be A Game Changer
Andrew Holden, MBChB

9:00 – 9:05
With Nellix Endografts What Happens To AAA Sac Pressure With Endoleaks: How Is It Different From What Happens With Standard Endografts
Jeffrey P. Carpenter, MD

9:05 – 9:10
Advantages And Disadvantages Of Nellix Endografts For EVAS Based On Experience In 5000 Cases
Dittmar Böckler, MD

9:10 – 9:15
How Does The Nellix Endograft Facilitate EVAR In Women And Asians
Boonpratisrit Kritpracha, MD

9:15 – 9:20
The Nellix Endografts And EVAS: The Good, The Bad And The Ugly In A Busy Vascular Center Experience (200 Cases)
Sebastian Zerwes, MD

9:20 – 9:25
CT Imaging After Nellix EVAS Procedures: How To Interpret Them And Detect Endoleaks: What Happens To The Aortic Necks And How Does It Differ From Behavior With Standard Endograft EVARs
Michel M.P. Reijnen, MD, PhD

9:25 – 9:30
Panel Discussion
Moderators: Matt M. Thompson, MD
Piergiorgio Cao, MD

9:30 – 9:35
Late Failure Modes After Nellix EVAS: Incidence, Mechanism And Treatment: How Do They Differ From Those After Standard EVAR
Ian Loftus, MD
Matt M. Thompson, MD

9:35 – 9:40
Infection After Nellix AAA Repair: Incidence And How To Diagnose And Treat It
Jan M.M. Heyligers, MD, PhD

9:40 – 9:45
The Downsides And Limitations Of Nellix EVAS Repair Of AAAs
Hence J.M. Verhagen, MD, PhD
Limitations Of Nellix EVAS And What Precautions Must Be Taken When Using It
Daniel G. Clair, MD

What Happens When Nellix EVAR Fails: How To Diagnose It And What Are The Endovascular Bailouts Or Treatments
Carlos E. Donayre, MD

Panel Discussion

Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 57 (Grand Ballroom West, 3rd Floor)
NEW AND IMPROVED DEVICES FOR THE ASCENDING AORTA, TEVAR, CH/EVAR AND F/EVAR
Moderators: Sebastian E. Debus, MD, PhD
Enrico Ascher, MD

Results Of Ascending Aortic Endografting With A Dedicated Cook Endograft: Indications, Limitations And Results
Tilo Kölbèl, MD, PhD
Sebastian E. Debus, MD, PhD

What Is The Safety Of Celiac Axis Coverage/Exclusion During Complex EVAR Or TEVAR: How To Prevent Foregut Ischemia
Martin R. Bach, MD

3-Year US Results With The Bolton Relay Endograft For TEVAR: Unique Characteristics And Why They Make A Difference: Status With The FDA
Mark A. Farber, MD

3-Year US And European Results With The Gore Conformable TAG Device For TEVAR: Concept, Advantages And Limitations
Dittmar Böckler, MD
William D. Jordan, Jr., MD

Multicenter Results And Advantages Of The Gore Conformable TAG Device For Treating TBADs (From The GREAT Registry)
Santi Trimarchi, MD, PhD

A New “Gutterless” Off-The-Shelf Device For Treating Pararenal And Paravisceral AAAs With Chimney EVAR: Concept And Results
Timur P. Sarac, MD

World Results With The Vascutek Fenestrated Anaconda Endograft For Treatment Of Juxta And Pararenal AAAs: Advantages, Limitations And Results
Donald B. Reid, MD

Advantages Of The Fenestrated Anaconda Graft In Treating Angulated No Neck AAAs: Why Type 1A Endoleaks Often Resolve With Them
Clark J. Zeebregts, MD, PhD
Afshin Assadian, MD

Comparison Of Cook And Anaconda F/EVARs: Are There Advantages Or Disadvantages To Each Graft System: From The GLOBALSTAR Registry
Michael P. Jenkins, MBBS, BSc, MS

Panel Discussion
SESSION 58 (Grand Ballroom West, 3rd Floor)

DEVICES AND APPROACHES TO TREAT THE THORACIC AORTA AND TAAAs

Moderators: Krassi Ivancev, MD, PhD
Mark A. Farber, MD

11:18 – 11:23
Transcarotid Access For TAVI And TEVAR: Indications, Precautions And Results
Erno Remsey-Semmelweis, MD
Claude D. Väisäri, MD

11:24 – 11:29
TEVAR With Proximal Scalloped Off-The-Shelf Bolton Endografts Perform Better Than Left Subclavian (LSA) Branched Endografts To Treat Most Lesions Near To Or Involving The LSA: Midterm Results
Jean-Marc Alsac, MD, PhD
Michael P. Jenkins, MBBS, BSc, MS

11:30 – 11:35
Cook Zenith Alpha Low Profile Endograft System For TEVAR: Advantages, Limitations And Clinical Results In Europe And The US
Giovanni Torsello, MD
W. Anthony Lee, MD

11:36 – 11:41
Lower Profile Deployment Systems And Small Diameter Endografts Facilitate TEVAR Treatment Of Blunt Aortic Injuries In Young People: Is The Zenith Alpha System A Game Changer: Are There Other Systems As Good
Benjamin W. Starnes, MD

11:42 – 11:47
The New Valiant EVO Device From Medtronic For TEVAR: What Makes It Better And Early Clinical Results
Ali Azizzadeh, MD

11:48 – 11:53
A New Universal Off-The-Shelf Endograft For Treating TAAAs: Concept, Device Details And Early Results
Juan C. Parodi, MD

11:54 – 12:00
Panel Discussion

12:00 – 1:00
Lunch Break – 2nd Floor Promenade
And Rhinelander Gallery
Visit Exhibit And Pavilions (2nd and 3rd Floors)

SESSION 59 (Grand Ballroom West, 3rd Floor)

NEW DEVICES AND TECHNIQUES FOR TREATING LOWER EXTREMITY OCCLUSIVE DISEASE; PROSTHETIC GRAFTS AND HEPARIN BONDING

Moderators: Russell H. Samson, MD, RVT
Ali F. AbuRahma, MD

1:00 – 1:05
Impact Of Foot Infection On Leg Bypass Outcomes In CLI Patients: What Can Be Done To Offset It
Joseph L. Mills, MD

1:06 – 1:11
Advantages And Early Clinical Experience With A Balloon That Does Not Straighten When It Inflates: How Does It Work
Timothy A.M. Chuter, DM

1:12 – 1:17
Techniques For Performing Successful Bypasses To Heavily Calcified (Pipe-Like) Tibial Arteries: Concept And Technical Tips For Rendering Bloodless, Incising And Suturing
Enrico Ascher, MD
Frank J. Veith, MD
Advanced (Guide) Wiring Techniques For BTK And Foot Arteries For Interventional Treatments: What Difference Do They Make
Hiroyoshi Yokoi, MD

Update On Spiral Laminar Flow Grafts: How Do They Work And Do They Prevent Intimal Hyperplasia And Enhance Patency
Hosam F. El Sayed, MD

HEPARIN BONDED GRAFTS

Heparin Bonded PTFE Grafts (Propaten From Gore) For BTK Bypasses In CLI: Advantages, Patency Results And Cost Issues
Yann Gouëffic, MD, PhD

DEBATE: Heparin Bonding Is Valuable In PTFE Fempop Bypass Grafts (Propaten): Long-Term Patency Results Show It
Richard F. Neville, MD
Russel H. Samson, MD, RVT

DEBATE: Not So: Heparin Bonding Does Not Improve Results With PTFE Bypasses
Jonathan D. Beard, ChM, Med

Panel Discussion

SESSION 60 (Grand Ballroom West, 3rd Floor) NEW DEVELOPMENTS IN ARTERIAL GRAFTS; STENTS AND STENT-GRAFTS; CONCEPTS AND TECHNIQUES TO IMPROVE THEIR USE AND RESULTS

Moderators: Joseph L. Mills, MD Johannes Lammer, MD

Tissue Engineered Blood Vessels For Arterial Bypass And Dialysis Access - They Really Work: Midterm Results In Patients
Jeffrey H. Lawson, MD, PhD

Present Status Of Bio-Resorbable DESs In The Heart And Peripheral Arteries: Future Potential And Is Increased Risk Of Stent Thrombosis A Problem
Ron Waksman, MD

How Bio-Resorbable Stents Work And Why They Should Improve Stent Outcomes: How Lessons Learned In The Coronary Arteries Can Be Applied To Other Arteries
Richard J. Rapoza, PhD

Tack Optimized Balloon Angioplasty In The SFA And BTK Arteries: Concept, How It Works And 1-Year Results: The TOBA-BTK Trial
Marianne Brodmann, MD

New Distal Filter Embolic Capture Device And Other Tips And Devices To Facilitate Lower Extremity And Pedal Interventions: 2.9 Fr Sheath And Compatible Balloon, Off-Road Reentry Device, Etc.
Andrej Schmidt, MD

The New Cordis Smart Flex Stent: Advantages, Limitations And What Is Different: From The REALISTIC Trial
Peter C.J. Goverde, MD
Andrej Schmidt, MD
The New Gore Hybrid (2-Component) Tigris Stent: Concept, Advantages And Clinical Results  
Maciej L. Dryjski, MD, PhD  
Konstantinos Katsanos, MSc, MD, PhD

Panel Discussion

Moderators: Dierk Scheinert, MD  
Brian G. DeRubertis, MD

THE INTERWOVEN SUPERA STENT

Value Of The Supera Stent In Non-Fempop Territories  
Rajiv Parakh, MBBS, MS

How To Optimally Deploy The Interwoven Supera Stent: Why It Matters: What Is The New Delivery System And Does It Help  
D. Christopher Metzger, MD

Supera vs. Standard Nitinol Stents For Chronic Total SFA Occlusions: Final Results Of The SUPERFAST Trial  
Konstantinos Katsanos, MSc, MD, PhD

ZILVER PTX STENT

Japanese Trial Of The Zilver PTX Stent In 974 Patients – Some With Long Difficult Lesions: 3-Year Results Confirm Its Value  
Kimihiro Komori, MD, PhD

STENTYS STENT

Status Of DESs For Infrapopliteal Arteries: The Self-Expanding Paclitaxel Eluting Stentys Stent From Spectranetics Is Better Than BMSs: >1-Year Results From The PES-BTK-70 Trial Show It  
Patrick Peeters, MD

VIABAHN BX STENT-GRAFT

New Viabahn Balloon Expandable Stent-Graft (From Gore): Its Value And 1-Year Results In Treating Iliac Artery Occlusive Disease: The VIABAHN BX Trial  
Andrew Holden, MBChB

Panel Discussion

Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 61 (Grand Ballroom West, 3rd Floor) ENDOLEAKS AND ENDOGRAFT MIGRATION: UPDATE ON ENDOANCHORS

Moderators: Keith D. Calligaro, MD  
Jean-Paul de Vries, MD, PhD

ENDOANCHORS – HELI-FX-APTUS-MEDTRONIC

Long-Term (>4 Years) Results Of Endoanchors In Minimizing EVAR Failures (Type 1A Endoleaks And Migration) In Hostile Aortic Necks: The ANCHOR Registry: When Don’t They Work  
William D. Jordan, Jr., MD  
Jean-Paul de Vries, MD, PhD

In Patients With Hostile Neck Anatomy Endoanchors Prevent Endoleaks And Migration: A Propensity Matched Comparison Of EVAR In Hostile Neck Patients With And Without Endoanchors  
Bart E. Muhs, MD, PhD
Indications And Technical Tips For Placing Endoanchors With EVAR And Chimney EVAR Procedures: How Do We Know They Work And Prevent Type 1A And Gutter Endoleaks
Frank R. Arko, MD

Endoanchors Can Prevent And Treat Gutter Endoleaks With Parallel Grafts: Technical Tips And Midterm Results: When Will They Not Work
Zvonimir Krajcer, MD

Endoanchors (Heli-Fx, Aptus-Medtronic) During EVAR And Ch/EVAR Decrease Endoleaks And The Need For Reinterventions: When Don’t They Work
Manish Mehta, MD, MPH

Can AAA Neck Dilatation After EVAR With Self-Expanding Endografts Be Prevented By Endoanchors
Apostolos K. Tassiopoulos, MD

Endoanchors In TEVARs And With Complex EVARs (F/EVAR And Ch/EVAR): When And How Should They Be Used And What Is Their Value
Jean M. Panneton, MD

Endoanchors For TEVAR: When, Why And How Should They Be Used
Grayson H. Wheatley, MD

Panel Discussion

SESSION 62 (Grand Ballroom West, 3rd Floor)
NEW DEVICES FOR EMBOLECTOMY, CLOT REMOVAL AND EMBOLIZATION
Moderators: Thomas O. McNamara, MD
Sharif H. Ellozy, MD

Role Of Mechanical Thrombectomy And Thrombolysis In Acute Limb Ischemia: Technical Tips: When Is Open Operation Indicated
Ali Amin, MD, RVT

Treatment Of Embolic Complications Of Peripheral Interventions: It Is Not Just The Clot Which Must Be Removed: Value Of Suction Techniques And Devices
Jos C. van den Berg, MD, PhD

Role Of Mechanical Debulking Devices To Optimize Endovascular Treatment: Value Of Rotarex And Aspirex Devices From Straub Medical: How They Work And Results
Michael K.W. Lichtenberg, MD

Multicenter Retrospective Analysis Of Results Of Penumbra Indigo System For Mechanical Clot Aspiration From Arteries: How It Works, Indications, Vessel Sizes And Decreased Need For Lytics: The PRISM Registry
James F. Benenati, MD
Richard R. Saxon, MD

Why The Indigo Catheter Mechanical Thrombectomy System Is A Better Way To Remove Clot And Debris From Blood Vessels And Decrease The Need For Lytic Drugs
Frank R. Arko, MD

Value Of Indigo Thrombus Aspiration System In Acute Limb Ischemia And Visceral Artery Thromboses Or Emboli: Why It Is A Game Changer
George L. Adams, MD
Endovascular Rescue Procedures For Acute Visceral Ischemia From Thrombo-Embolism; Tools, Devices, Tips And Tricks
Andrej Schmidt, MD

Use Of The Lantern Microcatheter And Ruby And POD Coils (Penumbra) For Arterial Embolization: What Are Their Advantages And Limitations TBD

Panel Discussion
End of Program H

PROGRAM I (SESSIONS 63-70)
SUPERFICIAL VENOUS DISEASE AND VARICOSE VEINS
Trianon Ballroom, 3rd Floor
Course Leaders: Jose I. Almeida, MD, RPVI, RVT
Lowell S. Kabnick, MD, RPhS
Thomas W. Wakefield, MD

SESSION 63 (Trianon Ballroom, 3rd Floor)
VENOUS CLINICAL EXAMINATION AND HEMODYNAMICS
Moderators: Jose I. Almeida, MD, RPVI, RVT
Lowell S. Kabnick, MD, RPhS
Thomas W. Wakefield, MD

7:29 – 7:30 Introduction To Veins At VEITH
Jose I. Almeida, MD, RPVI, RVT

7:31 – 7:36 Establishing The Treatment Plan With CEAP & VCSS
Jose I. Almeida, MD, RPVI, RVT

7:37 – 7:42 Outcome Assessment Of CVD
Lowell S. Kabnick, MD, RPhS

7:43 – 7:48 Identifying Reflux Pathways With Duplex Ultrasound Mapping
Neil M. Khilnani, MD

7:49 – 7:54 Symptoms Of Chronic Venous Disease: Definition And Significance
Raghu Kolluri, MD

7:55 – 8:00 Venous Flow And Pressure: Modern Concepts
Seshadri Raju, MD

8:01 – 8:06 Physiology Of Venous Return
Brajesh K. Lal, MD

8:07 – 8:12 What Is Chronic Venous Dysfunction
Joseph D. Raffetto, MD

8:13 – 8:18 Saphenous Sparing Venous Surgery: ASVAL Technique
Sylvain Chastanet, MD

8:19 – 8:24 Hemodynamics-Based Venous Surgery: CHIVA Technique
Todd Berland, MD

8:25 – 8:30 Panel Discussion

SESSION 64 (Trianon Ballroom, 3rd Floor)
VENOUS IMAGING TECHNIQUES
Moderators: William A. Marston, MD
Neil M. Khilnani, MD

8:31 – 8:36 The Optimal Venogram: My Technique
Akhilesh K. Sista, MD

8:37 – 8:42 How To Recognize Variants On The Venous Duplex Exam
Neil M. Khilnani, MD
SESSION 65 (Trianon Ballroom, 3rd Floor)
SUPERFICIAL VEIN TREATMENT STRATEGIES AND TECHNIQUES
Moderators: Alun H. Davies, MA, DM, DSc
Steve Elias, MD

9:19 – 9:24 Matching The Endovenous Modality To The Individual: A Real-World Evaluation
Manj S. Gohel, MD

9:25 – 9:30 Concomitant Treatment Of Truncal Reflux And Varicous Tributaries Is The Gold Standard
Alun H. Davies, MA, DM, DSc

9:31 – 9:36 Lessons Learned: RF Ablation
Alan M. Dietzek, MD, RPVI

9:37 – 9:42 Lessons Learned: Laser Ablation
Jean Luc Gerard, MD

9:43 – 9:48 Step By Step: Phlebectomy
Paul Pittaluga, MD

9:49 – 9:54 Superficial Reflux With Obstructed Deep Veins: When And When Not To Treat
Jose I. Almeida, MD, RPVI, RVT

9:55 – 10:00 Incidence, Causes, And Treatment Of Recurrent Varicos Veins Following Endovenous Thermal Ablation
Edward G. Mackay, MD

10:01 – 10:06 Panel Discussion

NON-THERMAL ABLATION

10:07 – 10:12 Challenges Of Implementing Proprietary Foam Into Practice: It’s Kind Of A Different Practice Model
Kathleen D. Gibson, MD

10:13 – 10:18 Step By Step: Cyanoacrylate Embolic Adhesive
Mr. Ian J. Franklin, MS

10:19 – 10:24 Cyanoacrylate Embolic Adhesive vs. RFA: 2-Year Follow-Up PIVOTAL Trial
Raghu Kolluri, MD

10:25 – 10:30 Perforating Vein Closure With Turkish Cyanoacrylate Adhesive: Interim Results Of 40 Patients
Kursat A. Bozkurt, MD
THURSDAY
SESSIONS 65–67

10:31 – 10:36 Lessons Learned: MOCA Ablation
Alan H. Davies, MA, DM, DSc

10:37 – 10:42 Mechanochemical Ablation: The 3-Year Outcome Of A Prospective Trial On 100 Patients With GSV Incompetence
Michel M.P. Reijnen, MD, PhD

10:43 – 10:48 Reflux Extending To The Ankle: When And How To Treat
Steve Elias, MD

10:49 – 10:54 Concomitant Truncal Venous Incompetence And Lymphedema: To Ablate Or Not To Ablate
Paul Pittaluga, MD

10:55 – 11:00 Panel Discussion

SESSION 66 (Trianon Ballroom, 3rd Floor)
VENOUS SOCIETAL AND GOVERNANCE
Moderators: Lowell S. Kabnick, MD, RPhS
Ronald M. Fairman, MD

11:01 – 11:06 IAC Vein Center Accreditation: Is It Important
Alan M. Dietzek, MD, RPVI

11:07 – 11:12 CMS Policy, Payments And Pitfalls
Harold J. Welch, MD

Sean P. Roddy, MD

11:19 – 11:24 Outpatient Interventions: Are Controls Needed
Paul J. Gagne, MD

11:25 – 11:30 VQI Varicose Vein Registry: First Six Months Results
Thomas W. Wakefield, MD

11:31 – 11:36 A National Coverage Determination Policy
Lowell S. Kabnick, MD, RPhS

11:37 – 11:42 How To Have A Paper Accepted To JVS Venous And Lymphatic And JVS Case Report
Peter F. Lawrence, MD

11:43 – 11:48 How Do Venous Leaders Deal With Over-Utilization And Inappropriate Use
Steve Elias, MD

11:49 – 11:54 We Need A Joint Venous Council
Jose I. Almeida, MD, RPVI, RVT

11:55 – 12:00 Panel Discussion

12:01 – 12:59 Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 67 (Trianon Ballroom, 3rd Floor)
EXAMINING THE EVIDENCE
Moderators: Thomas W. Wakefield, MD
Bo G. Eklof, MD, PhD

1:00 – 1:05 Review Of RCTs Comparing Foam Sclerotherapy And Endothermal Ablation
Andrew W. Bradbury, MD

1:06 – 1:11 Cyanoacrylate Adhesive: More Than One Product Available: Is There A Difference
Mr. Ian J. Franklin, MS

1:12 – 1:17 ASVAL For The Small Saphenous Vein
Sylvain Chastanet, MD

1:18 – 1:23 C6 With Arterial Claudication: Which Comes First
William A. Marston, MD
THURSDAY
SESSIONS 67–69

1:24 – 1:29 Thermal Ablation On Anticoagulated Patients: Is It Safe And Effective
Glenn Jacobowitz, MD

1:30 – 1:35 Is There A Need To Correct A Refluxing Accessory Thigh Vein
Elna M. Masuda, MD

1:36 – 1:41 Is C2 Disease Progressive
Mark H. Meissner, MD

1:42 – 1:47 Why Graduated Compression Is An Insurance Requirement
Fedor Lurie, MD, PhD

1:48 – 1:53 Panel Discussion

SESSION 68 (Trianon Ballroom, 3rd Floor)
MORE USEFUL SUPERFICIAL VEIN INFORMATION
Moderators: Mr. Ian J. Franklin, MS
Edward G. Mackay, MD

1:54 – 1:59 What Is The Duplex Criteria For Pediatric Reflux Testing
Dawn M. Coleman, MD

2:00 – 2:05 Sclerotherapy Pearls
Edward G. Mackay, MD

2:06 – 2:11 Should You Use Foam For Telangiectasia Or Reticular Veins: Where Is The Evidence
Mr. Ian J. Franklin, MS

2:12 – 2:17 How To Treat Labial Varices: Sclerotherapy vs. Phlebectomy
Ellen D. Dillavou, MD

2:18 – 2:23 Physician Compounded Foam vs. Proprietary Compounded Foam
Lowell S. Kabnick, MD, RPhS

2:24 – 2:29 Laser Or Ohmic Devices For Telangiectasia: When And Why
Mr. Ian J. Franklin, MS

2:30 – 2:35 Management Of Calf Vein Thrombosis After Venous Procedures
Elna M. Masuda, MD

2:36 – 2:41 SVT In The Pregnant Patient
Ellen D. Dillavou, MD

2:42 – 2:47 Panel Discussion

SESSION 69 (Trianon Ballroom, 3rd Floor)
SUPERFICIAL VENOUS ABLATION, COMPRESSION AND RESEARCH
Moderators: Joseph A. Caprini, MD
Mark A. Adelman, MD

2:48 – 2:53 How To Properly Design And Interpret Clinical Trials
Thomas W. Wakefield, MD

2:54 – 2:59 The Maradona Trial: RCT Comparing MOCA With RFA
Michel M.P. Reijnen, MD, PhD

3:00 – 3:05 Creating WAVES: First US Post Market Results Using Venaseal™ Closure System Without Compression
Kathleen D. Gibson, MD

Fedor Lurie, MD, PhD
Does It Matter What Device You Use Regarding Vein Wall Thickness
Mark S. Whiteley, MS

Endovenous Thermal Ablation RCTs: Do We Know Enough
Bo G. Eklof, MD, PhD

SECURE Trial: Update On Perforator Ablation
Mark A. Adelman, MD

When Should We Use Prophylactic Anticoagulation In Saphenous Ablation
Joseph A. Caprini, MD

How Do Compression Garments Actually Work
John Blebea, MD, MBA

Which Patients Benefit From A Lymphedema Pump
Thomas S. Maldonado, MD

When To Use Inelastic Compression
Joseph A. Caprini, MD

Panel Discussion

Non-Thermal Devices Are Available For Truncal Ablation: How To Implement In Practice Without Dedicated CPT Codes
Steve Elias, MD

DEBATE: C2 Disease Should Not Be A Covered Insurance Benefit
Jose I. Almeida, MD, RPVI, RVT

DEBATE: C2 Disease Should Be A Covered Insurance Benefit
Alan M. Dietzek, MD, RPVI

The Future Of Venous Reimbursement In A Non-Fee For Service Environment
Thomas F. O’Donnell, Jr., MD

The Efficient Venous Practice: Evaluate With Lean Six Sigma
Christopher M. Banoub, MPA

Ask The Experts
Panelists: Steve Elias, MD
Jose I. Almeida, MD, RPVI, RVT
Ellen D. Dillavou, MD
Alan H. Davies, MA, DM, DSc
Mr. Ian J. Franklin, MS
Jean Luc Gerard, MD
Kathleen D. Gibson, MD
Lowell S. Kabnick, MD, RPhS
Marc A. Passman, MD
Alan M. Dietzek, MD, RPVI

End of Program I
FRIDAY, NOVEMBER 18, 2016
6:00 A.M. General Registration — Rhinelander Gallery, 2nd Floor
6:00 A.M. Faculty Registration — Morgan Suite, 2nd Floor
6:15 A.M. Continental Breakfast — Rhinelander Gallery, 2nd Floor

CONCURRENT FRIDAY PROGRAMS

PROGRAM J: (SESSIONS 71-78)
New Carotid Technology, Techniques And Concepts; Spinal Cord Ischemia (SCI); Carotid Related Topics And Controversies – CEA vs. CAS vs. Medical Therapy; Late Breaking Carotid Trial Information And Updates; New Concepts And Updates In PEVAR And Vascular Disease Treatment
6:40 A.M. – 5:58 P.M.
Grand Ballroom East, 3rd Floor

PROGRAM K: (SESSIONS 79-86)
Popliteal Aneurysms And Disease; Management Of Infected Arteries, Prosthetic Grafts And Endografts; Advances In Imaging And Hybrid Suites; New Developments In Thoracic Outlet Syndromes, Cardiac Evaluation, Vascular Trauma, Medical Topics And Treatments, CCSVI And Radiation Safety; Recorded Live Cases From Münster & The Mayo Clinic
6:40 A.M. – 5:35 P.M.
Grand Ballroom West, 3rd Floor

PROGRAM L: (SESSIONS 87-91)
New Developments In Deep Venous Disease And Its Treatment
6:58 A.M. – 5:12 P.M.
Trianon Ballroom, 3rd Floor
Course Leaders: Jose I. Almeida, MD, RPVI, RVT
Lowell S. Kabnick, MD, RPhS
Thomas W. Wakefield, MD

PROGRAM M: (SESSIONS 92-98)
The Challenging World Of The Diagnosis And Treatment Of Vascular Malformaitons: An Orphan Disease That Has Now Come Of Age
6:45 A.M. – 1:30 P.M.
Gramercy Suites East and West, 2nd Floor
Course Leaders: Wayne F. Yakes, MD
Krassi Ivancev, MD, PhD
Robert L. Vogelzang, MD

PROGRAM J (SESSIONS 71-78)
NEW CAROTID TECHNOLOGY, TECHNIQUES AND CONCEPTS; SPINAL CORD ISCHEMIA (SCI); CAROTID RELATED TOPICS AND CONTROVERSIES – CEA vs. CAS vs. MEDICAL THERAPY; LATE BREAKING TRIALS, INFORMATION AND UPDATES; NEW CONCEPTS IN VASCULAR DISEASE TREATMENT
Grand Ballroom East, 3rd Floor
SESSION 71 (Grand Ballroom East, 3rd Floor)
UPDATED OR NEW CAROTID ASSESSMENT TECHNIQUES, TECHNOLOGY OR CONCEPTS
Moderators: Ali F. AbuRahma, MD
Glenn Jacobowitz, MD
ASSESSMENT OF CAROTID PLAQUE RISK

6:40 – 6:45
Progress In Non-Invasive Prediction Of High Risk Asymptomatic Carotid Plaques Using Bio-Optical Imaging To Detect Macrophage Infiltration And MMPs Clark J. Zeebregts, MD, PhD

6:46 – 6:51
Use Of Web-Based Platforms And Features Of The Arterial Wall For Risk Stratification Of Asymptomatic Carotid Plaques: Can These Features And Risks Be Modified By Statins Christos D. Liapis, MD

6:52 – 6:57
Can We Identify The Small Percentage Of ACS Patients Who May Benefit From CEA Or CAS: What Is That Percentage Henrik Sillesen, MD, DMSc

6:58 – 7:03
Assessment Of Carotid Plaque Embolic Risk With 3D MRI: Correlation With TCD And Diffusion Weighted Brain MRI Peter L. Faries, MD

7:04 – 7:09
How Plaque Morphological Studies Can Resolve The Controversy Regarding Treatment Of Patients With Asymptomatic Carotid Stenosis (ACS) And Which Patients Should Undergo Invasive Treatment Jose Fernandes e Fernandes, MD, PhD

7:10 – 7:15
Carotid Interventions Should Not Be Based On Consensus Duplex Velocity Criteria: More Stringent Criteria Can Reduce Unnecessary Procedures And Show The Value Of Interventions In CREST 2 Mark F. Fillinger, MD

7:16 – 7:21
Pitfalls In The Sole Use Of Duplex Scans In Decision Making For Treatment Of Carotid Lesions Glenn M. LaMuraglia, MD Richard P. Cambria, MD

7:22 – 7:27
What Is The Significance Of Asymptomatic Emboli During Carotid Procedures: They Cannot Be Good Mark H. Wholey, MD

7:28 – 7:33
How Can Asymptomatic Carotid Stenosis Progression Be Predicted And How Can It Help Clinical Decision Making Bruce A. Perler, MD, MBA

7:34 – 7:39
Current Status Of Methods To Reliably And Non-Invasively Detect Asymptomatic Plaques At A High Risk Of Causing A Stroke Brajesh K. Lal, MD

7:40 – 7:46
Panel Discussion

SESSION 72  (Grand Ballroom East, 3rd Floor)
SPINAL CORD ISCHEMIA (SCI) WITH TAAA AND THORACIC ANEURYSM (TAA) REPAIRS; ITS PATHOGENESIS, PREVENTION AND TREATMENT
Moderators: Richard P. Cambria, MD Matthew J. Eagleton, MD

7:46 – 7:51
Critical Review Of Spinal Cord Protection From SCI In TAAAs – Open And Endo: Current Concepts And Future Prospects Christian D. Etz, MD, PhD

7:52 – 7:57
The 4-Territory Hypothesis For Risk Stratification In SCI And How It Can Help In Prophylaxis And Treatment Of SCI With Thoracic Aortic Procedures Martin Czerny, MD
Hamdy Awad, MD

8:04 – 8:09 Mechanisms Of SCI In Open TAAA Repair And F/BEVAR: How Do They Differ And How Should Prevention And Management Differ
Charles W. Acher, MD

8:10 – 8:15 Update On Prevention And Consequences Of SCI During Open And Endo TAAA And TAA Repairs: What Is Different Between Open And Endo Procedures And Treatment
Germano Melissano, MD
Roberto Chiesa, MD

8:16 – 8:21 Motor Evoked Potentials (MEPs) As An Indicator For Selective Staging Of B/FEVARs And TAAA Repairs: Technique And Results
Geert Willem H. Schurink, MD, PhD
Michael J. Jacobs, MD

8:22 – 8:27 Relevance Of MEPs In Endovascular TAAA Repairs And Strategies To Decrease Paraplegia
Piotr M. Kasprzak, MD

8:28 – 8:33 Value Of Intrathecal Papaverine In Decreasing SCI And Paraplegia With Complex TAA And TAAA Repairs
Eric E. Roselli, MD
Lars G. Svensson, MD, PhD

8:34 – 8:39 Technique And Limits Of Spinal Drainage With TAA And TAAA Repairs: How To Prevent Spinal Drain Complications
Mark A. Farber, MD
Anthony L. Estrera, MD

8:40 – 8:45 The Real Truth About The Incidence And Consequences Of SCI After Open And Endo TAAA Repair: Methods Of Prevention
Nicholas J.W. Cheshire, MD

8:46 – 8:51 Remote Ischemic Pre-Conditioning: What Is It And Can It Protect Against SCI
Thomas L. Forbes, MD

8:52 – 9:00 Panel Discussion

9:00 – 9:12 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 73 (Grand Ballroom East, 3rd Floor)
CAROTID RELATED TOPICS
Moderators: Thomas S. Riles, MD
J. David Spence, MD

9:12 – 9:17 Emergency CEA For A Stroke In Evolution: When Is It Indicated And How Should It Be Performed
Afshin Assadian, MD
Hans-Henning Eckstein, MD, PhD

Wei Zhou, MD
Christos D. Liapis, MD

Prospective Comparison Of Neuropsychologic Outcomes After CEA And Protected CAS (TCAR): Despite An Increase In Emboli And DW MRI Lesions With CAS, No Differences Were Noted On Testing
Frank E.G. Vermassen, MD, PhD

Comparison Of Left Carotid Subclavian Bypass And Transposition: Pros And Cons Of Each For Primary Subclavian Disease And With TEVAR
Mark K. Eskandari, MD

Proper Technique For Subclavian To Carotid Artery Transposition
Mark D. Morasch, MD, RPVI Ramon Berguer, MD, PhD

Comparison Of Left Carotid Subclavian Bypass And Transposition: Pros And Cons Of Each For Primary Subclavian Disease And With TEVAR
Mark K. Eskandari, MD

Fate Of Non-Operated False Aneurysms After Acute Carotid Dissections: How Should They Be Managed
Ross Naylor, MD

Management Of Carotid Patch Infection With And Without False Aneurysms: Proving Infection Can Be Hard – How To Do It
Patrick A. Stone, MD Ali F. AbuRahma, MD

Systematic Review Of Stroke And Death Rates After CAS And CEA In 21 Contemporary Big Registries: These Adverse Event Rates Are Higher Than Expected From RCTs: In Symptomatic And Asymptomatic Patients
Ross Naylor, MD Kosmas I. Paraskevas, MD

Use Of Covered Stents (Stent-Grafts) For Carotid Artery Injuries, Patch And Tumor False Aneurysms And Blowouts: How To Use Them Safely And Long-Term Results
Michael B. Silva, Jr., MD

What Is Wrong With Current Carotid Guidelines: How Important Is Bias: What Would An Evidence-Based Carotid Guideline Look Like
Anne L. Abbott, MD, PhD

How Low Do Statins Have To Go To Drive LDL-C To Produce Carotid Plaque Regression And Improved Echogenicity; Value Of Ezetimibe In Getting There And Of 3D Ultrasound In Detecting Regression
J. David Spence, MD

Contralateral ICA Occlusion Is A Major Stroke/Death Risk Factor For CEA But Not For CAS: Single Center And A Meta-Analysis Show It
Gianluca Faggioli, MD Andrea Stella, MD Mauro Gargiulo, MD
New Developments In Transcranial Doppler (TCD) Testing: How It Can Help In Everyday Clinical Practice  
Zsolt Garami, MD

Endovascular ICA Occlusion After Intracranial Thrombus Removal In Patients With Tandem (Intracranial And Extracranial Lesions) To Prevent Further Intracranial Embolization And Second Strokes: Advantages, Precautions And Limitations  
Emmanuel M. Houdart, MD

Decrease In Mental Acuity, DW MRI Lesions And Cranial Nerve Injuries Should Be Outcome Measures (End Points) In Comparisons Of CAS And CEA  
Sumaira Macdonald, MBChB, PhD

Impact Of Post-Procedural TIAs On Long-Term Survival After CAS And CEA: TIAs Are Not Innocuous  
Andrea Stella, MD  
Gianluca Faggioli, MD

Panel Discussion

Moderators: Frank J. Veith, MD  
Ross Naylor, MD

What Are Predictors Of Bad Outcomes After CAS; After CEA: They Are Not The Same  
Kim J. Hodgson, MD

Anatomical And Technical Predictors Of Stroke And Death After CAS  
Ali F. AbuRahma, MD

Mechanisms Of Procedural Strokes In The ICSS And ACST I Trials: What Are The Practice Implications And What Is The Value Of Troponins In Patients Undergoing CEA Or CAS  
Gert J. de Borst, MD

Clinical And Procedural Variables That Modify The Risk Of Stroke, MI And Death After CEA And CAS In Symptomatic Carotid Stenosis Patients: What Can Be Done To Lower These Risks  
Afshin Assadian, MD  
Hans-Henning Eckstein, MD, PhD

What Is The Current Gold Standard Of Cerebral Protection With CAS  
Giancarlo Biamino, MD, PhD

When Can A Mini-Incision (1.5 inches – 4 cm) CEA Be Performed With Or Without A Shunt: Tips And Tricks To Do It Safely  
Alan M. Dietzek, MD, RPVI

Diaphragm Of The ICA: An Underdiagnosed Cause Of Recurrent Stroke: How Can It Best Be Diagnosed And Treated  
Emmanuel M. Houdart, MD

Panel Discussion

Lunch Break – 2nd Floor Promenade
Visit Exhibits And Pavilions (2nd and 3rd Floors)
SESSION 75  (Grand Ballroom East, 3rd Floor)
MORE CAROTID DISEASE AND TREATMENT RELATED TOPICS AND CONTROVERSIES; TRANSCERVICAL CAS (TCAR) AND NEW MESH COVERED CAROTID STENTS
Moderators: Klaus D. Mathias, MD
Claudio J. Schonholz, MD

1:00 – 1:05
Midterm Results Of The ROADSTER PIVOTAL Trial Of The Silk Road System For TransCarotid Artery Stent Revascularization (TCAR) In High Risk Patients With Carotid Stenosis
Mahmoud B. Malas, MD, MHS
Christopher J. Kwolek, MD
Richard P. Cambria, MD

1:06 – 1:11
New Developments In The Silk Road System For TCAR: Details And Improvements In The Enroute System For CAS: How It Works And Achieves Flow Reversal Embolic Protection: Indications, Contraindications And Learning Curve Issues
Christopher J. Kwolek, MD
Richard P. Cambria, MD

1:12 – 1:17
Early Results Of The ROADSTER 2 Post-Market Registry Of TCAR In Normal Risk And High Risk Patients With Carotid Stenosis
Vikram S. Kashyap, MD
Peter A. Schneider, MD

MEGA DEBATE ON TIMING AFTER SYMPTOM ONSET

1:18 – 1:23
DEBATE: Early CEA After Symptom Onset Is Beneficial To Patients: The Earlier The Better After Certain Requirements Are Met
Ross Naylor, MD

1:24 – 1:29
Ian Loftus, MD

1:30 – 1:35
DEBATE: Early CEA (Within 48 Hours) After TIA Or Stroke: A Balanced View: What Are The Risks And Benefits: Early Brain Imaging And Carotid Duplex Can Help Select Patients For Safe, Early Intervention
Laura Capoccia, MD, PhD

1:36 – 1:41
DEBATE: Another Balanced View: When Is Early CEA After Symptom Onset In Patients With Carotid Stenosis Safe And Beneficial And When Is It Not
Martin Björck, MD, PhD

1:42 – 1:47
NEW MESH COVERED CAROTID STENTS
Comparison Of 3 Micromesh Covered Stents For CAS: Indications For Each And > 1-Year Clinical Results With The Terumo Roadsaver Stent
Max Amor, MD

1:48 – 1:53
Impact Of TCAR And Micro-Mesh Stent Usage With The C-Guard Stent (Inspire MD) On CAS: Do They Decrease DW MRI Cerebral Embolic Lesions: Which Helps Most
Piotr Musialek, MD, DPhil
Mariusz Trystula, MD, PhD
1:54 – 1:59 Dual Layer Micromesh Stents Decrease New Ischemic Brain Lesions After CAS: What Is The Functional Significance And Will These Micromesh Stents Have Downsides
Maria Antonella Ruffino, MD

2.00 – 2.06 Panel Discussion

SESSION 76 (Grand Ballroom East, 3rd Floor)
LATE BREAKING INFORMATION AND TRIAL STATUS RELATED TO CAROTID DISEASE AND ITS TREATMENT: CREST 2, ECST 2 AND ACST 2 STATUS AND ISSUES
Moderators: Enrico Ascher, MD
Richard P. Cambria, MD

CREST 2 RELATED TOPICS

2.06 – 2.11 Where Do We Stand With CREST 2 And What Will It Tell Us
Thomas G. Brott, MD
Brajesh K. Lal, MD

2.12 – 2.17 Will CREST 2 Incorporate Recent Advances In CAS (Cervical Access, Reversal Of Flow And Mesh Covered Stents) And What Will It Tell Us
L. Nelson Hopkins, MD

2.18 – 2.23 CREST 2 May Change Little Or Nothing In Carotid Treatment Practice: Why Is This So
Anne L. Abbott, MD, PhD

2.24 – 2.29 Why CREST 2 May Tell Us Very Little But Still Be Bad For Carotid Stenting (CAS)
Mark H. Wholey, MD

2.30 – 2.35 Barriers To Enrollment In CREST 2: How Can They Be Overcome
Mark Conrad, MD, MMSc

2.36 – 2.41 History Of Transcervical CAS And How To Do It With Standard Equipment
Enrique Criado, MD

2.42 – 2.48 Panel Discussion
Moderators: L. Nelson Hopkins, MD
Max Amor, MD

2.48 – 2.53 New Findings From CREST 1: Relationship Between Plaque Morphology And Post-Procedural Neurologic Events: Which Plaques Are High Risk For CAS But Not For CEA
Wesley S. Moore, MD

2.54 – 2.59 Update On The ECST 2 Trial: What Is It Telling Us Relevant To Carotid Lesion Treatment
Jonathan D. Beard, ChM, MEd
Martin M. Brown, MD
Leo H. Bonati, MD

3.00 – 3.05 Update On The ACST 2 Trial Comparing CAS And CEA In Asymptomatic Patients: Lessons Learned To Date
Richard Bullbulia, MA, MD
Alison Halliday, MS

3.06 – 3.11 Current Optimal Management Of Radiation Carotid Stenosis: Risk Of CEA And CAS And Which Is The Best Treatment For Symptomatic And Asymptomatic Disease In This Setting
Peter L. Faries, MD
SESSION 77 (Grand Ballroom East, 3rd Floor) NEW TECHNIQUES, TECHNOLOGIES, CONCEPTS – CAROTID RELATED

Moderators: Ali F. AbuRahma, MD  
Bruce A. Perler, MD, MBA

3:36 – 3:41 Carotid Pseudo-Occlusions: How Are They Best Diagnosed And Treated: What Are The Results Of Treatment And No Treatment  
Sonia Ronchey, MD, PhD

Nicos Labropoulos, BSc (Med) PhD, DIC, RVT

3:48 – 3:53 Carotid Bypass With Gore Hybrid Graft As A Rescue Method For CEA Gone Bad During The Operation: Technique And 1-Year Results  
Domenico Valenti, DMChir, PhD

3:54 – 3:59 Contemporary Population-Based Outcomes For CAS And CEA: From The SVS Registry: How Do We Know The Data Are Accurate  
Joseph L. Ricotta II, MD, MS

4:00 – 4:05 Comparison Of Mesh Covered C-Guard Stent vs. Wallstent For CAS: DW MRI And Clinical Results Show Benefit Of Mesh Covered Stent  
Laura Capoccia, MD, PhD

4:06 – 4:11 Are There Clinical Advantages Of Micromesh Covered And Dual Layer Stent Designs Over Closed Cell Stents In CAS  
Stefan Müller-Hülsbeck, MD

4:12 – 4:17 DEBATE: CAS Has No Increased Cost Consequences Compared To CEA  
Brajesh K. Lal, MD  
Thomas G. Brott, MD

4:18 – 4:23 DEBATE: Not So: CEA Costs Less Than CAS: Why The Discrepancy  
Kosmas I. Paraskevas, MD

4:24 – 4:29 Carotid Webs Can Cause Strokes: How Should They Be Diagnosed And Treated: Should They Be Treated If Asymptomatic  
Evan C. Lipsitz, MD

4:30 – 4:35 Current Status Of Surgery For Carotid Body Tumors: What Is New With Techniques And Adjuncts  
Peter F. Lawrence, MD

4:36 – 4:42 Panel Discussion
SESSION 78 (Grand Ballroom East, 3rd Floor)

NEW CONCEPTS AND UPDATES RELATED TO PERCUTANEOUS EVAR (PEVAR), WOUND CARE, SYMPATHECTOMY, MULTIPLE ANEURYSMS, ENDOVASCULAR NARROWING AND BRIDGING ANTICOAGULATION

Moderators: Peter F. Lawrence, MD
Jerry Goldstone, MD

UPDATE ON PEVAR

4:42 – 4:47
New Developments And Devices For PEVAR: What Is On The Horizon – Especially For Large Bore Sheaths
Zvonimir Krajcer, MD

4:48 – 4:53
Percutaneous EVAR (PEVAR) vs. Open Surgical Access For EVAR: A Single Center RCT And The Multicenter PIERO RCT: An Overview Of Cost Effectiveness And Complications Of Both Procedures
Afshin Assadian, MD
Clark J. Zeebregts, MD, PhD

4:54 – 4:59
How To Perform PEVAR: Tips And Tricks (Video Presentation)
Zoran Rancic, MD, PhD

5:00 – 5:05
Update On Fascial Suture Closure For PEVAR: Safety, Technical Tips And How It Saves Time And Money
Thomas Larzon, MD, PhD

5:06 – 5:11
Large Sheath Closure With The Proglide Device: Tips, Tricks And Economic Value
Giovanni Pratesi, MD

5:12 – 5:17
Cost Implications Of PEVAR: How Can It Be Made Cost Effective
Maciej L. Dryjski, MD, PhD

OTHER NEW CONCEPTS

5:18 – 5:23
What's New In Wound Care In PAD, The Diabetic Foot And Combined Arterial And Venous Ulcerations
Katherine A. Gallagher, MD

5:24 – 5:29
Renaissance For Chemical Sympathectomy In A Vascular Practice: Indications, Techniques And Results
Donald B. Reid, MD

5:30 – 5:35
Multifocal Synchronous Aorto-Iliac Femoro-Popliteal Aneurysms: Sequence And Strategies For Access And Treatment: Does It Depend On Aneurysm Size
Jacques Busquet, MD

5:36 – 5:41
Onion Skin And Other Techniques For Decreasing, In A Controlled Manner, Excessive Flows Through Blood Vessels Or Stent-Grafts While Maintaining Patency
Jerry Matteo, MD

5:42 – 5:47
Best Current Bridging Treatment For Anticoagulated Patients Requiring Vascular Surgery
Don Poldermans, MD

5:48 – 5:58
Panel Discussion

End of Program J
NEW DEVELOPMENTS IN THE TREATMENT OF ANEURYSMS AND OTHER DISEASES INVOLVING THE POPLITEAL ARTERY

Moderators: Eric L.G. Verhoeven, MD, PhD
Martin Björck, MD, PhD

**POPLITEAL ANEURYSMS**

6:40 – 6:45 Why Do We Still Need Open Surgery For Some Popliteal Aneurysms: What Are The Indications – Relative And Absolute
Jose Fernandes e Fernandes, MD, PhD

6:46 – 6:51 Comparison Of Open And Endo Popliteal Aneurysms Repair In The Same Patients
Samy S. Nitecki, MD

Irwin V. Mohan, MBBS, MD

6:58 – 7:03 DEBATE: Not So: Open Repair Is Better For Most Popliteal Aneurysm Patients: Endo Repair Is Sometimes A Failed Experiment
Martin Björck, MD, PhD

7:04 – 7:09 How Should Giant Popliteal Aneurysms Be Treated: Open vs. Endo And Tips And Tricks
Jacques Busquet, MD

Natalie A. Marks, MD, RPVI, RVT
Enrico Ascher, MD
Anil P. Hingorani, MD

**POPLITEAL ENTRAPMENT SYNDROMES**

7:16 – 7:21 New Developments In And Present Status Of Diagnosis And Treatment For Popliteal Entrapment Syndromes
Niten Singh, MD

7:22 – 7:27 When Should Patients With Popliteal Arterial Compression Be Treated By PTA Plus Surgical Decompression: Long-Term (10-Year) Results Show It Is Sometimes The Better Treatment
Beatrice R. Amann-Vesti, MD

7:28 – 7:33 Why Flexed Knee Angiography Should Always Be Performed To Control All Popliteal Interventions Or Procedures
Roberto Ferraresi, MD

7:34 – 7:40 Panel Discussion
SESSION 80 (Grand Ballroom West, 3rd Floor)
INFECTED ARTERIES AND ARTERIAL GRAFTS AND THEIR TREATMENT: INFECTED EVARs; MYCOTIC AAAs; INFECTED AORTIC/ARTERIAL PROSTHETIC GRAFTS; TREATMENT OF AORTO-ESOPHAGEAL FISTULA

Moderators: Glenn Jacobowitz, MD
Gary Giangola, MD

MANAGEMENT OF INFECTED EVARs

7:40 – 7:45
DEBATE: Update On Treatment Of Infected Aortic Endografts: Open Surgical Graft Excision Is Always Indicated
Kamphol Laohapensang, MD

7:46 – 7:51
DEBATE: Not So: Semi-Conservative Treatment Without Graft Excision And With Drainage And Antibiotic Irrigation Of AAA Sac Can Be Effective Treatment: Longer-Term Results Prove It
Martin Malina, MD, PhD

7:52 – 7:57
Treatment Of Infected Abdominal Endografts: Radical vs. Conservative: Late Survival Results With Each Treatment – From A Multicenter Study
Samuel R. Money, MD, MBA

TREATMENT OF MYCOTIC AAAs

7:58 – 8:03
Long-Term Outcome Of EVAR Treatment For Mycotic AAAs: What Risk Factors Impact On Late Survival
I-Hui Wu, MD, PhD

8:04 – 8:09
When Aortic Infections And Mycotic AAAs Are Treated By EVAR, Early Success Does Not Equal Late Success: The Infection Returns: What To Do About It
Ramesh K. Tripathi, MD

8:10 – 8:15
For Mycotic AAAs What Is The Value Of Endovascular Techniques And EVAR: When Are They Temporary Solutions And When Durable Treatment
Thomas C. Bower, MD

8:16 – 8:21
Value Of Vein Graft Covered Stent For Treatment Of Mycotic AAAs: Technique And Results
Klaus M. Overbeck, MD, MPhil

8:22 – 8:28
Panel Discussion
Moderators: Thomas C. Bower, MD
Keith D. Calligaro, MD

TREATMENT OF AORTIC GRAFT INFECTION

8:29 – 8:33
Intra-Abdominal Extra-Anatomic Reconstruction For Suprarenal Aortic And Graft Infection: Techniques And Results
Manju Kalra, MBBS
Thomas C. Bower, MD

8:34 – 8:39
Current Status Of Treatment For Aortic Graft Infection: When Should Cryopreserved Allografts Be Used And When Not: How Well Do They Work Long-Term
Peter F. Lawrence, MD

8:40 – 8:45
New Developments In The Treatment Of Prosthetic Aortic Graft Infection Facilitate In Situ Repair: Negative Pressure Wound Therapy And Bovine Pericardium Vascular Grafts: Techniques And Results
Max Zegelman, MD
8:46 – 8:51  Good Early Results Of Negative Pressure Wound Non-Excisional Treatment For Prosthetic Graft Infection Are Durable: It Is A Game Changer: Techniques And Long-Term Results

Dieter O. Mayer, MD
Barbara Hasse, MD
Mario L. Lachat, MD
Zoran Rancic, MD, PhD (Presenter)

8:52 – 8:57  Treatment Of Unilateral Limb Infection Of An Aortobifemoral Prosthetic Graft: Single Limb Excision Is Effective In ~50% Of Cases: When Should It Be Attempted: Diagnosis And Techniques

Gregory L. Moneta, MD

THORACIC GRAFT INFECTIONS

8:58 – 9:03  How Best To Treat Infectious Complications Of Open And Endo Thoracic Aortic Repairs

Germano Melissano, MD
Roberto Chiesa, MD

9:04 – 9:09  Treatment Of Post-TEVAR Aorto- Esophageal Fistula: Only Radical Surgery Can Be Effective: Techniques And Sequence Of Treatment

Michael J. Jacobs, MD

9:10 – 9:16 Panel Discussion

9:16 – 9:24 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 81 (Grand Ballroom West, 3rd Floor)
ADVANCES IN IMAGING, GUIDANCE AND HYBRID SUITES/ORs

Moderators: Gustavo S. Oderich, MD
Martin Malina, MD, PhD


Michael H. Wholey, MD, MBA

9:30 – 9:35  3D Live Interactive Holography For Vascular Interventions: Advantages And Limitations

Elchanan Bruckheimer, MBBS

ADVANCED RADIOGRAPHIC IMAGING: FUSION AND DYNA-CT

9:36 – 9:41  Principles Of Fusion Techniques And Dyna-CT: Advantages And Limitations During EVAR And TEVAR

Dittmar Böckler, MD

9:42 – 9:47 DEBATE: Hybrid Rooms With Fixed Fluoroscopy Units, Fusion And Dyna-CT Are Essential For Complex EVAR Procedures (F/BEVAR)

Stephan Haulon, MD

9:48 – 9:53 DEBATE: Not So: Results With Complex EVARs (F/BEVAR) Performed With C-Arm Mobile Imaging Fluoroscopy Units Are As Good As Those Done With Fixed Equipment In A Hybrid Suite

Geert Willem H. Scharinck, MD, PhD

9:54 – 9:59 Advantages Of The Ziehm Vision RFD Hybrid Mobile Motorized C-Arm And Stile ImagiQ2 Floating Table: How Do They Compare With Fixed Hybrid Equipment For Complex Aortic Procedures

Peter C. J. Goverde, MD

SESSIONS 80–81
10:00 – 10:05 3D Fusion Is Possible With Any Digital C-Arm Mobile Fluoroscope Using the Cydar Software System: How It Works And Can Simplify And Improve Fusion Techniques
   Tom Carrell, MD, MChir
   Cynthia K. Shortell, MD

10:06 – 10:12 Panel Discussion
   Moderators: Frans L. Moll, MD, PhD
   Daniel G. Clair, MD

10:12 – 10:17 New Developments In Imaging That Are On The Horizon And That Will Change Our Management Of Most Complex Vascular Interventional Treatments
   Lieven F. Maene, MD

10:18 – 10:23 The Future Of Vascular Imaging And Guidance: Where Are They Going
   Alan B. Lumsden, MD

   Jihad A. Mustapha, MD

10:30 – 10:35 DEBATE: Not So: Fluoroscopy And Angiography Are The Best Way To Control Distal Puncture Procedures And Lesion Crossing: Technical Tips And Tricks
   Andrej Schmidt, MD

10:36 – 10:41 Advanced Imaging Tools (The Vessel Assist System From GE) Can Improve 3D Imaging And Fusion And Facilitate Lower Extremity And CAS Procedures
   Koen Deloose, MD

10:42 – 10:47 Why IVUS Use Should Become Standard Of Care In An Endovascular Practice: In What Procedures Is It A Must
   Donald B. Reid, MD

   Peter Henke, MD

10:54 – 11:00 Panel Discussion

SESSION 82 (Grand Ballroom West, 3rd Floor)
NEW DEVELOPMENTS IN THE TREATMENT OF THORACIC OUTLET SYNDROMES (TOS) AND CARDIAC EVALUATION
   Moderators: Larry H. Hollier, MD
   Gregory L. Moneta, MD

11:00 – 11:05 New Objective Outcomes Reporting For Neurogenic TOS
   Karl A. Illig, MD

11:06 – 11:11 Neurogenic TOS In Competitive Athletes: Is It Real: How Is It Best Diagnosed And Managed
   Michael J. Singh, MD

11:12 – 11:17 Diagnosis And Optimal Treatment For Neurogenic TOS: The Supraclavicular Approach For First Rib Resection Is Best: How To Do It Well
   Robert W. Thompson, MD

11:18 – 11:23 What Comprises TOS Specific Physical Therapy And How Often Is It Effective In Neurogenic TOS
   Jason T. Lee, MD
TREATMENT OF VENOUS TOS

11:30 – 11:35
Optimal Way To Diagnose And Treat Venous TOS With Axillary-Subclavian Vein Thrombosis: Both The Supraclavicular And Infraclavicular Approaches Are Needed For Vein Exposure And Reconstruction
Robert W. Thompson, MD

11:36 – 11:41
Tips And Tricks For Transaxillary First Rib Resection For Venous TOS: The Subclavian Vein Seldom If Ever Needs To Be Surgically Reconstructed
Benjamin M. Jackson, MD

11:42 – 11:47
Infraclavicular Approaches To Venous TOS: Technique, Advantages And Limitation: What Can Be Done If The Subclavian Vein Needs To Be Reconstructed Or Cleaned Out
Joseph J. Ricotta II, MD, MS

PRE-OP CARDIAC EVALUATION

11:48 – 11:53
Peter Henke, MD

11:54 – 12:00
Panel Discussion

SESSION 83 (Grand Ballroom West, 3rd Floor)

NEW OR UPDATED CONCEPTS AND TREATMENTS FOR VASCULAR TRAUMA AND TAKAYASU’S DISEASE; MEDICAL TOPICS AND TREATMENTS
Moderators: Michael B. Silva, Jr., MD Joanelle Z. Lugo, MD

1:00 – 1:05
How To Reduce Door-To-Reperfusion Time With Severe Arterial Trauma
Markus K. Furrer, MD

1:06 – 1:11
New Developments In Endovascular Treatment And Balloon Occlusion For Major Arterial Trauma: What Is REBOA And Does Partial Aortic Balloon Occlusion Have Value
Tal M. Hörer, MD, PhD

1:12 – 1:17
Resuscitative Endovascular Balloon Occlusion Of The Aorta (REBOA) For Trauma Or Ruptured AAA: Is There A Role For IVUS Guidance To Facilitate Placement By Non-Interventionalists
Donald L. Jacobs, MD

1:18 – 1:23
Update On An Improved Classification System, TEVAR Devices And Techniques For Blunt Thoracic Aortic Injury (BTAI)
Ali Azizzadeh, MD
Benjamin W. Starnes, MD

1:24 – 1:29
Indications For Early Non-Operative Treatment With BTAI: It Is Safe And Lowers Mortality In Selected Patients: Indications For Early TEVAR
Robert S. Crawford, MD
Donald G. Harris, MD
1:30 – 1:35
Endovascular Treatment Of Traumatic Aortic Rupture In Children: What Devices Can Be Used For TEVAR
Gabriel Szendro, MD

1:36 – 1:41
Tips And Tricks For Recognizing And Treating Acute Popliteal Artery Injuries (Lacerations And Occlusions) After Orthopedic Knee Surgery: They Are Often Missed
SoHail Khan, MD

TAKAYASU’S DISEASE

1:42 – 1:47
Bypasses vs. Endovascular Treatments For Symptomatic Takayasu’s Arteritis: Pros And Cons Of Each
Byung-Boong Lee, MD

OTHER TOPICS

1:48 – 1:53
Current Management Strategies For Ehlers Danlos Syndrome And Role Of Endografts In The Treatment Of Its Arterial Lesions
James H. Black III, MD

1:54 – 1:59
Preop Non-Invasive Fractional Flow Reserve (FFR) Evaluation Of Coronary Lesion Can Improve Care And Decrease Costs In Vascular Patients: Technique And Results
Tej M. Singh, MD, MBA

2:00 – 2:08
Panel Discussion

SESSION 84 (Grand Ballroom West, 3rd Floor)
NEW DEVELOPMENTS AND UPDATES REGARDING CCSVI IN MULTIPLE SCLEROSIS; USE OF DRUGS IN VASCULAR DISEASE PATIENTS AND WAYS TO PREDICT RISKS OF ADVERSE EVENTS
Moderators: Caron B. Rockman, MD
Russell H. Samson, MD, RVT

CCSVI

2:08 – 2:13
Multicenter Blinded RCT To Determine Safety And Effectiveness (Quality Of Life) Of Venous PTA For Multiple Sclerosis (The BRAVE DREAMS Trial): Design And Progress: Will It Settle The Controversy
Paolo Zamboni, MD

DRUG TREATMENT OF VASCULAR DISEASES

2:14 – 2:19
How Can Statins And Other Medical Treatment Decrease The Amputation And Major Adverse Limb Event Rates After Revascularizations For CLI: What Are The Optimal Drugs And Dosages
Aravinda Najundappa, MD

2:20 – 2:25
Optimal Use Of ACE Inhibitors, Cilostazol, And Statins In Patients Undergoing Open And Endovascular Procedures
Anthony J. Comerota, MD

2:26 – 2:31
Update On When And How Should Beta Blockers Be Used In Low Risk And High Risk Vascular Patients Generally And When They Undergo Operations And Interventions: Dosage Is Key
Caron B. Rockman, MD
Jeffrey S. Berger, MD, MS

2:32 – 2:37
Improving Non-Coronary Stent Outcomes By Pharmacological Manipulations – 2C19 And Plavix: How Do They Do It
Karthikeshwar Kasirajan, MD
Jeffrey S. Berger, MD, MS
Caron B. Rockman, MD

2:44 – 2:50 Panel Discussion
Moderators: Anthony J. Comerota, MD
Elliot L. Chaikof, MD, PhD

2:50 – 2:55 Benefits Of Perioperative Statins In Improving Outcomes And Decreasing Adverse Events After AAA And Carotid Procedures – Endo And Open: Optimal Timing, Drug And Dosage
Bruce A. Perler, MD, MBA

2:56 – 3:01 Update On The Medical (Drug) Treatment Of AAA Disease: What Does Metformin Do: Does Any Drug Slow AAA Growth
Ronald L. Dalman, MD

3:02 – 3:07 Should Bivalirudin Replace Heparin In Non-Cardiac Interventions: Advantages And How To Use It
George H. Meier III, MD

3:08 – 3:13 Biomarkers Can Predict Long-Term (~10 Years) Adverse Cardiovascular Events In Vascular Patients: Which Ones And How Can They Be Used
Beatrice R. Amann-Vesti, MD

3:14 – 3:19 How To Identify Patients At Risk Of Cardiovascular Adverse Events After EVAR
Janet T. Powell, MD, PhD

3:20 – 3:26 Panel Discussion

3:26 – 3:36 Break – Visit Exhibits And Pavilions (2nd and 3rd Floors)

SESSION 85 (Grand Ballroom West, 3rd Floor)
NEW CONCEPTS AND TECHNIQUES TO DECREASE RADIATION EXPOSURE FOR ENDOVASCULAR SURGEONS/SPECIALISTS AND PATIENTS
Moderators: Barry T. Katzen, MD
Evan C. Lipsitz, MD

3:36 – 3:41 Crucial Elements In Radiation Safety For Non-Radiology Interventionists: Advice From A Radiologist
Jos C. van den Berg, MD, PhD

3:42 – 3:47 Comparison Of Radiation Dosage And Safety Between Mobile C-Arm Fluoroscopes And Fixed Hybrid Units
Mark G. Davies, MD

Lindsay Machan, MD

3:54 – 3:59 How To Minimize Radiation Exposure During Complex Endovascular AAA Repairs: Tips And Tricks
Neal S. Cayne, MD

4:00 – 4:05 New Processing Software And Other Techniques For Reducing Radiation Exposure During Complex Interventional Procedures
Carlos H. Timaran, MD
4:06 – 4:11 How OCT (Optical Coherence Tomography) Imaging Can Control Crossing Of CTOs And Decrease Radiation Exposure: So Too Can Expanded Use Of Duplex And IVUS
Todd R. Vogel, MD, MPH

4:12 – 4:17 Worrisome Biologic And Dosimetric Effects Of Operator Radiation Exposure During Complex Interventional Procedures: How Can They Be Measured And Decreased
Bijan Modarai, MD, PhD

4:18 – 4:23 Malignancies Occurring During CT Follow-Up Of EVAR: It Is A Real Risk And What To Do About It
Ramesh K. Tripathi, MD

4:24 – 4:32 Panel Discussion

SESSION 86 (Grand Ballroom West, 3rd Floor)
RECORDED LIVE CASES OF COMPLEX AORTIC ANEURYSM TREATMENT WITH ENDOVASCULAR TECHNIQUES
Moderators: Giovanni Torsello, MD
Gustavo S. Oderich, MD

4:32 – 4:52 Complex Cases From Münster
Giovanni Torsello, MD

4:52 – 5:02 Questions And Discussion

5:03 – 5:23 Complex Cases From The Mayo Clinic – Including Use Of A 3D Model With Pump Perfusion (Sande Stable) For Planning And Simulation
Gustavo S. Oderich, MD

5:23 – 5:35 Questions And Discussion

End of Program K

PROGRAM L  (SESSIONS 87-91)
DEEP VENOUS DISEASE
Trianon Ballroom, 3rd Floor
Course Leaders: Jose I. Almeida, MD, RPVI, RVT
Lowell S. Kabnick, MD, RPhS
Thomas W. Wakefeld, MD

SESSION 87 (Trianon Ballroom, 3rd Floor)
VENOUS CROSS-SECTIONAL IMAGING TECHNIQUES, PELVIC VENOUS DISORDERS
Moderators: Jose I. Almeida, MD, RPVI, RVT
Lowell S. Kabnick, MD, RPhS

CROSS-SECTIONAL IMAGING

6:58 – 6:59 Introduction To Deep Veins
Lowell S. Kabnick, MD, RPhS

7:00 – 7:05 Evaluation Of The Severity Of Venous Obstruction
Olivier Hartung, MD

7:06 – 7:11 Getting A Look At Inflow With Duplex Ultrasound Prior To Endovascular Reconstruction Of Post-Thrombotic Iliocaval Disease
Jose I. Almeida, MD, RPVI, RVT

7:12 – 7:17 How To Measure Iliac Vein Stenosis
Seshadri Raju, MD

7:18 – 7:23 Pertinent IVUS Anatomy
Paul J. Gagne, MD

7:24 – 7:29 Novel Imaging Techniques With MRI For Thrombus Aging
Stephen A. Black, MD
7:30 – 7:35 The Bull’s-Eye Sign And Other Iliocaval-Femoral Venographic Findings: A New Classification To Limit The Use Of Intravascular Ultrasound
Enrico Ascher, MD

7:36 – 7:41 A New Look At Venous Hemodynamics: Measuring Reflux And Venous Outflow Obstruction
Andrew N. Nicolaides, MS

7:42 – 7:47 MRV And Major Venous Interventions
Mark G. Davies, MD

7:48 – 7:53 MRV And CTV In Imaging Of Pelvic And Abdominal Venous Compressive Syndromes: Which Is Better And Why
Constantino Pena, MD

7:54 – 7:58 Panel Discussion

PELVIC VENOUS DISORDERS

7:59 – 8:04 Reasons New Nomenclature Is Needed For Pelvic Venous Disorders
Mark H. Meissner, MD

8:05 – 8:10 Pelvic Venous Incompetence And Leg Varicosities: Start From Above Or Below
Melvin Rosenblatt, MD

8:11 – 8:16 Pelvic Varices Are Best Studied With Trans-Vaginal Duplex Ultrasound
Mark S. Whiteley, MS

8:17 – 8:22 Venographic Technique To Identify Pelvic Anatomy And Escape Points
Mark H. Meissner, MD

8:23 – 8:28 Ovarian Vein Incompetence Or Renal Vein Compression
Jose I. Almeida, MD, RPVI, RVT

8:29 – 8:34 Acute Or Chronic Ovarian Vein Thrombosis: What To Do
Mikel Sadek, MD

8:35 – 8:40 DEBATE: Renal Vein Transposition (With Patch) Is The Ideal Treatment For Nutcracker Syndrome, Not Stenting
Olivier Hartung, MD

8:41 – 8:46 DEBATE: Gonadal Vein Transposition Is The Ideal Treatment For Nutcracker Syndrome
Cynthia K. Shortell, MD

8:47 – 8:52 DEBATE: Stenting Is The Ideal Treatment For Nutcracker Syndrome
Thomas S. Maldonado, MD

8:53 – 8:58 DEBATE: Hybrid Endo-Open Surgery Is The Ideal Treatment For Nutcracker Syndrome
Manju Kalra, MBBS

8:59 – 9:04 Panel Discussion

SESSION 88 (Trianon Ballroom, 3rd Floor)
FEMORO-ILIACAL INTERVENTIONAL STRATEGIES TO REDUCE VENOUS HYPERTENSION, HOT IDEAS FOR RECANALIZING CHRONIC TOTAL OCCLUSIONS
Moderators: Jose I. Almeida, MD, RPVI, RVT
Lowell S. Kabnick, MD, RPhS

9:05 – 9:10 Exactly What Is The Tissue Causing Post-Thrombotic Venous Obstruction
Anthony J. Comerota, MD

SESSION 87 (Foyer)
FRIDAY
9:11 – 9:16 DEBATE: Open Excisional Surgery For Post-Thrombotic Common Femoral Vein Obstruction (Endophlebectomy) Is Of Limited Value In the Endovascular Era
Jose I. Almeida, MD, RPVI, RVT

9:17 – 9:22 DEBATE: Open Excisional Surgery For Post-Thrombotic Common Femoral Vein Obstruction (Endophlebectomy) Is Standard Of Care
Cees H.A. Witten, MD, PhD

9:23 – 9:28 Step By Step Endophlebectomy Of Common Femoral Vein
Marzia Lugli, MD

9:29 – 9:34 Surgical Reconstruction Of Deep Veins: Do I Do It To Improve Inflow Of Obstructive Disease Or To Control Reflux
Stephen A. Black, MD

STENTS AND STENT TRIALS

9:35 – 9:40 Engineering Challenges Required For An Ideal Ilio-Caval Stent
Lowell S. Kabnick, MD, RPhS

9:41 – 9:46 Dedicated Venous Stents Make Sense
Michael K.W. Lichtenberg, MD

9:47 – 9:52 Results With Dedicated Venous Self-Expanding Oblique Hybrid Nitinol Stent
Iris Baumgartner, MD

9:53 – 9:58 Vernacular (Venovo) Stent Trial And Methodology
Michael D. Dake, MD

9:59 – 10:04 An Update On VIVO-EU: The Zilver Vena Venous Stent Study In Europe
Gerard J. O’Sullivan, MD

10:05 – 10:10 VIRTUS - 12-Month Results: VICI Venous Stent – Feasibility Study
Lowell S. Kabnick, MD, RPhS

10:11 – 10:16 The Modena Iliac Vein Stent Experience
Marzia Lugli, MD

OFF-LABEL STENT USE

10:17 – 10:22 Crossing Femoro-Iliocaval Chronic Total Occlusions: From Soft Wires To Sharp Harpoons
Jose I. Almeida, MD, RPVI, RVT

10:23 – 10:28 DEBATE: Femoral Vein Stenting Succeeds Under These Conditions
Brian G. DeRubertis, MD

10:29 – 10:34 DEBATE: Femoral Vein Stenting Fails Often And Early
Jose I. Almeida, MD, RPVI, RVT

10:35 – 10:40 DEBATE: Femoral Vein Angioplasty (Not Stents): Must Look And Treat Popliteal Vein And Below To Succeed Often
Mark J. Garcia, MD

10:41 – 10:46 Panel Discussion
SESSION 89 (Trianon Ballroom, 3rd Floor)
STRATEGIES FOR CORRECTING SEVERE DEEP VENOUS REFLUX AND/OR OBSTRUCTION; WOUNDS AND NEW HORIZONS FOR VENOUS DISEASE MANAGEMENT
Moderators: Marc A. Passman, MD
Joseph D. Raffetto, MD

10:47 – 10:52
Years Of Planning Venous Stents: What I Have Learned
Olivier Hartung, MD

10:53 – 10:58
Z-Stent Extension Into The Cava: Reduces Contralateral Iliac Vein Thrombosis: Short Term Data
Erin H. Murphy, MD

10:59 – 11:04
Step By Step Deep Venous Valve Repair Or Creation
Oscar Maleti, MD

11:05 – 11:10
Deep Venous Reflux Reconstruction Techniques
Ramesh K. Tripathi, MD

11:11 – 11:16
Deep Venous Obstruction Reconstructive Techniques
Ramesh K. Tripathi, MD

WOUNDS AND NEW HORIZONS

11:17 – 11:22
Venous Ulcer: Clinical Evaluation Wound Care, Compression, Surgical Treatment, Ancillary Measures
Marc A. Passman, MD

11:23 – 11:28
RCT Demonstrating Benefits Of Sulodexide For Venous Ulcers
Joseph D. Raffetto, MD

11:29 – 11:34
Important RCTs For Venous Wound Healing
William A. Marston, MD

11:35 – 11:40
Surgical Intervention On Venous Ulcer Based On Cost-Effectiveness: Is It Different Than C2
Thomas F. O’Donnell, Jr., MD

11:41 – 11:46
Proteomics And Degradomics In Venous Leg Ulcers
Joseph D. Raffetto, MD

11:47 – 11:52
Not All Leg Ulcers Are Venous
Raghu Kolluri, MD

11:53 – 11:59
Panel Discussion

12:00 – 1:00
Lunch Break – 2nd Floor Promenade
Visit Exhibits and Pavilions (2nd and 3rd Floors)

SESSION 90 (Trianon Ballroom, 3rd Floor)
STRATEGIES FOR THROMBOEMBOLIC EVENTS IN THE VENOUS SYSTEM INCLUDING THE AXILLO-SUBLAVIAN SYSTEM
Moderators: Brian G. DeRubertis, MD
Suresh Vedantham, MD

1:00 – 1:05
Experimental Insights Into Acute DVT And Post-Thrombotic Syndrome (PTS)
Peter Henke, MD

1:06 – 1:11
Calf Muscle Compartment Pressure In Acute Iliofemoral DVT And The Effect Of Early Thrombus Removal
Bo G. Eklof, MD, PhD

1:12 – 1:17
Update On Reversal Agents For The Direct Oral Anticoagulants (DOACs)
Timothy K. Liem, MD, MBA

VENOUS THROMBOEMBOLISM (VTE) - MEDICAL
1:18 – 1:23 Isolated Soleal And Gastrocnemius Vein Thrombosis  
Clifford M. Sales, MD, MBA

1:24 – 1:29 Popliteal Venous Entrapment: When And What Do You Do  
Alun H. Davies, MA, DM, DSc

1:30 – 1:35 Biomarkers Of Venous Thromboembolism: Do They Have A Current Role  
Thomas W. Wakefield, MD

1:36 – 1:41 What Is The True Incidence Of PE In Patients With Ilio-Femoral DVT: How Many Of These Have Right Ventricular Strain  
Divya Sridhar, MD

1:42 – 1:47 Which DOAC For Which DVT: Can We Stratify Yet  
Timothy K. Liem, MD, MBA

1:48 – 1:54 Panel Discussion

VTE - INTERVENTIONAL

Moderators: Brian G. DeRubertis, MD, Suresh Vedantham, MD

1.55 – 2.00 Technical Considerations And Emerging Technology For Chronic Venous Occlusions  
Brian G. DeRubertis, MD

2.01 – 2.06 What Is The Best Method To Measure Venous Thrombolysis Resolution  
Akhilesh K. Sista, MD

2.07 – 2.12 If The ATTRACT Trial Is Positive What Will Happen In US/Europe/Asia  
Suresh Vedantham, MD

2:13 – 2:18 Prevention Of PTS: Is The Jury Still Out: Statins And VTE  
Andrew N. Nicolaides, MS

2.19 – 2.23 D-Dimer And/Or Duplex Findings To Manage DVT  
Timothy K. Liem, MD, MBA

2.24 – 2.29 Impact Of Caval Occlusion On The Outcomes Of Thrombolysis For Iliofemoral DVT  
Rabih A. Chaer, MD

2.30 – 2.35 Vacuum-Assisted Venous Thrombectomy: Where, When, And How  
Mikel Sadek, MD

2.36 – 2.41 An Algorithm For The Treatment Of Paget-Schroetter’s Syndrome  
Thomas S. Maldonado, MD

2.42 – 2.47 Venous Issues In Thoracic Outlet Syndrome: Lysis, Venoplasty, First Rib Resection: Staged Or Same Setting  
Enrique Criado, MD

2.48 – 2.53 QOL After Deep Venous Recanalization Procedures: Any Relation To Patency  
Cees H.A. Wittens, MD, PhD

2.54 – 2.59 Evolution Of Venous In-Stent Stenosis: Do Anti-Platelet Agents Help Mitigate  
David M. Williams, MD

3.00 – 3.05 Treating Venous Thromboembolism Without Lytic Medications  
Constantino Pena, MD

3.06 – 3.11 Panel Discussion
SESSION 91 (Trianon Ballroom, 3rd Floor)
ENDOVASCULAR AND OPEN SOLUTIONS FOR INFERIOR VENA CAVA TUMORS AND OCCLUSIONS, VENA CAVA FILTRATION STRATEGIES, PITFALLS, AND COMPLICATIONS AND MORE ABOUT ILIAC VEIN STENTING
Moderators: Jose I. Almeida, MD, RPVI, RVT
William A. Marston, MD

MORE FEMORAL-ILIOCAVAL FLOW ISSUES

3:12 – 3:17 IVC Agenesis – Is This A Real Entity
David M. Williams, MD

3:18 – 3:23 IVC Occlusion – Where To Reroute
Mark G. Davies, MD

3:24 – 3:29 Benign And Malignant Caval Tumors
William A. Marston, MD

3:30 – 3:35 Thrombosed IVC Filter: How To Recanalize The Cava And Manage The Filter
Jose I. Almeida, MD, RPVI, RVT

3:36 – 3:41 IVC Replacement For Malignancy: How To Do It
Thomas C. Bower, MD

3:42 – 3:47 Conduit Choices For In-Line Caval Reconstruction
William A. Marston, MD

Samuel R. Money, MD, MBA

3:54 – 3:59 Panel Discussion

CAVAL INTERRUPTION
Moderators: John E. Rectenwald, MD, MS
David L. Gillespie, MD

4:00 – 4:05 Indications For IVC Filters: Are They Being Observed
John E. Rectenwald, MD, MS

4:06 – 4:11 Update On The Sentry Bioconvertible Non-Retrieval IVC Filter
David Rosenthal, MD

4:12 – 4:17 IVC Filter Retrieval Rates: The Influence Of Filter Design, Practice Administration And The Operator
David L. Gillespie, MD

4:18 – 4:23 The PREPIC Trial: Fact Or Fiction
John E. Rectenwald, MD, MS

4:24 – 4:29 Update On The PRESERVE Vena Cava Filter Study
David L. Gillespie, MD

4:30 – 4:35 Ulcer Healing And Quality Of Life Outcomes After Endovascular Iliocaval Reconstruction (Stenting) In Patients With Concomitant IVC And Iliac Occlusive Disease
Steven D. Abramowitz, MD
Edward Y. Woo, MD

4:36 – 4:41 Major Complications After IVC Filter Placement And How To Avoid Them
Clifford M. Sales, MD, MBA

4:42 – 4:47 Difficult Caval Filter Retrieval: Tips And Tools
Brian G. DeRubertis, MD

4:48 – 4:53 What To Do With Fractured Filters And Embolic Filter Fragments
Constantino Pena, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:54 – 5:00</td>
<td>Which Bariatric Surgery Patients Benefit From Prophylactic Caval Filtration</td>
<td>Nicholas J. Gargiulo III, MD, RPVI, RVT, RDMS</td>
</tr>
<tr>
<td>5:01 – 5:12</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>5:12 – 5:17</td>
<td>End of Program L</td>
<td></td>
</tr>
</tbody>
</table>

**PROGRAM M (SESSIONS 92–98)**

**THE CHALLENGING WORLD OF THE DIAGNOSIS AND TREATMENT OF VASCULAR MALFORMATIONS: AN ORPHAN DISEASE THAT HAS NOW COME OF AGE**

Gramercy Suites East and West, 2nd Floor
Course Leaders: Wayne F. Yakes, MD
Krassi Ivancev, MD, PhD
Robert L. Vogelzang, MD

**SESSION 92 (Gramercy Suites East and West, 2nd Floor)**

**INTRODUCTION TO VASCULAR MALFORMATIONS**

Moderators: Krassi Ivancev, MD, PhD
Furuzan Numan, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 – 6:50</td>
<td>Welcome</td>
<td>Krassi Ivancev, MD, PhD</td>
</tr>
<tr>
<td>6:50 – 7:00</td>
<td>The ISSVA Vascular Anomalies Classification System</td>
<td>Leo J. Schultze-Kool, MD, PhD</td>
</tr>
<tr>
<td>7:00 – 7:10</td>
<td>MR Imaging And MR Guided Treatment Techniques Of Congenital Vascular Malformations</td>
<td>R. Sean Pakbaz, MD</td>
</tr>
<tr>
<td>7:10 – 7:20</td>
<td>Techniques And Considerations For Endovascular Access And Embolization Procedures In A Specialized Population: Neonates And Children</td>
<td>James Donaldson, MD</td>
</tr>
<tr>
<td>7:20 – 7:30</td>
<td>The Yakes AVM Classification System And Its Therapeutic Implications In Challenging Cases</td>
<td>Wayne F. Yakes, MD</td>
</tr>
</tbody>
</table>

**SESSION 93 (Gramercy Suites East and West, 2nd Floor)**

**HIGH FLOW VASCULAR MALFORMATION MANAGEMENT STRATEGIES**

Moderators: Robert L. Vogelzang, MD
Xin Dong Fan, MD
Wayne F. Yakes, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 – 7:40</td>
<td>Tips And Tricks For nBCA AVM Embolization: Long-Term Patient Outcomes And Complications: The Lenox Hill Heart &amp; Vascular Institute of New York Experience</td>
<td>Robert J. Rosen, MD</td>
</tr>
<tr>
<td>7:40 – 7:50</td>
<td>Current Interventional Endovascular Treatment Options For Vascular Malformations: The Miami Vascular Institute Experience</td>
<td>Guilherme Dabus, MD</td>
</tr>
<tr>
<td>7:50 – 8:00</td>
<td>nBCA And Ethanol Endovascular Techniques Used For Complex AVM Treatment Strategies: The University of California at San Diego Medical Center Experience</td>
<td>R. Sean Pakbaz, MD</td>
</tr>
<tr>
<td>8:00 – 8:10</td>
<td>Tips And Tricks Of Complex Peripheral AVM Endovascular Treatment With Onyx: The University of Istanbul Medical Center Experience</td>
<td>Furuzan Numan, MD</td>
</tr>
</tbody>
</table>
Onyx AVM Embolotherapy: Detailed Histologic Evaluation Of Post-Op Resected Specimens: The University of Arkansas at Little Rock Experience
Mollie Meek, MD

Odyssey From Onyx To Ethanol In AVM Endovascular Treatment: The University of Warsaw Medical Center Experience
Mikolaj Wojtaszek, MD, PhD

Use Of A New AVM Classification System To Treat High-Flow Vascular Malformations At The University of Olomouc Medical Center: The Czech Experience
Martin Köcher, MD

Salvage Endovascular Procedures For Onyx AVM Treatment Failures: A Worldwide Experience
Wayne F. Yakes, MD

DEBATE: PALLIATIVE POLYMERIZING AGENTS vs. CURATIVE ETHANOL/COILS APPROACHES: WHICH IS BEST

The Best Management For AVMs Is Done With Polymerizing Agents (NBCA, Onyx)
Furuzan Numan, MD

The Best Management For AVMs Is Done With Polymerizing Agents (NBCA, Onyx)
Robert J. Rosen, MD

The Best Management For AVMs Is Done With Ethanol, And In Yakes Type I/IIa/IIb AVMs With Coils/Ethanol
Robert L. Vogelzang, MD

The Best Management For AVMs With Ethanol And/Or Coils By SMC Classification
Young Soo Do, MD, PhD

The Interventional Radiologist's Role In The Klippel-Trenaunay & Parkes – Weber Syndromes And Other Tissue Overgrowth Disorders: The Emory University Medical Center Experience
Louis G. Martin, MD
10:00 – 10:10
Complex Low-Flow Vascular Malformations And
The Journal Reports Of Multiple Sclerosant Agents: A
World In Endovascular Confusion And Chaos
Wayne F. Yakes, MD

10:10 – 10:30
Break – Visit Exhibits And Pavilions (2nd and 3rd
Floors)

SESSION 95 (Gramercy Suites East and West, 2nd Floor)
SURGERY IN VASCULAR MALFORMATION
MANAGEMENT
Moderators: Jai Wei Zheng, PhD
Dong-ik Kim, MD

10:30 – 10:40
Surgical Approaches To Vascular Malformation
Management: Triumphs And Pitfalls
Christopher J. Morin, MD

10:40 – 10:50
Combined Endovascular And Surgical Management
Strategies In Complex Vascular Malformation
Treatment At The Samsung Medical Center: The
Seoul Experience
Dong-ik Kim, MD

10:50 – 11:00
Reconstructive Surgical Issues With Complex Vascular
Malformations
Tanya M. Oswald, MD

11:00 – 11:10
Surgical Strategies For Lymphatic Malformations At
The Ninth People's Hospital: The Shanghai Experience
Jai Wei Zheng, PhD

11:10 – 11:20
Surgical Reconstructions And Patient Normalization
Post-Endovascular Ablation Of Head & Neck Vascular
Malformations
Randolph C. Robinson, MD, DDS

SESSION 96 (Gramercy Suites East and West, 2nd Floor)
AVM COMPLICATIONS WE ALL ENCOUNTER - IF
YOU ARE DOING AVM CASES, THESE WILL OCCUR -
LET US LEARN TOGETHER FOR OUR PATIENTS' SAKE
Moderators: Robert J. Rosen, MD
Louis G. Martin, MD

11:20 – 11:25
AVM Complications Case Presentation
Krassi Ivancev, MD, PhD

11:25 – 11:30
AVM Complications Case Presentation
Robert J. Rosen, MD

11:30 – 11:35
AVM Complications Case Presentation
Robert L. Vogelzang, MD

11:35 – 11:40
AVM Complications Case Presentation
Louis G. Martin, MD

SESSION 97 (Gramercy Suites East and West, 2nd Floor)
HOW DO I DO THESE CASES RIGHT
Moderators: Young Soo Do, MD, PhD
Iris Baumgartner, MD

11:40 – 11:45
How Do I Determine Where The Damn Nidus Is
Robert L. Vogelzang, MD

11:45 – 11:50
Upper Extremity And Hand AVMs: How I Do It
Young Soo Do, MD, PhD

11:50 – 11:55
How I Treat Plantar Foot AVMs
Iris Baumgartner, MD

11:55 – 12:00
How I Treat Pelvic AVMs
Furuzan Numan, MD
SESSION 98 (Gramercy Suites East and West, 2nd Floor)
COMPLEX AVMs THAT PURPOSEFULLY CONFOUND US
Moderators:  R. Sean Pakbaz, MD
Martin Köcher, MD
Guilherme Dabus, MD

12:20 – 12:30  Curative Endovascular AVM Treatment Techniques Using The Retrograde Vein Approach: The Northwestern Memorial Hospital Experience In Chicago
Robert L. Vogelzang, MD

12:30 – 12:40  Complex AVM Curative Endovascular Treatment At The Samsung Medical Center: The Korean Experience
Young Soo Do, MD, PhD

12:40 – 12:50  The Vascular Malformation International Road Show At The International Medical Center In Cairo And At The Medical University Hospital Of Lubin, Poland
Krassi Ivancev, MD, PhD

12:50 – 1:00  Curative Treatment Of Challenging Scalp, Ear And Mandible AVMs At The Ninth People’s Hospital: The Shanghai Experience
Xin Dong Fan, MD

1:00 – 1:10  Complex AVM Endovascular Management Techniques: The University of Arkansas at Little Rock Experience
Mollie Meek, MD

1:10 – 1:20  Endovascular Curative Treatment Strategies Of Patients With Multiple Complex AVMs: The Denver Experience
Wayne F. Yakes, MD

1:20 – 1:30  Panel Discussion (All AVM Faculty)
End of Program M
6:15 A.M. General Registration – 2nd Floor Promenade
6:15 A.M. Faculty Registration – Morgan Suite – 2nd Floor
6:30 A.M. Continental Breakfast – 3rd Floor Foyer/Promenade

CONCURRENT SATURDAY PROGRAMS

PROGRAM N: (SESSIONS 99-105)
New Developments In The Treatment Of Diseases Of The Lower Extremities, Carotid Arteries, The Aorta And Its Branches
6:46 A.M. – 4:16 P.M.
Grand Ballroom East, 3rd Floor

PROGRAM O: (SESSIONS 106-110)
New Developments In Vascular Access For Hemodialysis
8:00 A.M. – 4:00 P.M.
Grand Ballroom West, 3rd Floor
Course Leaders: Larry A. Scher, MD
Anton N. Sidawy, MD, MPH

PROGRAM P: (SESSIONS 111-115)
New Developments In Treatment Of The Aorta, Carotid Arteries And Lower Extremity Arteries; Important Updates And New Concepts
6:50 A.M. – 2:00 P.M.
Trianon Ballroom, 3rd Floor

SESSION 99 (Grand Ballroom East, 3rd Floor)
NEW DEVELOPMENTS IN THE TREATMENT OF DISEASES OF THE LOWER EXTREMITIES
Moderators: Evan C. Lipsitz, MD
Joseph L. Mills, MD

6:46 – 6:51
Why Patients Get Readmitted After Lower Extremity Procedures And How To Solve The Readmission Problem
Todd R. Vogel, MD, MPH

6:52 – 6:57
12-Month Results Of Different Strategies For Using The 4-French Pulsar-18 Self-Expandable Nitinol Stent For Treatment Of Femoropopliteal Occlusive Lesions: Do Supplemental DCBs Or Atherectomy Improve Outcomes
Michael K.W. Lichtenberg, MD

6:58 – 7:03
Medicare Data Comparing Endovascular And Open Revascularizations For Peripheral Arterial Disease: What New And Interesting Information Does It Provide
K. Craig Kent, MD

7:04 – 7:09
What Are The Disadvantages And Limitations Of The Supera Stent
Gabriel Szendro, MD
SESSION 100  (Grand Ballroom East, 3rd Floor)
MORE HOT TOPICS IN TREATING LOWER EXTREMIT Y DISEASE

Moderators:  Neal S. Cayne, MD  
            K. Craig Kent, MD

7:10 – 7:15  The Wingman CTO Catheter: A New Innovative CTO Recanalization Device (From ReFlow Medical) For Crossing Long Difficult Occlusions: How It Works And Results
            Michael K.W. Lichtenberg, MD

7:16 – 7:21  Strategies For Treating Occluded Popliteal Arteries With No Trifurcation Outflow Endovascularly
            George H. Meier III, MD

7:22 – 7:27  Value Of An Implantable O2 Sensor In Treating Lower Extremity Disease: The Lumee Device And The Global Experience With It
            Miguel F. Montero-Baker, MD

7:28 – 7:34  Panel Discussion

7:34 – 7:39  Experience With A New BioMimics 3-Dimensional Helical Stent In Fempop Arteries: Why Is It Different And What Are Its Theoretical And Clinical Advantages
            Michael K.W. Lichtenberg, MD  
            Thomas Zeller, MD

7:40 – 7:45  5-Year Experience With Coronary DESs In The Tibial And Peroneal Arteries
            Michael J. Wilderman, MD

DRUG ELUTING STENTS (DESs)

7:46 – 7:51  Comparative Performance Of DCBs In Women; And In Diabetics In The In.Pact SFA And Lutonix Trials
            Peter A. Schneider, MD

7:52 – 7:57  Value Of Pre-Clinical Studies Of DCBs: All DCBs Are Not Equal: How Can Performance Be Predicted: Will DCBs Ever Work Effectively In BTK Arteries
            Renu Virmani, MD

7:58 – 8:03  Differences And Similarities In All The DCB Registries And RCTs: All DCBs And All Studies Are Not Equal
            Marianne Brodmann, MD

8:04 – 8:09  What Is The Economic Impact Of DCBs On A Global Level: They Are Cost Effective
            Ulrich Beschorner, MD  
            Thomas Zeller, MD

8:10 – 8:16  Panel Discussion

SESSION 100  (Grand Ballroom East, 3rd Floor)
MORE HOT TOPICS IN TREATING LOWER EXTREMIT Y DISEASE

Moderators:  Gregg S. Landis, MD  
            K. Craig Kent, MD

7:16 – 7:21  Strategies For Treating Occluded Popliteal Arteries With No Trifurcation Outflow Endovascularly
            George H. Meier III, MD

7:22 – 7:27  Value Of An Implantable O2 Sensor In Treating Lower Extremity Disease: The Lumee Device And The Global Experience With It
            Miguel F. Montero-Baker, MD

7:28 – 7:34  Panel Discussion

7:34 – 7:39  Experience With A New BioMimics 3-Dimensional Helical Stent In Fempop Arteries: Why Is It Different And What Are Its Theoretical And Clinical Advantages
            Michael K.W. Lichtenberg, MD  
            Thomas Zeller, MD

7:40 – 7:45  5-Year Experience With Coronary DESs In The Tibial And Peroneal Arteries
            Michael J. Wilderman, MD

DRUG COATED BALLOONS (DCBs)

7:46 – 7:51  Comparative Performance Of DCBs In Women; And In Diabetics In The In.Pact SFA And Lutonix Trials
            Peter A. Schneider, MD

7:52 – 7:57  Value Of Pre-Clinical Studies Of DCBs: All DCBs Are Not Equal: How Can Performance Be Predicted: Will DCBs Ever Work Effectively In BTK Arteries
            Renu Virmani, MD

7:58 – 8:03  Differences And Similarities In All The DCB Registries And RCTs: All DCBs And All Studies Are Not Equal
            Marianne Brodmann, MD

8:04 – 8:09  What Is The Economic Impact Of DCBs On A Global Level: They Are Cost Effective
            Ulrich Beschorner, MD  
            Thomas Zeller, MD

8:10 – 8:16  Panel Discussion

SESSION 100  (Grand Ballroom East, 3rd Floor)
MORE HOT TOPICS IN TREATING LOWER EXTREMIT Y DISEASE

Moderators:  Neal S. Cayne, MD  
            K. Craig Kent, MD

8:16 – 8:21  The SVS WIFI Classification For CLI With Foot Wounds: How Is It Working Out And How Helpful Is It: Has It Been Validated
            Joseph L. Mills, MD

8:22 – 8:27  The SVS WIFI Classification Helps To Predict Wound Healing But Not Amputation In Diabetic Limb Salvage Patients
            Christopher J. Abularrage, MD
8:28 – 8:33 Should Complications Or Modes Of Failure Affect Our Choice Of Treatment (Endo vs. Open) With Complex Fempop Lesions
Thomas E. Brothers, MD

8:34 – 8:39 Why Hybrid Revascularization For Complex Multifocal Lower Extremity Occlusive Disease Is A Better Way To Treat CLI
Hosam F. El Sayed, MD

8:40 – 8:45 How To Create And Fund A Patient Driven Supervised Exercise Program: How Can VQI Help
Tej M. Singh, MD, MBA

8:46 – 8:51 Role Of Distal SFA Puncture For TASC D Lesions And Flush SFA Origin Occlusions: Techniques, Advantages And Results
Arobinda Nanjundappa, MD

8:52 – 8:57 Efficacy Of Endovascular Treatment Of CLI In Hemodialysis Patients: What Are The Mid- And Long-Term Results
Roberto Ferraresi, MD

8:58 – 9:04 Panel Discussion

9:04 – 9:16 Break – Visit Exhibits And Pavilions (3rd Floor)

SESSION 101 (Grand Ballroom East, 3rd Floor)

KEY NEW DEVELOPMENTS IN TREATING CAROTID ARTERY DISEASE
Moderators: Bruce J. Brener, MD Glenn Jacobowitz, MD

9:16 – 9:21 Risk Of Stroke Due To Restenosis After CAS And CEA: Data From The CREST Trial
Fred A. Weaver, MD

9:22 – 9:27 Factors Predicting Progression Of Asymptomatic Carotid Stenosis
Mark Conrad, MD, MMSc Richard P. Cambria, MD

9:28 – 9:33 Bleeding After CEA Is Not Increased In Patients On Plavix Provided Certain Strategies Are Followed
Ashraf Mansour, MD

9:34 – 9:39 Equipment, Tips And Tricks To Perform CAS Via A Radial Approach
Max Amor, MD

9:40 – 9:45 Clinical Results With The Gore PTFE Mesh Covered Carotid Stent For CAS: The SCAFFOLD Trial
Claudio J. Schonholz, MD Peter A. Schneider, MD D. Christopher Metzger, MD

9:46 – 9:51 CAS For Restenosis After CEA Yields Imperfect Results: Open Repair With A PTFE Or Vein Graft Has Better Outcomes
Francesco Spinelli, MD

9:52 – 9:57 Which Carotid Stenosis Patients Are Unsuitable For CAS: How Should They Be Treated
Klaus D. Mathias, MD

9:58 – 10:03 Value Of A Frailty Index In Patients Who Are Candidates For CEA
Anton S. Sidawy, MD, MPH Richard F. Neville, MD

10:04 – 10:09 What Is The Association Between Physical Activity, Carotid Stenosis And Lower Extremity PAD
Caron B. Rockman, MD
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:10 – 10:15</td>
<td>Duplex Derived Carotid Bifurcation Geometry Is A Marker Of Carotid Stenosis: Implications For Treatment</td>
<td>Athanasios D. Giannoukas, MSc, MD, PhD</td>
</tr>
<tr>
<td>10:16 – 10:24</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

**SESSION 102 (Grand Ballroom East, 3rd Floor)**

**MORE KEY TOPICS RELATING TO CAROTID, VERTEBRAL AND AORTIC BRANCH DISEASE**

Moderators: Klaus D. Mathias, MD  
Caron B. Rockman, MD

**CAROTID AND VERTEBRAL TOPICS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:24 – 10:29</td>
<td>Value Of EEG With Transcarotid CAS (TCAR)</td>
<td>Vikram S. Kashyap, MD</td>
</tr>
<tr>
<td>10:30 – 10:35</td>
<td>Long-Term Comparative Outcomes Of CAS For Post CEA Stenosis vs. CAS For De Novo Lesions</td>
<td>Albeir Y. Mousa, MD</td>
</tr>
</tbody>
</table>
| 10:36 – 10:41 | What Constitutes Best Medical Treatment For Patients With Symptomatic And Asymptomatic Carotid Stenosis | Kosmas I. Paraskevas, MD  
Dimitri P. Mikhailidis, PhD |
| 10:42 – 10:47 | Redo CEA vs. Redo CAS For Recurrent Carotid Stenosis: What Is The Comparative Durability And Midterm Outcomes | Mahmoud B. Malas, MD, MHS                                      |

**VERTEBRAL ARTERY DISEASE**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:48 – 10:53</td>
<td>Indications For And Tips And Tricks To Use With Vertebral Artery Interventions</td>
<td>D. Christopher Metzger, MD</td>
</tr>
<tr>
<td>10:54 – 10:59</td>
<td>Clinical Significance Of Duplex Detected Reversal Of Flow In A Vertebral Artery</td>
<td>Thomas S. Maldonado, MD</td>
</tr>
<tr>
<td>11:00 – 11:05</td>
<td>Positional Vertebro-Basilar Ischemia: How To Diagnose It And How To Treat It</td>
<td>Enrique Criado, MD</td>
</tr>
</tbody>
</table>

**WITH CAROTID ANEURYSMS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:06 – 11:11</td>
<td>Natural History And Optimal Treatment For Extracranial Carotid Aneurysms: From An International Registry</td>
<td>Gert J. de Borst, MD</td>
</tr>
<tr>
<td>11:12 – 11:18</td>
<td>Panel Discussion</td>
<td></td>
</tr>
</tbody>
</table>

Moderators: Mark A. Adelman, MD  
Peter A. Schneider, MD

**RENNAL AND VISCERAL ARTERY TOPICS**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:18 – 11:23</td>
<td>Update On Retrograde Superior Mesenteric Artery (SMA) Stenting During Laparotomy For Ischemic Bowel: How To Prepare For And Do The Procedure: Advantages And Results</td>
<td>Richard J. Powell, MD</td>
</tr>
<tr>
<td>11:24 – 11:29</td>
<td>Technique, Results And Complications Of Endovascular Treatment Of Hepatic Artery Stenosis After Liver Transplantation</td>
<td>W. Charles Sternbergh III, MD</td>
</tr>
</tbody>
</table>
11:30 – 11:35 Update On The Value And Advantages Of Covered Stents For The Treatment Of SMA Occlusive Lesions
Gustavo S. Oderich, MD

11:36 – 11:41 Endovascular Repair Of Renal And Visceral Artery Aneurysms: When Indicated, When Contraindicated: Techniques And Tips
Michael D. Duke, MD

11:42 – 11:47 Natural History, Diagnosis And Treatment (When Indicated) Of Visceral Artery Dissections
Vivian Gahtan, MD

11:48 – 11:53 Percutaneous Axillary Artery Access For Branch Grafting For Complex TAAAs And Pararenal AAs: How To Do It Safely
Daniela Branzan, MD
Andrej Schmidt, MD
Dierk Scheinert, MD

11:54 – 12:00 Panel Discussion

12:00 – 12:54 Lunch Break – 3rd Floor Foyer/Promenade
Visit Exhibits And Pavilions (3rd Floor)

SESSION 103 (Grand Ballroom East, 3rd Floor)
KEY NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC DISEASE
Moderators: Mark K. Eskandari, MD
Firas F. Musa, MD

12:54 – 12:59 Does Avoiding Perioperative Hyperglycemia Decrease The Incidence Of Spinal Cord Ischemia After Endovascular TAAA Repair
Jade S. Hiramoto, MD
Timothy A.M. Chuter, DM

1:00 – 1:05 Minimally Invasive Segmental Artery Coil Embolization (MISACE) To Prevent Spinal Cord Ischemia Associated With TAAA Repairs: Technique And Initial Clinical Experience
Daniela Branzan, MD
Christian D. Etz, MD, PhD
Dierk Scheinert, MD
Andrej Schmidt, MD

1:06 – 1:11 Immediate And Two-Year Outcomes After EVAR In "On-Label" And "Off-Label" Neck Anatomies Using Different Commercially Available Devices
Francesco Speziale, MD

1:12 – 1:17 Status Of The LEOPARD Trial Comparing EVAR With An Endograft Fixated On The Aortic Bifurcation (AFX, Endologix) With EVAR Done With Standard Endografts
Christopher J. Kwolek, MD
Benjamin W. Starnes, MD

1:18 – 1:23 Is It Worthwhile Transferring RAAA Patients To A Regional Center – Especially Patients With Complex RAAAs: Tips For Doing So Relatively Safely
Michael P. Jenkins, MBBS, BSc, MS

1:24 – 1:29 When After EVAR Can Vigorous Surveillance Be Minimized: What Are The Advantages Of Doing So Frans L. Moll, MD, PhD

1:30 – 1:35 F/BEVAR To Salvage Failed Infrarenal Endo And Open AAA Repairs, And Why Is 3- Or 4- Fenestration FEVAR Better Than 2-Fenestration FEVAR
Eric L.G. Verhoeven, MD, PhD
Athanasios Katsargyris, MD
SESSIONS 103–104

1.36 – 1.41 Techniques For Overcoming Hostile Access Vessels And Maintaining Distal Limb Perfusion During Complex AAA And TAAA Repairs
Thomas Larzon, MD, PhD

1.42 – 1.48 Panel Discussion
Moderators: Christopher J. Kwolek, MD ShenMing Wang, MD, PhD

1.48 – 1.53 Secondary Interventions After TEVAR: What Is The Source And Significance Of Type 2 Endoleaks: How To Prevent And Treat Them
Mark K. Eskandari, MD

1.54 – 1.59 Pitfalls Of Upper Extremity Access For F/BEVAR And Parallel Grafts: How To Avoid These Pitfalls
Luis A. Sanchez, MD

2.00 – 2.05 Developing A Program For Advanced Aortic Endovascular Interventions: How To Do It
Rocco Giudice, MD

2.06 – 2.11 Open Repair Of TAAAs In Marfan’s Syndrome Patients: Tips, Tricks And Results
Germano Melissano, MD Roberto Chiesa, MD

2.12 – 2.17 Role Of Stent-Grafts In The Treatment Of Marfan’s Syndrome Patients With Aortic Aneurysms
James H. Black III, MD

2.18 – 2.23 How To Predict AAA Growth Rates With Ultrasound And Elastography Techniques
Michael C. Stoner, MD

2.24 – 2.29 Endovascular Treatment Of Giant Renal Or Visceral Artery A-V Fistulas: Techniques, Tips, Tricks And Precautions
Manju Kalra, MBBS

2.30 – 2.36 Panel Discussion

SESSION 104 (Grand Ballroom East, 3rd Floor)
MORE KEY NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC DISEASE
Moderators: Luis A. Sanchez, MD Germano Melissano, MD

2.36 – 2.41 How Leaving A Catheter In The AAA Sac After EVAR Can Be Helpful: Angiography, Pressure Measurement, Embolization Of Thrombin-Gelfoam, Etc. All Can Have Value: Techniques And Results
David H. Deaton, MD

2.42 – 2.47 Incidence Of Sac Enlargement After TEVAR For TAAs: What Factors Predict It And What Should Be Done About It
Matt M. Thompson, MD

2.48 – 2.53 Carotid-Subclavian Bypasses Can Be Difficult And Have Complications: Carotid-Axillary Bypass May Be A Better Alternative: How To Do It
Frank J. Criado, MD

2.54 – 2.59 Choice Of Devices And Techniques For In Situ Left Subclavian Fenestration To Perform Branched TEVAR Repairs
Wayne W. Zhang, MD

3.00 – 3.05 What Happens When A Patient With An Infrarenal Endograft Develops A TBAD: What Can Be Done To Treat The Problem
William J. Quinones-Baldrich, MD
Comparative Analysis Of Open And Endo Repairs Of TAAAs: Which Technique Is Best And When
Piergiorgio Cao, MD

Serious TBADs Are More Common Among Non-Caucasian Patients: What Are The Therapeutic Implications When A Patient Presents With A TBAD
Robert S. Crawford, MD

How To Treat Type 1A Endoleaks After EVAR When Fenestrated Cuffs Are Not Feasible: What Are The Circumstances And The Solutions
Benjamin W. Starnes, MD

Panel Discussion
Refreshments Available

SESSION 105 (Grand Ballroom East, 3rd Floor)
MORE KEY NEW DEVELOPMENTS IN THE TREATMENT OF TRAUMATIC VASCULAR INJURIES AND AORTIC DISEASE
Moderators: Benjamin W. Starnes, MD
Matt M. Thompson, MD

TRAUMATIC AND IATROGENIC VASCULAR INJURIES

Catheter Based Treatment Of Traumatic And Iatrogenic Vascular Injuries: Tips And Tricks
Luis A. Sanchez, MD

Optimal Management Techniques For Iatrogenic Injuries To The Subclavian And Carotid Arteries
Ashraf Mansour, MD

Surgical And Endo Approaches To Vertebral Artery Injuries
Domenico Valenti, DMChir, PhD

Vascular Injuries In Pediatric Patients: Tips And Tricks For Managing And Results
Mark G. Davies, MD

MORE ON AORTIC DISEASE

A Complex EVAR Experience In A Community Setting: The Good, The Bad And The Ugly
Mazin Foteh, MD

Upward (Cranial) Migration Of Thoracic Endografts: Etiology And How To Prevent And Treat It
Vicente Riambau, MD, PhD

Panel Discussion
End of Program N

PROGRAM O (SESSIONS 106–110)
IMPROVING OUTCOMES IN HEMODIALYSIS ACCESS
Grand Ballroom West, 3rd Floor
Course Leaders: Larry A. Scher, MD
Anton N. Sidawy, MD, MPH

SESSION 106 (Grand Ballroom West, 3rd Floor)
PLANNING FOR HEMODIALYSIS ACCESS
Moderators: Larry A. Scher, MD
Anton N. Sidawy, MD, MPH

Introduction
Anton N. Sidawy, MD, MPH
Larry A. Scher, MD
8:08 – 8:15 Strategies For Venous Preservation In Patients With CKD: Why Is This So Difficult
Charmaine Lok, MD

Eric S. Chemla, MD

8:24 – 8:31 Use Of The UCLA/RAND Appropriateness Method To Standardize And Optimize Vascular Access Placement
David L. Call, MD

8:32 – 8:39 Cannulation Mapping To Identify Optimal Access Sites: Should It Be Routine
Surendra Shenoy, MD, PhD

8:40 – 8:50 Panel Discussion

8:51 – 8:58 Vascular Access Process Of Care: What Is It And How Does It Improve Outcomes
Janet Holland, RN

8:59 – 9:06 Vascular Access Training Across Disciplines: Defining And Measuring Competency In Vascular Access
Marc H. Glickman, MD

9:07 – 9:14 Use Of Bedside Ultrasound For Assessment And Cannulation Of Hemodialysis Access
Sandra Donnelly, MDCM, MSc

9:15 – 9:22 Use Of Simulators For Cannulation Training
David L. Call, MD

9:23 – 9:35 Panel Discussion

9:36 – 10:00 Break – Visit Exhibits And Pavilions (3rd Floor)

SESSION 107 (Grand Ballroom West, 3rd Floor)

OPTIMIZING OUTCOMES IN HEMODIALYSIS ACCESS

Moderators: David L. Call, MD
Marc H. Glickman, MD

10:01 – 10:08 Who Are The Elderly And What Access Should They Have
Clifford M. Sales, MD, MBA

10:09 – 10:16 Is There A Role For Drug Eluting Balloons And Stents In Dialysis Access
Theodore F. Saad, MD

10:17 – 10:24 Should Stent Grafts Be First Line Therapy In Dialysis Access
John E. Aruny, MD

10:25 – 10:32 Can Iodinated Contrast Be Used Safely In Patients With Compromised Renal Function
David Fox, MD, RPVI

10:33 – 10:40 Outcome Assessment In Vascular Access Clinical Trials: Anatomic vs. Functional Endpoints
Sriram S. Iyer, MD

10:41 – 10:51 Panel Discussion

10:52 – 10:59 Algorithms For Management Of Steal Syndrome
Scott S. Berman, MD, MHA

11:00 – 11:07 High Flow Arteriovenous Fistulas: When And How To Intervene
John R. Ross, Sr., MD

11:08 – 11:15 Management Of Life-Threatening Complications In The Outpatient Access Center
Gregg A. Miller, MD

SESSIONS 106–107

SATURDAY

109
Cerebral Hypertension And Other Unintended Consequences Of Central Venous Catheters
Haimanot (Monnie) Wasse, MD, MPH

Management Of Dialysis Access Hemorrhage
Theodore F. Saad, MD

Panel Discussion

Lunch Break – Visit Exhibits And Pavilions (3rd Floor Promenade)

SESSION 108 (Grand Ballroom West, 3rd Floor)
POLITICAL, ECONOMIC AND LEGAL ISSUES IN HEMODIALYSIS ACCESS
Moderators: Larry A. Scher, MD
John E. Aruny, MD

Honored Guest Lecture: Historical Perspective On The Development Of The AV Fistula For Hemodialysis Access
Michael J. Brescia, MD

Quality Over Quantity: How ESRD Seamless Care Organizations (ESCOs) Will Drive Adoption Of Cost-Effective Therapies
Jeffrey Y. Wang, MD

Review Of Major Changes In Hemodialysis Access Coding Planned For 2017
Sean P. Roddy, MD

Informed Consent For Vascular Access Surgery: What To Discuss And What To Document
O. William Brown, MD, JD

Health Economics And Cannulation Grafts
Scott S. Berman, MD, MHA

Innovation In Vascular Access: Where Are We Headed
Jeffrey H. Lawson, MD, PhD

Percutaneous Vascular Access: Results Of The NEAT Trial
Charmaine Lok, MD

What Is The Optimal Dialysis Catheter: Do Coatings And Tip Design Matter
John R. Ross, Sr., MD

Radial Artery Deviation And Reimplantation (RADAR) Inhibits Juxtaanastomotic Stenosis And Improves Fistula Patency
Nirvana Sadaghianloo, MD

Improving AV Fistula Outcomes: Pharmacologic Approaches
Surendra Shenoy, MD, PhD

Improving AV Fistula Outcomes: Mechanical Approaches
Eric S. Chemla, MD

Panel Discussion
SESSION 110 (Grand Ballroom West, 3rd Floor)

UPDATE ON CLINICAL ISSUES IN HEMODIALYSIS ACCESS

Moderators: Larry A. Scher, MD  
Anton N. Sidawy, MD, MPH

2:25 – 2:32  
Forty Years Of Prosthetic Vascular Access For Hemodialysis: What Have We Learned And Where Are We Going  
Marc H. Glickman, MD

2:33 – 2:40  
Assessment And Treatment Of Dialysis Access Aneurysms And Pseudoaneurysms: What Is The Risk Of Rupture  
Karl A. Illig, MD

2:41 – 2:48  
Options For Dealing With The Deep Fistula: VWING vs. Liposuction vs. Superficialization  
Surendra Shenoy, MD, PhD

2:49 – 2:56  
Treatment Of Dialysis Access Infections: Is There A Role For Cryopreserved Allograft  
Peter F. Lawrence, MD

2:57 – 3:04  
The End Stage Of Dialysis Access: Femoral AV Graft vs. HeRO  
Virginia L. Wong, MD

3:05 – 3:16  
Panel Discussion

3:17 – 3:24  
Approaches To Central Venous Obstruction In Hemoaccess Patients  
Matthew J. Dougherty, MD

3:25 – 3:32  
Options For Early Access After AV Fistula Revision: Avoiding Vascular Catheters  
Christian Ochoa, MD

3:33 – 3:40  
Maximizing Dialysis Performance With Disadvantaged Venous Anatomy  
Paul B. Kreienberg, MD

3:41 – 3:48  
Incidence Of Complications Of Tunneled Dialysis Catheters: Is Fistula First Always The Best Strategy  
Alan M. Dietzke, MD, RPVI

3:49 – 4:00  
Panel Discussion

End of Program O

PROGRAM P (SESSIONS 111-115)

NEW DEVELOPMENTS IN TREATMENT OF DISEASES OF THE AORTA, CAROTID AND LOWER EXTREMITY ARTERIES; IMPORTANT UPDATES AND NEW CONCEPTS

Trianon Ballroom, 3rd Floor

SESSION 111 (Trianon Ballroom, 3rd Floor)

INTERESTING TOPICS RELATED TO THE AORTA, TAAAs AND TBADs AND THEIR TREATMENT

Moderators: Nicholas J.W. Cheshire, MD  
Gilbert R. Upchurch, MD

6:50 – 6:55  
Endovascular Treatment Of A Ruptured AAA Using A Standard EVAR Device And A Nellix EVAS Device In The Same Patient: Lessons Learned  
Jan M.M. Heyligers, MD, PhD

6:56 – 7:01  
Predictive Factors For Persistent Patent False Lumen And Aneurysm Formation After TEVAR For Uncomplicated TBAD  
Richard G.J. Gibbs, FRCS
7:02 – 7:07 Persistent Patent False Lumen After TEVAR Is The Achilles Heel Of Treatment For TBADs: What Can Be Done To Fix the Problem
Frank R. Arko, MD

7:08 – 7:13 Value Of Duplex Surveillance With Parallel Grafts For Complex AAAs: What Can It Tell You And What To Look For
Ross Milner, MD

7:14 – 7:19 Management Of Type 1A Endoleaks After F/EVAR Is Not Easy: What Endo Strategies Can Work And When Is Open Treatment Necessary
Michael J. Singh, MD

7:20 – 7:25 Pitfalls And Tips And Tricks For Open Repair After Failed EVAR: When Is It Necessary
Germeno Melisano, MD
Roberto Chiesa, MD

7:26 – 7:31 Tips And Tricks To Perform Successful Bifurcated EVAR When The Distal Aorta Is Small (10-16 mm) And Possibly Heavily Calcified
Gustavo S. Oderich, MD

7:32 – 7:37 Tips And Technical Tricks For Open Retroperitoneal Approach To The Juxta- And Pararenal Aorta
R. Clement Darling III, MD

7:38 – 7:46 Panel Discussion

SESSION 112 (Trianon Ballroom, 3rd Floor)
MORE INTERESTING TOPICS RELATED TO AORTIC DISEASES AND THEIR TREATMENT
Moderators: R. Clement Darling III, MD
Enrico Ascher, MD

7:46 – 7:51 Hybrid Procedures For Arch TAAs Are Effective And Durable At Least 5 Years: Are Fully Endo Approaches Equally Effective And Durable
Colin D. Bicknell, MD

7:52 – 7:57 What Can A Bench Model Teach Us About Optimizing Fenestration Alignment And How Can Balloons Outside The Main Endograft Facilitate Branch Alignment During F/BEVAR
David J. Minion, MD

7:58 – 8:03 Technique Of 2 Chimney (Renal) And 2 Sandwich (Visceral) Parallel Grafts For Supraceliac AAAs And TAAAs: They Can Produce Very Secure Repairs
James F. McKinsey, MD

8:04 – 8:09 Tips And Tricks To Make Chimney And Sandwich EVAR Work Well
Edward Y. Woo, MD

8:10 – 8:15 A New Thoracic Graft For TAAAs: A Double-Barred Configuration Decreases Aortic Coverage: Concept, Device And Early Results
Piotr M. Kasprzak, MD

8:16 – 8:21 Complex Techniques For Endoleak Treatment With Microcatheters And Transgluteal And Transcaval Approaches
Michele Rossi, MD

8:22 – 8:27 Tips, Tricks, Indications And Precautions For Transcaval Access To Treat Type 2 Endoleaks
Edward Y. Woo, MD

8:28 – 8:34 Panel Discussion
AAA Screening Can Be Effective In Preventing Rupture, Decreasing Cost And Saving Lives  
Anders Wanhainen, MD, PhD  

Does AAA Screening Save Lives: It Matters How The Numbers Are Interpreted  
Frank A. Lederle, MD  

Modifiable Factors To Decrease Length Of Stay (LOS) And Improve Quality Of Care And Outcomes After EVAR  
Gilbert R. Upchurch, MD  

Aortic Outflow Obstruction And Increased Percent Of Intraluminal Thrombus Predispose To AAA Rupture At A Smaller Size  
Gregory L. Moneta, MD  

Variations In AAA Juxtarenal Landing Zones And Their Suitability For Various Commercial Endografts; Which Graft Is Best In Which Circumstances  
Jan D. Blankensteijn, MD  
Kak Khee Yeung, MD, PhD  

Elective AAA Repair In Those Over 80 Years: EVAR Is Better Than Open Repair With Lower 30-Day And 1-Year Mortality: EVAR Is Clearly The Preferred Treatment In Octogenarians  
Mahmoud B. Malas, MD, MHS  

Recent US National Trends In AAA Repair: Open And Total Repairs Are Decreasing; EVAR And F/BEVAR Are Increasing: What Are The Implications  
Mark F. Fillinger, MD  

When With Aortoiliac Occlusive Disease Are Covered Stents Better Than Bare Stents  
Franco Grego, MD  

Complications Of F/BEVAR And How To Treat Them Endovascularly  
Robert A. Morgan, MD  

Long-Term Cost Effectiveness Of EVAR vs. Open Repair: From The OVER Trial  
Frank A. Lederle, MD  

Transcaval Embolization Of Endoleaks: Indications, Technique, Advantages And Precautions  
Tilo Köbel, MD, PhD  

New Endovascular Technique For Repairing Chronic TBAD Involving Branch Vessels Originating From The True And False Lumens  
Patrick W. Kelly, MD  

Factors Predisposing To Retrograde Dissection During TEVAR And Endovascular Arch Repair: How Can It Be Prevented And How Is It Best Treated  
Ludovic Canaud, MD, PhD
Type 1A Leaks After EVAR: When Can They Safely Be Observed Without Treatment And When Is Banding, FEVAR, ChEVAR Or Open Conversion Indicated
Jean-Pierre Becquemin, MD

Panel Discussion

SESSION 114 (Trianon Ballroom, 3rd Floor)
INTERESTING TOPICS RELATED TO DISEASES OF CAROTID AND LOWER EXTREMITY ARTERIES AND THEIR TREATMENT
Moderators: Kenneth Ouriel, MD, MBA
Sean P. Lyden, MD

CAROTID TOPICS

Biomechanics Of The Vulnerable Plaque: How Does Plaque Motion Matter
Brajesh K. Lal, MD

Tips And Techniques For Managing Carotid And Vertebral Dissections – Symptomatic And Asymptomatic
Mark G. Davies, MD

LOWER EXTREMITY TOPICS

Diagnosis And Treatment Of Closure Device Complications: Tips And Tricks For Preventing And Treating
Jos C. van den Berg, MD, PhD

How To Set Up A Limb Salvage Program That Works: Administrative, Clinical And Financial Issues That Need To Be Resolved
Richard F. Neville, MD

Validation Of The Value Of Atherectomy In Infrapopliteal Occlusive Disease By Using The WIFI Score
Miguel F. Montero-Baker, MD

The Cost Of Improved Technology In The Lower Extremity: Does Increased Spending Correlate With Better Limb Salvage And Amputation-Free Survival: What Are The Implications
Philip P. Goodney, MD, MS

SPY Technology: What Is It, How Does It Work And How Can It Evaluate The Outcomes Of Lower Extremity Revascularizations
Wei Zhou, MD

How To Manage Acute Stent Thromboses During Femoral Interventions: It Makes A Difference In The Outcome
Yann Goëffic, MD, PhD

Panel Discussion
Moderators: Keith D. Calligaro, MD
Frank J. Veith, MD

How Can Duplex Ultrasonography Replace Angiography, Improve Interventional Procedures In The Lower Extremity And Decrease Radiation Exposure To The Operator And Staff: What Is Needed To Do It
Enrico Ascher, MD
Natalie A. Marks, MD, RPVI, RVT
11:18 – 11:23
Midterm Results With Drug Eluting Balloons For SFA Lesions In Patients With CLI: Comparison With Results Of Conventional Bypass Surgery
Onur S. Goksel, MD

11:24 – 11:29
Does Hyperbaric Oxygen Therapy Really Work For Ischemic Ulcers In Diabetics – Or Is It A Hoax: Results Of The Dutch 30-Center DAMOCLES Trial
Katrien T.B. Santema, MD, MSc
Dirk T. Ubbink, MD, PhD

11:30 – 11:35
Next Generation Stent Systems For Non-Cardiac Arterial Occlusive Lesions: What Are They And What Are Their Prospects
Brian G. DeRubertis, MD

11:36 – 11:41
The Vasostat Device To Aid Hemostasis After Tibial, Pedal, Radial And Other Extremity Punctures: How It Works And Results
Timothy W.I. Clark, MD

11:42 – 11:47
Treatment Of CLI And Intermittent Claudication: National Data From Germany: What % Endo; What % Open: What Are The Implications
Sebastian E. Debus, MD, PhD

11:48 – 11:53
Post Revascularization Management After Interventions For CLI: It Is Critically Important And Must Be Done Right: Tips And Details To Do So
Mehdi H. Shishehbor, DO, MPH, PhD

11:54 – 12:00
Panel Discussion

12:00 – 1:00
Lunch Break – 3rd Floor Foyer/Promenade
Visit Exhibits And Pavilions (3rd Floor)

SESSION 115 (Trianon Ballroom, 3rd Floor)
IMPORTANT UPDATES AND NEW CONCEPTS AND LATE BREAKING RESULTS
Moderators: Ali F. AbuRahma, MD
Enrico Ascher, MD

1:00 – 1:05
Use And Misuse Of Peri-Procedural Blood Transfusions In Vascular Patients: When And How Should They Be Used
Peter Henke, MD

1:06 – 1:11
Exodaban Plus Aspirin May Be Better Than Plavix (Clopidogrel) And Aspirin After Endovascular Interventions: How Should They Be Used
Frans L. Moll, MD, PhD

1:12 – 1:17
Value Of 3D Printing In Vascular Surgery
Lieven F. Maene, MD

1:18 – 1:23
iCAST™ Balloon Expandable Covered Stent For Iliac Artery Lesions: 3-Year Results From The ICARUS Multicenter Study
John R. Laird, MD

1:24 – 1:29
How Can A Cell Phone App Improve Surgical Care, Follow-Up And Quality Of Life: How Can We Get The App
K. Craig Kent, MD

1:30 – 1:35
Strategies And Methods To Achieve Smoking Cessation In Vascular Patients: How Effective Can They Be
Philip P. Goodney, MD, MS

1:36 – 1:41
Frailty Scores And Their Usefulness In Lower Extremity And AAA Procedures
Mohammad H. Eslami, MD, RPVI
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:42 – 1:47</td>
<td>Diagnosis And Treatment Of The Vascular Complications Of ECMO (Extracorporeal Membrane Oxygenation) Cynthia K. Shortell, MD</td>
</tr>
<tr>
<td>1:48 – 1:53</td>
<td>Value Of The Low Frequency Vascular Consortium: What Has It Studied And How Has It Helped In The Treatment Of Rare Vascular Diseases Peter F. Lawrence, MD</td>
</tr>
<tr>
<td>1:54 – 2:00</td>
<td>Panel Discussion</td>
</tr>
</tbody>
</table>

End of Program P

Please visit the Grand Ballroom East and/or West for more interesting VEITHsymposium topics.
Anne L. Abbott, MD, PhD, FRACP
Melbourne, Australia
Dorothy Z. Abel, MS
Portland, Oregon
Steven D. Abramowitz, MD
Washington, District of Columbia
Christopher J. Abularrage, MD
Baltimore, Maryland
Ali F. AbuRahma, MD
Charleston, West Virginia
Charles W. Acher, MD
Madison, Wisconsin
George L. Adams, MD
Raleigh, North Carolina and Chapel Hill, North Carolina
Joshua D. Adams, MD
Charleston, South Carolina
Mark A. Adelman, MD
New York, New York
Sam S. Ahn, MD, FACS, MBA
Los Angeles, California and Dallas, Texas
Francesco A. Aiello, MD
Worcester, Massachusetts
Eric Allaire, MD, PhD
Crepin, France
Jose I. Almeida, MD, RPVI, RVT, FACS
Miami, Florida
Jean-Marc Alsac, MD, PhD
Paris, France
Beatrice R. Amann-Vesti, MD
Zurich, Switzerland
Ali Amin, MD, RVT, FACS, FACC
Reading, Pennsylvania
Max Amor, MD
Essex-Les-Nancy, France
Gary M. Ansel, MD
Columbus, Ohio
Frank R. Arko, MD
Charlotte, North Carolina
John E. Aruny, MD
New Haven, Connecticut
Enrico Ascher, MD
Brooklyn, New York
Afshin Assadian, MD
Vienna, Austria
Lambros Athanasiou, MD
Cambridge, Massachusetts
Hamdy Awad, MD
Upper Arlington, Ohio
Ali Azizadeh, MD
Houston, Texas
Nobuyoshi Azuma, MD
Asahikawa, Hokkaido, Japan

Domenico Baccellieri, MD
Milan, Italy
Martin R. Back, MD
Tampa, Florida
Christopher M. Banoub, MPA
New York, New York
Stephen M. Bauer, MD
Greenwich, Connecticut
Iris Baumgartner, MD
Brooklyn, New York
Hernan Bazan, MD, FACS
New Orleans, Louisiana
Jonathan D. Beard, ChM, MEd, FRCS
London, United Kingdom
Adam Beck, MD
Birmingham, Alabama

Jean-Pierre Becquemin, MD, FRCS
Crepin, France
Michael Belkin, MD
Boston, Massachusetts
James F. Benenati, MD
Miami, Florida
Jeffrey S. Berger, MD, MS, FAHA, FACC
New York, New York
Ramon Berguer, MD, PhD
Ann Arbor, Michigan
Todd Berland, MD
New York, New York
Scott S. Berman, MD, MHA
Tucson, Arizona
Ulrich Reschmoner, MD
Bad Kreuzingen, Germany
Giancarlo Biamino, MD, PhD
Impruneta, Italy
Colin D. Bicknell, MD, FRCS
London, United Kingdom
Jean Bismuth, MD
Houston, Texas
Martin Björk, MD, PhD
Uppsala, Sweden
James H. Black III, MD
Baltimore, Maryland
Stephen A. Black, MD
London, United Kingdom
Jan D. Blankensteijn, MD
Amsterdam, The Netherlands
John Blebea, MD, MBA
Tulsa, Oklahoma
Erwin Blessing, MD
Karlsruhe, Germany
Dittmar Böckler, MD
Heidelberg, Germany
Thomas C. Bower, MD
Rochester, Minnesota
Mr. Jonathan R. Boyle, MD, FRCS
Cambridge, United Kingdom
Kursat A. Bozkurt, MD
Istanbul, Turkey
Andrew W. Bradbury, MD, FRCS Ed
Birmingham, United Kingdom
Daniela Brankan, MD
Leipzig, Germany
Bruce J. Brener, MD
Livingston and Newark, New Jersey
Michael J. Brescia, MD
Bronx, New York
Marianne Brodmann, MD
Austria, Europe
Thomas E. Brothers, MD
Charleston, South Carolina
Thomas G. Broti, MD
Jacksonville, Florida
O. William Brown, MD, JD
Royal Oak, Michigan
Elchachan Bruckheimer, MBBS
Petah-Tikva, Israel
Jan S. Brunkwald, MD, PhD
Cologne, Germany
Clifford J. Buckley, MD
Temple, Texas
Richard Bulbulia, MA, MD, FRCS
Oxford and Cheltenham, United Kingdom
Jacques Busquet, MD
Paris, France

Keith D. Calligaro, MD
Philadelphia, Pennsylvania
Richard P. Cambria, MD
Boston, Massachusetts
Eric E. Roselli, MD  
Cleveland, Ohio  
Robert J. Rosen, MD  
New York, New York  
Melvin Rosenblatt, MD  
Fairfield, Connecticut  
Kenneth Rosenfield, MD  
Boston, Massachusetts  
David Rosenthal, MD  
Atlanta, Georgia  
Rachel Rosovsky, MD, MPH  
Boston, Massachusetts  
John R. Ross, Sr., MD  
Orangeburg, South Carolina  
Michele Rossi, MD  
Rome, Italy  
Plinio Rossi, MD  
Rome, Italy  
Maria Antonella Ruffino, MD, EBIR  
Torino, Italy  
John H. Rundback, MD, FSIR, FAHA  
Teaneck, New Jersey  
S  
Theodore F. Saad, MD  
Newark, Delaware  
Nirvana Sadaghianlooo, MD  
Nice, France  
Mikel Sadek, MD  
New York, New York  
Hazen J. Safi, MD  
Houston, Texas  
Yoshikatsu Saiki, MD, PhD  
Sendai, Japan  
Natzli Sakhalilasan, MD, PhD  
Sart Tilman, Liege, Belgium  
Clifford M. Sales, MD, MBA, FACS  
Summit, New Jersey  
Russell H. Samson, MD, RVT, FACS  
Sarasota, Florida  
Luis A. Sanchez, MD  
St. Louis, Missouri  
Katrien T.B. Santema, MD, MSc  
Amsterdam, The Netherlands  
Timur P. Saric, MD  
New Haven, Connecticut  
Andres Schanzer, MD  
Worcester, Massachusetts  
Dierk Scheinert, MD  
Leipzig, Germany  
Larry A. Scher, MD  
Bronx, New York  
Marc L. Schermerhorn, MD  
Boston, Massachusetts  
Andrej Schmidt, MD  
Leipzig, Germany  
Darren B. Schneider, MD  
New York, New York  
Peter A. Schneider, MD  
Honolulu, Hawaii  
Claudio J. Schonholz, MD  
Charleston, South Carolina  
Martin L. Schuman, MD  
Manhasset, New York  
Leo Schultz Kool, MD, PhD  
Nijmegen, The Netherlands  
Israel Schur, MD  
New York, New York  
Geert Willem H. Schurink, MD, PhD  
Maarssen, The Netherlands  
Bernard J. Segers, MD  
Brussels, Belgium  
Carlo Setacci, MD  
Siena, Italy  
Francesco Setacci, MD  
Monaster, Italy  
Julien G. Sfeir, MD  
Beirut, Lebanon  
Murray L. Shames, MD  
Tampa, Florida  
Palma M. Shaw, MD  
Syracuse, New York  
Surendra Shenoy, MD, PhD  
St. Louis, Missouri  
Chun Che Shih, MD, PhD  
Taipei, Taiwan  
Mehdi H. Shishehbor, DO, MPH, PhD  
Cleveland, Ohio  
Cynthia K. Shortell, MD  
Durham, North Carolina  
Chang Shu, MD  
Beijing, China & ChangShu, Hunan Province, China  
Anton N. Sidawy, MD, MPH  
Washington, District of Columbia  
Horst Sievert, MD  
Frankfurt, Germany  
Henrik Silesen, MD, DMSc  
Copenhagen, Denmark  
Michael B. Silva, Jr., MD  
Galveston, Texas  
Michael J. Singh, MD  
Pittsburgh, Pennsylvania  
Niten Singh, MD  
Seattle, Washington  
Tej M. Singh, MD, MBA  
Mountain View, California  
Akhiles K. Sista, MD  
New York, New York  
Björn Sonesson, MD, PhD  
Malmö, Sweden  
J. David Spence, MD  
London, Canada  
Francesco Spinelli, MD  
Rome, Italy  
Antonio M. Spiaotti, MD  
Charleston, South Carolina  
Diwy Sridhar, MD  
New York, New York  
James C. Stanley, MD  
Ann Arbor, Michigan  
Benjamin W. Starnes, MD  
Seattle, Washington  
Andrea Stella, MD  
Bologna, Italy  
W. Charles Sterbehn III, MD  
New Orleans, Louisiana  
Johnny Steuer, MD, PhD  
Stockholm, Sweden  
Scott L. Stevens, MD  
Knoxville, Tennessee  
Allan Stewart, MD  
New York, New York  
Gregg W. Stone, MD  
New York, New York  
Patrick A. Stone, MD  
Charleston, West Virginia  
Michael C. Stone, MD  
Rochester, New York  
Timothy M. Sullivan, MD  
Minneapolis, Minnesota  
Sherif A.H. Sultan, MD, FRCS  
Dublin, Qatar  
Galway, Ireland  
Bauer E. Sumpio, MD, PhD  
New Haven, Connecticut  
Lars G. Svensson, MD, PhD  
Cleveland, Ohio  
Gabriel Szendro, MD  
Beer Sheva, Israel  
Piotr Szopsinski, MD  
Warsaw, Poland
REGISTRATION

Tuesday, November 15 – Saturday, November 19, 2016

NEW YORK HILTON - MIDTOWN
1335 Avenue Of The Americas | New York, NY 10019

Meeting Registration
(See Registration Form on reverse side)

Refund: There is a $95 cancellation fee if canceled by October 14, 2016. No refunds will be made thereafter.

Online: http://www.veithsymposium.org

Phone: 800-987-9314, Ext. 200 or 718-549-3140 with your payment information.

Fax: the reverse form with your credit card payment to 888-418-7043

Mail: this form with your payment to:
The Cleveland Clinic Educational Foundation
Attn: VEITH 02010552
P.O. Box 931653
Cleveland, OH 44193-1082

Full Registration

<table>
<thead>
<tr>
<th>Practicing Physicians</th>
<th>$1399</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practicing Physicians Combination Rate</td>
<td>$1899</td>
</tr>
<tr>
<td>VEITHsymposium, AIMsymposium and AVIsymposium</td>
<td></td>
</tr>
</tbody>
</table>

US and Canadian Vascular Surgery Fellows in Training

<table>
<thead>
<tr>
<th>Non-U.S. Fellows</th>
<th>Nurse Practitioners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician Assistants</td>
<td>$699</td>
</tr>
<tr>
<td>Residents</td>
<td>Nurses</td>
</tr>
</tbody>
</table>

Medical Students

| Letter of verification from Dean must be obtained and faxed to 888-418-7043 | $500 |
| Allied Health Care Professionals | $950 |

Thursday Only

<table>
<thead>
<tr>
<th>Tuition includes access to VEITHsymposium Thursday Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovation and Investment Roundtable (This is a non-CME activity)</td>
</tr>
</tbody>
</table>

Saturday Only Components

<table>
<thead>
<tr>
<th>Tuition includes access to any Saturday Only Component</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEITHsymposium Miscellaneous Topics</td>
</tr>
<tr>
<td>Hemodialysis Access</td>
</tr>
</tbody>
</table>

Additional Information

VEITHsymposium
4455 Douglas Avenue, Suite 11E
Riverdale, New York 10471

Phone: 800-987-9314 or 718-549-3140
E-mail: registrar@veithsymposium.org or admin@veithsymposium.org
REGISTRATION

Full Registration
☐ Practicing Physicians .......................................................... $1399
☐ Practicing Physicians Combination Rate
VEITHsymposium, AIMsymposium and
AVIDsymposium ............................................................. $1899
☐ US and Canadian Vascular Surgery Fellows
In Training” ................................................................. Complimentary
*US 2nd-Year Fellows in an RRC-approved 2-Year Vascular Fellowship OR 6th-Year Vascular Resistant in an approved Vascular Surgery Residency as of November 2016, AND Canadian Vascular Surgery Fellows in Training (Tuition is provided through an Educational Grant by W.L. Gore & Associates Inc.) Letter of verification from Chief of Service must be obtained prior to registration and faxed to (888) 418-7043. The letter must include the start and end dates of Vascular Surgery Fellowship.

☐ Non-U.S. Fellows ☐ Nurse Practitioners
☐ Physician Assistants .......................................................... $699
☐ Residents ☐ Nurses ☐ Technologists ................................. $650
☐ Medical Students
Letter of verification from Dean must be obtained and faxed to 888-418-7043. ...... $500
☐ Allied Health Care Professionals ........................................ $950

Thursday Only
Tuition includes access to VEITHsymposium Thursday Sessions.

☐ Innovation and Investment Roundtable
(This is a non-CME activity) ................................................... $349

Saturday Only Components
Tuition includes access to any Saturday Only Component.

☐ VEITHsymposium Miscellaneous Topics .............................. $349
☐ Hemodialysis Access .......................................................... $349

First Name: ____________________________________________________________
Last Name (Surname) ___________________________________________________
Degree: ________________________________________________________________
Specialty: ________________________________________________________________
☐ Physician ☐ Non-Physician Cleveland Clinic Employee? ☐ Yes ☐ No
Affiliation: ______________________________________________________________
Address Type: ☐ Home ☐ Other
Address: ________________________________________________________________
City: ___________________________ State/Province _________________________
Zip Code: ______________________ Country _______________________________
E-mail: _________________________________________________________________
Phone: _________________________ Fax _________________________________

Payment Method
Check: Please make checks payable to the Cleveland Clinic Educational Foundation and mail to:
The Cleveland Clinic Educational Foundation
Attn: VEITH 02010552
P.O. Box 931653
Cleveland, OH 44193-1082

Credit Card:
Name on Card: _________________________________________________________
Credit Card Number: ___________________________________________________
Verification Code (3-4 Digit Code on Credit Card): ____________________ Expiration Date ______
Zip Code: ______________________ Country _______________________________
Signature: ______________________
SAVE THE DATE

Tuesday - Saturday, November 14–18, 2017

Symposium Chairman
Frank J. Veith, MD

Symposium Co-Chairmen
Enrico Ascher, MD
Kenneth Ouriel, MD, MBA
Sean P. Lyden, MD

Sponsored by
Cleveland Clinic

www.VEITHsymposium.org
Non-profit Org
US Postage
PAID
White Plains, NY
Permit No. 7033

THE CLEVELAND CLINIC EDUCATIONAL FOUNDATION
PO BOX 931653
CLEVELAND, OH 44193-1082

WEDNESDAY, NOVEMBER 16, 2016
Venous Venous Venous Workshops at VEITHsymposium

THURSDAY, NOVEMBER 17, 2016
Innovation and Investment Roundtable

SATURDAY, NOVEMBER 19, 2016
Hemodialysis Access

AGAIN THIS YEAR
Associate Faculty Global Podium Presentations Program